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ABSTRACT

THE USE OF MATHEMATICAL AND COMPUTATIONAL
MODELS TO DEFINE THE ROLE OF MUTATION AND
INFECTION IN COLORECTAL CANCER
CHANDLER D. GATENBEE

November

19, 2012

Research over the past twenty five years has led to the development of the
hypothesis that colorectal cancer is caused by the accumulation of mutations
in tumor suppressor genes and proto-oncogenes. The last ten years has also revealed that the common JC Virus (JCV) is frequently found in colorectal tumors.
This has led to the hypothesis that the virus, which is known to cause tumors in
the lab, may playa role in colorectal cancer. However, the presence of JCV in colorectal tumors does not necessarily indicate a cause-effect relationship. Unlike in
vivo and in vitro studies, mathematical and computational modeling provides an

opportunity to evaluate the roles that mutation and infection play in colorectal
tumorigenesis. Three probability models are developed to asses whether colorectal cancer can occur by mutation alone or if infection is required. Two models
find that JCV is required for tumorigenesis, and that mutation alone is unable to
generate any tumors. The third probability model finds the opposite; mutation is
able to generate realistic numbers of colorectal cancer patients, while infection is
not. All three models do indicate that selection for a stem cell mutation rate that
is

100

times lower than transit cells provides protection from cancer, confirming

the findings of other research groups. An agent based model is also developed
to simulate many of the complexities that cannot be modeled in the probability
v

models. The results from the agent based model indicate that ICV exacerbates
colorectal cancer and greatly increases the risk of developing cancer. It also finds
that mutation alone is able to cause colorectal cancer, although not as frequently
as IC virus associated cases. All together, these models indicate that both mutation and infection have the capacity to drive tumorigenesis, but that the presence
of IC Virus increases the risk of developing colorectal cancer. This strongly suggests that the role of ICV in colorectal cancer deserves more attention. If future
studies confirm these findings, it would indicate that the prevalence of colorectal
cancer can be reduced by taking measures to prevent infection by IC Virus.

vi

TABLE OF CONTENTS
1

THE BARRIERS TO CANCER

1

1.1

Overview....

1

1.2

What is Cancer?

1

1.3 Removing the Cancer Barriers .
1.4

2

9

Cancer as an Evolutionary Process

MUTATION AND COLORECTAL CANCER

17
18

2.1

Overview . . . . . . . . . . . .

18

2.2

Structure of Colon and Crypts

18

2.3 Mutation Model: The Canonical View of Colorectal Cancer

3 JC VIRUS AND COLORECTAL CANCER

21

33

3.1 Overview . . . . . . . . . . .

33

3.2 Polyomaviruses and Tumors

33

3.3 JCV Epidemiology . . . . . .

35

3.4 JCV Structure and Lifecycle

37

3.5 JCV Oncoproteins and the Host Proteins they Manipulate.

39

3.6 In the Lab: JCV and Tumorigenesis . . . . . . . . . .

44

3.7 An Association Between JCV and Colorectal Cancer

46

4 A NEED FOR MODELING.

54

5 PROBABILITY MODELS

58

5.1 Overview . . . . . . . .

58

5.2 Original Calabrese Model

58

[17] .

5.3 Infection Model Derived from the Calabrese Model

60

5-4 Calabrese Models with New Parameters (CNP)

66

5.5 Genomic Instability Models . , .

69

vii

5. 6 Conclusions . . . . . .

73

6 GEOMETRIC MODEL

75

6.1 Overview ......

75

6.2 The Geometric Model

75

6·3 Implementation

76

6·4 Results . . . .

77

6·5 Conclusions .

78
83

7 AGENT BASED MODEL
7. 1 Overview ........

83

7. 2 Need for an Agent Based Model .

83

7·3 Overview of Models . . . . . . . .

85

7·4 Modeling the Structure of a Colon Crypt .

87

7·5 Wild-type Behavior

89

7. 6 Modeling Mutation

90

7·7 Mutant Behavior .

94

7.8 Tumor Emergence

96

7·9 Results . . . .
7.10 Conclusions.

99
115

8 CONCLUSIONS.

120

REFERENCES . . . . . . . . . . . . . . . . . . . . . . . . .

123

ApPENDIX A
A.l

R CODE FOR PROBABILITY MODELS

Estimating Prevalence of Colon Cancer: Constant Mutation, Constant Stem Cell Population . . . . . . . . . . . . . . . . . . . . . . .. 148

A.2 Estimating Incidence of Colon Cancer: Genomic Instability Model. 165
ApPENDIX B

R CODE FOR GEOMETRIC MODEL

182

B.l

Setup . . . . . .

182

B.2

Mutation Model

183
186

B.3 Infection Model

viii

B.4 Binning Data . . . . . . . . . . . . .

188

B.5 Converting Incidence to Prevalence

191

B.6 Build Final Data Frame

194

B.7 Prevalence Plot . . . . .

197

B.8 Euclidian Distance and Plot

199

ABM ODD

203

ApPENDIX C
C.1

Overview . . . .

203

C.2

Design Concepts

208

C. 3

Details . . . . . .

21 5

ApPENDIX D

246

ACRONYMS

CURRICULUM VITAE

ix

LIST OF FIGURES

Figure 5.1

Modeled Incidence, Mutation

Figure 5.2

Prevalence of JCV .

Figure 5.3

Incidence, COP ..

Figure 5.4

Euclidian Distance Between Modeled Incidence and Observed Incidence, Using Original Parameter Values

Figure 5.5

Incidence, CNP . . . . . . . . . . . . . . . . . . . . .

Figure 5.6

Euclidian Distances between Models With New Parameter
Values . . . . . . . . . . . . . . .

68

Figure 5.7

Incidence, Genomic Instability

71

Figure 5.8

Euclidian Distance, Genomic Instability

72

Figure 6.1

Modeled Incidence, Geometric Model .

79

Figure 6.2

Modeled Prevalence,Geometric Model .

80

Figure 6.3

Euclidian Distance, Geometric Model

81

Figure

7.1

Modeled Prevalence of JCV

86

Figure

7.2

Modeled Colon Crypt ...

88

Figure 7.3

Age Distribution of Colorectal Cancer by Model

99

Figure 7.4

Age Distribution of Colorectal Cancer by Model

100

Figure 7.5

Example of Initiating Event

102

Figure 7.6

Initiating Events . . . . . . .

103

Figure 7.7

Creating an Immortal Cell .

105

Figure 7.8

Creating an Immortal Cell .

106

Figure 7.9

Role of Infection in Colorectal Cancer

108

Figure

7.10

Number of Tumors by Model

110

Figure

7.11

Metastatic Cell Type
x

Figure 7.12

Modeled Prevalence, ABM .

116

Figure 7.13

Euclidian Distances, ABM .

117

xi

CHAPTER 1

1.1

THE BARRIERS TO CANCER

OVERVIEW

Multicellular organisms have evolved several mechanisms to prevent an individual cell from dividing uncontrollably, a process that results in cancer and possibly
death. These mechanisms include: tight regulation of the cell cycle; using apoptosis to kill cells that have accumulated too much damage; limiting the cell's
maximum number of divisions; and keeping the cell anchored to the matrix of
underlying tissue. It happens that interfering with these mechanisms can drive
a cell to divide uncontrollably, leading to the formation of tumors. It is for this
reason that these mechanisms have been identified as "cancer barriers", as when
their presence prevents tumors from forming. These barriers can be removed via
any combination of mutations (somatic or germline), non-infectious environmental carcinogens, and infection. The following chapter will review each barrier, the
relevant signaling pathways, and provide examples of how each barrier can be
removed.

1.2

WHAT IS CANCER?

Imagine if the cells in your body began to divide uncontrollably and without
limit. Within a relatively short amount of time, the progeny of those cells would
. form large masses of tissue, called tumors, in and on your organs. Those organs
would soon cease to function normally, and death would be imminent. It is for
this reason that cells of multicellular organisms have evolved several sophisti-
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cated mechanisms, herein referred to as cancer barriers, that regulate when and
where cells can survive and divide. These barriers have been subject to positive selection, as without them the individual would never survive to reproduce.
However, transforming from a normal cell into a cancer cell is not like flipping a
switch, which occurs in an instant; instead, tumor progression is a multistep process that can take years to complete. Through careful examination of many types
of cancers, researchers have been able to identify many of the common steps that
occur during tumor progression, each of which is considered a hallmark of cancer [67, 50]. We will now briefly review how each barrier protects the individual,
and how disruption of the barrier provides that cell with a selective advantage,
driving it one step closer to evolving into a cancer cell.

1.2.1

De-regulation of the Cell Cycle: Pro-growth and Anti-growth Barriers

One of the largest barriers to cancer is the extremely tight regulation over the cell
cycle, which determines when and where a cell can divide. The cell cycle consists
of four distinct phases: G1,S,G2,M. When a cell is stimulated to divide it starts
an intracellular signaling cascade that stimulates the formation of CDK:cyclin,
which in turn catalyzes the phosphorylation of pRb. Hypophosphorylated pRb
keeps the cell frozen in Gl by binding to the E2F transcription factors [146]; phosphorylation deactivates the inhibitory properties of pRb, freeing the transcription
factors and driving the cell into S phase.
DNA replication takes place during S phase. Afterwards, the cell makes sure
that no significant DNA damage has occurred during replication, and if there
is not any the cell continues on into the G2 phase. Gz is in tum followed by M
phase, which consists of mitosis (division of DNA between daughter cells) and
cytokinesis (division of cytoplasm and organelles between daughter cells). Afterwards, the cell moves back into G1 . Once in G1, the cell ensures that it received
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the correct number of chromosomes, and if it did not it commits apoptosis (cell
suicide).
The cell cycle is primarily regulated in two ways: 1) the cell is stimulated to
divide in the presence of pro-growth signals; 2) the is cell forced to stop dividing in the presence of anti-growth signals. Pro-growth signals typically come in
the form of growth factors. Growth factors are secreted by other cells, and when
they bind to another cell's growth factor receptor, they stimulate that cell to divide by inactivating pRb. If a cell is not stimulated by enough growth factors
it will remain in G1; if in G1 for a prolonged period of time, the cell is said be
in a quiescent state termed Go. Anti-growth signals come in the form of soluble
signals and embedded signals, which can block cell division in one of two ways:
either they force the cell into the Go (quiescent) state, or they force the cell to
relinquish its ability to divide, usually due to terminal differentiation[50]. Normal cells have thus evolved pro-growth and anti-growth barriers to regulate cell
division, helping prevent uncontrolled growth.
Cancer cells de-regulate the cell-cycle by removing the pro-growth and antigrowth barriers that normally determine when and where the cell can divide.
The pro-growth barrier is frequently removed in one of three ways: 1) the cell
starts producing its own growth factors (autocrine stimulation); 2) the cell produces growth factor receptors that are permanently activated; 3) the signaling
pathway from the growth factor receptor is altered [67, 50]. No matter the path,
the result is that the cell divides even when it is not externally stimulated by
growth factors. Similarly, the anti-growth barrier can be removed in several different ways, although most of them converge on pRb [50]. The reason for this
convergence is that if pRb is removed, the cell will always move from Gl into
S phase, preventing the cell from entering a quiescent state. Another common
strategy for removing the anti-growth barrier is to avoid terminal differentiation,
thus allowing the cell to continue dividing. A cancer cell might accomplish this by
constitutively producing the Myc protein, which supplants Mad in the Mad:Max
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complex, creating Myc:Max, a protein complex that that impairs differentiation
and promotes growth [41].
While some have argued that the pro-growth barriers and anti-growth barriers
are separate and distinct [50], others feel that the two should be combined into
one barrier [38,93]. The debate arises because the two barriers often converge on
the same pathways, and both lead to a cell that constantly divides. For example,
removal of pRb is said to remove the anti-growth barrier, yet up-regulation of
CDI<4 (which is in the same pathway as pRb) is said to remove the pro-growth
barrier (reviewed in [93]).
Regardless of whether or not the two barriers are distinct, their removal increases their replication rate, resulting in increased fitness. This cell will then
experience positive selection, as it can replicate more frequently, leading to an
increase in its frequency throughout the population.

1.2.2

Apoptosis Barrier

Removal of the pro-growth and anti-growth barriers bring the cell very close
to uncontrolled growth. However, there are several cell-cycle checkpoints that
ensure the integrity of the cell's DNA; if the cell has accumulated too much damage (i.e. too many mutations, incorrect number of chromosomes, etc. .. ), the P53
protein accumulates. Accumulation of P53 stimulates the transcription of p21, a
Cyclin Dependent Kinase (CDK) inhibitor. When there is too much DNA damage,
P53 indirectly halts the cell cycle, giving the cell time to repair the damage. If
the damage cannot be repaired, P53 activates Puma (P53 up-regulated modulator
of apoptosis), which binds to, and inhibits, the omnipresent anti-apoptotic Bcl-2
protein, increasing the permeability of the mitochondrial membrane, allowing for
the secretion of cytochrome c. Cytochrome c then stimulates a caspase cascade
that leads to cell suicide, a process termed apoptosis. Cells not only respond to
internal DNA damage, but also to other stressors, such as infection or hypoxia
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[67, 74]. Furthermore, cells can also undergo apoptosis in response to external
signals, such as TNF-a or FASL, both of which might be secreted in response to
infection.
Given the stopping power of apoptosis, a cell that successfully removes both
pro-growth and anti-growth barriers still has a very good chance of being killed
off by the accumulation of too many deleterious mutations, being infected, or
experiencing hypoxia. Such a cell that is continuously dividing will almost inevitably acquire so many deleterious mutations that it undergoes apoptosis, thus
successfully removing a pre-cancerous cell. However, as one might suspect, the
apoptotic barrier is indeed removed in most cancers, as its removal provides the
cell with a selective advantage by increasing its survival rate. In fact, inhibition of
P53 by mutation alone is estimated to occur in 50% of cancers [51]. This statistic

not only testifies to the critical role of P53, but also to the importance of apoptosis, which is able to eliminate unhealthy cells. If those cells cannot be eliminated,
they remain free to divide, and thereby remove the remaining barriers.

1.2.3

Replication Limit Barrier

Removing the pro-growth, anti-growth, and apoptosis barriers should, theoretically, drive the cell to divide uncontrollably. However, it turns out that there is an
another barrier that limits cellular replication, and this one does not depend upon
cell-to-cell signaling. At the ends of each chromosome are several thousand 6bp
repeats called telomeres. After each division, -50 - 100bp of the telomeres are
lost, due to the inability of DNA polymerase to completely replicate the 3' ends
of chromosomal DNA during cellular division [67]. Over enough replication cycles, the telomeres are lost, the chromosomes fuse, the cell experiences crisis and
eventually is subject to apoptosis. In other words, the cell has its own internal
mechanism to limit the number of divisions it can undergo, and thus potentially
how long a cancer lineage would survive. However, 85 - 95% of cancer cells
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remove this barrier by up-regulating the expression of telomerase, an enzyme
that adds the 6bp repeat back onto the chromosome's ends [123]; the remaining
5 - 15% remove the barrier using a recombination-based inter-chromosomal ex-

change mechanism termed the Alternative Lengthening of Telomere (ALT) pathway [15]. Replacement of telomeres, and thus resetting of the cell's clock and
removal of the replication limit barrier, gives the cell a selective advantage by
giving it the potential to divide without limit.

1.2.4

Angiogenesis: An Intermediate Event

If a cell gains the ability to divide wherever it wants, without limit, it seems that

cell would be able to create a massive tumor in a short amount of time. However,
this is not necessarily the case. It has been demonstrated that tumors grown in
absence of a blood supply, such as in the anterior chamber of the eye, only grow
to 2 - 3mm [67,42]. Yet when these same cancer cells are placed in tissue with
a proper blood supply they are able to rapidly generate large tumors. It seems
that access to oxygen and nutrients, provided by the blood, are critical for large
tumor growth. It appears the reason that tumor size is capped at 2 - 3mm when
in a vessel deprived environment is that the tumor cell outgrow the other cells in
their micro-environment, including the oxygen supplying capillary Endothelial
cell (EC)s [42, 136, 135]. As the tumor grows, the distance between the innermost tumor cells and the nearest capillary increases. Lack of oxygen (hypoxia)
prevents those innermost tumor cells from replicating, as they are on the verge
necrosis. The tumor initially manages to supply the hypoxic cells with oxygen
first by co-opting the surrounding ECs. However, the inner-most tumor cells remain isolated from the co-opted blood vessels, and respond to their hypoxic
condition by over-expressing compounds, such as Vascular Endothelial Growth
Factor (VEGF) and fibrolast growth factor (FGF), that induce the production of
new blood vessels from pre-existing blood vessels, a process called angiogenesis
6

[1I8]. In fact, the amount of VEGF produced is enhanced by hypoxia [62], as the
most hypoxic tumor cells produce the most VEGF, creating a gradient of VEGF
from the hypoxic tumor cell to the oxygen supplying EC [58,73]. Taken together,
these observations suggest that VEGF produced by hypoxic tumor cells will lead
to the rapid extension of vessel tips, which will eventually "crawl" their way towards the hypoxic tumor cells. Once those cells receive the oxygen they crave,
they are able to divide, and the tumor grows beyond 2-3mm.
While angiogenesis is primarily activated by pro-angiogenic molecules like
VEGF and FGF, the process is also controlled by inhibitors, such as thromspondin.
Therefore, the must be more activators than inhibitors for angiogenesis to be initiated [67]. As angiogenesis permits an increase in size of an already growing
tumor, it generally considered an early to mid-stage event [50].

1.2.5

Metastasis Barrier

While cells dividing uncontrollably can lead to tumors, they may often be benign and removed surgically. If not removed early enough these benign tumors
may begin to produce cells that invade new tissues, a process call metastasis.
Unlike benign tumors these metastatic tumors are deadly, a fact illustrated by
the observation that 90% of human cancer deaths are from metastases [131]. The
acquisition of mobility is a complex process that is facilitated by angiogenesis.
Part of the reason for this relationship is that during angiogenesis the dividing
endothelial cells produce matrix metalloproteinases (MMPs), which break down
both the extracellular matrix and the basal lamina, a process which creates an
opening for mobile metastatic cancer cells to enter the blood supply [67]. A second reason is that VEGF also directly increases the permeability of the vascular
wall by loosening cell-cell contacts, making it easier for mobile cancer cells to
enter the blood stream (reviewed in Saharinen et al. [118]). Finally, the simple ex-
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istence of more blood vessels increases the opportunities for mobile cancer cells
to enter to blood stream and eventually invade new tissue.
As already noted, for a cell to gain entry into the blood stream it must first
acquire mobility. All cells have the fundamental molecular tools for locomotion, but most are rendered immobile because they are bound to the extracellular matrix via integrins, and to their surrounding cells via Cell-Cell Adhesion
Molecules (CAM)s , such as E-cadherin. Cancer cells, on the other hand, frequently have non-functional CAMs, allowing them to separate from their neighbors [67,5°]. Cancer cells also frequently have the ability to vary which integrins
they express, giving them the ability to attach to whichever surface they may
move to [50]. Together, loss of cell-cell adhesion and the an ability to bind to
different surfaces provides cancer cells the opportunity to separate from the primary tumor mass and move throughout the environment. Thus, while CAMs
and integins undoubtedly serve other purposes, they also serve as an effective
barrier that protects the individual from having rogue cells wander throughout
the body.
The next question is where should the mobile cancer cells go, and how do they
get there? Chen et a1. [21] have developed an agent based model to answer this
very question. This model is built upon evolutionary dispersal theory, which suggests that when there is resource variability (oxygen, nutrients, etc .. ) in the tumor,
such as when tumor-induced angiogenesis occurs, mobile cells are selected for,
as they have the ability to move to areas of high resource concentrations, such
as where new blood vessels have formed during angiogenesis. Mobile cells may
move towards the underlying blood vessels by producing proteases, which degrade the basal lamina, giving the mobile cell the ability to burrow through the
underlying tissue and enter the bloodstream.
Once in circulation the chances of cell survival are low. In an experiment cancer
cells were radioactively labeled and injected into the bloodstream of lab animals,
and after a few weeks only one in one thousand were still alive, indicating that
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very few cancer cells can survive in the bloodstream (described in [67]). However,
if that cell is able to survive the trip through the bloodstream and move into new

tissue (metastasize), it will, at least initially, be privy to additional resources. If
the other barriers have been removed, this metastatic cell will be able to divide
indefinitely, leading to the formation of a potentially deadly metastatic tumor
[so].

1.3

REMOVING THE CANCER BARRIERS

The causes of disease fall into one of three categories: genetic (mutation and
methylation), non-infectious environmental, or infectious [23]. However, in many
cases, diseases have primary causes and secondary causes; the disease cannot occur without the primary causes, and is exacerbated by the secondary cause(s) [38].
In much the same way, each cancer barrier can potentially be removed by mu-

tation (somatic or germline), non-infectious environmental factors, or infectious
agents [67]. As cancer is a multi-step process requiring the removal of several
protective barriers, it may also be that for many cancers there are also primary
and secondary causes. For example, cervical cancer may primarily caused by
HPV infection, but the rate of tumor progression may be accelerated by inherited
mutations in TNF-£x [153]. The following section will review how each of the
different causes can remove the barriers to cancer.

1.3.1

Genetic Changes and Genomic Instability

Mutations that remove cancer barriers can generally be divided into two categories: germline mutations and somatic mutations. A classic example of a germline
mutation that can increase the risk of cancer is the inheritance of one defective or missing pRb gene, which can increase an individual's risk of developing
retinoblastoma by 90% [67]. However, before retinoblastoma can actually develop,
9

the second copy of pRb must also be rendered defective. The dramatic increase
in cancer risk by simply removing pRb illustrates the protein's key role in regulating division, and how its removal can lead to de-regulation of the cell cycle,
allowing the cell to divide in the absence of growth factors [67].
Novel mutations can potentially occur every time a cell divides, as they result
from replication errors. It has been estimated that the probability of nucleotide
mis-incorporation is _10- 6 per replication event, but proof-reading exonucleases
and mismatch repair improves replication fidelity -1000 fold[143], leading to
a mutation rate of 10-9 , or one mis-incorporation for every 109 bp every cell
generation (J].
This extremely low mutation rate led Hanahan and Weinberg [50] to state that
"mutations are rare events, indeed so rare that the multiple mutations known to
be present in tumor cell genomes are highly unlikely to occur within a human
lifespan". This observation leads to two (not mutually exclusive) explanations for
how cells acquire the ability cause cancer: 1) one or more of the other categories
of barrier-removal is involved (i.e. non-infectious environmental, or infectious);
2) tumor cells have increased mutability, a phenomenon known as genomic in-

stability.
There are three types of genomic instability: increased point mutation rates,
Microsatellite Instability (MSI), and Chromosomal Instability (CIN). MSI may
be caused by mutations in Mismatch Repair Enzymes (MMR), which can cause
DNA polymerase to slip during replication of tandem repeats, resulting in the
insertion/ deletion of microsatellites [143]. CIN leads to alterations in large segments of chromosomes, including losses, gains, translocations, inversions, deletions, amplifications, and frequently aneuploidy [143]. Both MSI and CIN are
observed in cancers, as MSI is frequently seen in individuals with hereditary
non-polyposis colorectal cancer (HNPCC), while CIN is characteristic of most
cancers and will be discussed more thoroughly [93].
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Approximately seven genes have been associated with CIN and somatic mutation, which is believed to cause CIN through one of three pathways: chromosome segregation defects, telomere dysfunction, and dysregulation of DNA
damage response [102]. Normally, the mitotic checkpoint ensures that chromosomes are segregated properly, but mutations in genes that regulate segregation
can result in an unequal distribution of chromosomes, leading to aneudploidy
[102]. Some of the frequently mutated genes are: mitotic arrest-deficient (MAD),
budding uninhibited by benzimidazoles (BUB), anaphase-promoting complex/C
(APC/C; not to be confused with adenomatous poplyposis coli (APC) discussed
in Chapter 2)[102]. Additionally, an abnormal number of centrosomes can lead to
formation of multiple spindle fibers during mitosis, which can also result in aneuploidy [102]. Telomere dysfunction can induce CIN when telomeres become extremely short, as the ends begin to fuse with neighboring chromosomes, resulting
breakage-fusion-bridge cycles that can lead to dramatic genome reorganization[ 102].
However, if telomerase is up-regulated during later stages of cancer such CIN
may cease to occur, and the reorganized tumor cell may gain immortalitY[102].
Finally, impaired DNA damage responses can also induce CIN. Normally, DNA
damage responses protect the cell from exogenous and endogenous stresses by
initiating signaling cascades that result in cell cycle arrest or apoptosis. If the
DNA damage responses are impaired, the cell may accumulate large numbers
of mutations, some of which may result in CIN. Many of the genes involved in
these DNA damage responses are frequently mutated in cancers. Some of the
more commonly mutated genes include: ataxia telangiectasia mutated (ATM),
ataxia telangiectasia and Rad3-related (ATR) protein kinases, P53, BRCA1, and
BRCA2.[102]. Of them all, P53 mutations are the most common [93].
CIN can dramatically increase the rate at which the above barriers are removed. If one allele of a gene is mutated (either through inheritance, novel mutation, or methylation) the cell is considered heterozygous, and may still function normally. However, if the second allele is also knocked out, possibly by
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CIN, the heterozygous state is lost, a process known as Loss of Heterozygosity
(LOH) [67]. LOH is far more common than mutation, occurring
ery

1000

~

lOut of ev-

cell divisions[67], and on average results in the loss of 25%-30% of

all alleles in a tumor[102]. In fact, LOH is so common that it is considered the
"hallmark" of CIN-positive tumors [67, 102]. LOH is believed to be caused by
three different processes: mitotic non-disjunction, mitotic recombination, and
gene conversion.[67, 102]' During mitotic non-disjunction, one chromatid fails
to separate during mitosis, resulting in one cell that has 3 copies of a chromosome, and a second cell with only one chromosome. Thus, the cell with one
chromosome would have lost its heterozygous state [67]. Mitotic recombination
involves the exchange of DNA between homologous chromosomes, a process
that generates diversity. However, such recombination can also result in a cell
that is homozygous for an allele, should the swapped allele segregate with a homologous chromosome containing the same allele [67]. Gene conversion occurs
when one of the two homologous chromosomes copies and inserts a segment
of its DNA into the other homologous chromosome, resulting in a cell that has
three copies of the same allele[67]. After segregation, one of the cells will become
homozygous for that allele that was copied. LOH is so dangerous because if the
allele that becomes homozygous is a defective tumor suppressor gene, a barrier
to cancer will be removed and that cell will be one step closer to becoming a
cancer cell.
In addition to mutation, genes may also be silenced via epigenetic changes
(heritable changes not encoded in DNA) induced by methylation of a gene's
promoter region [67]. Methylation occurs when methyl groups attach to the 5'
position of a cytosine (C) nucleotide [67,4]. In humans, the promoter region of
DNA often contains unmethylated CpG islands. Transcription may be inhibited
if these CpG islands become methylated, effectively "silencing" the gene [67,4].

Such gene silencing via methylation is believed to be just as common as mutation,
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and so it is possible that mutation could remove one allele while methylation
silences the other [67,4].

1.3.2

Non-Infectious Environmental Carcinogens

The second way in which a cell's cancer barriers might be removed is via exposure to various non-infectious environmental compounds. Examples of such
chemical carcinogens include: polycyclic aromatic hydrocarbons (found in coal
tars, soots, and oils); aromatic amines (found in dyes, tobacco smoke); N-nitroso
compounds (some are present in cigarette smoke); alkylating agents (used in production of plastics, antifreeze, "mustard gas"); various inorganic substances (i.e.
asbestos); and other natural products, such as aflatoxin, a carcinogen produced
by the mold Aspergillus [67]. Many of these carcinogens are metabolized in the
liver, where they become electrophillic and thus tend to bind to electron-rich
DNA. The interaction between these carcinogens and DNA causes the DNA double helix to distort, resulting in an increased number of mutations during cell
division[67]. Once the damaged DNA molecule has been replicated, it can be
almost impossible for the cell to repair the damage, and so the mutation can be
inherited by daughter cells. Once a mutation has occurred, the growth of those
cells may initially be dependent upon promoting agent carcinogens. Over time,
however, these cells may acquire additional mutations or epigenetic changes that
allow them to divide in the absence of the promoting agent, leading to the evolution of self-sufficient cancer cell.

1.3.3

Infection

While it is not in the interest of a pathogen to induce cancer in its host, there are
several reasons why one would expect that most chronic pathogens would evolve
mechanisms that remove some of the cell's cancer barriers. De-regulation of the
13

cell cycle allows the intracellular pathogen to divide along with the cell while
minimizing detection by the immune system; inhibiting apoptosis would allow
the pathogen to survive infection-induced apoptosis; up-regulating telomerase
increases the number of divisions the host cell and its pathogen can undergo;
and removing metastasis barrier gives the pathogen the ability to move to different areas within the host, where it may have access to more resources or more
easily get transmitted to other hosts [38]. The virus can increase its intra-host
fitness by removing several barriers to cancer. However, a strain that frequently
removed of all barriers would have a lower inter-host fitness, as its host would
succumb to cancer soon after infection, limiting the number of possible transmissions. It may be that pathogens have to walk a fine line between these competing
levels of selection, and that many have struck a balance between intra- and interhost fitness. Evidence for this hypothesis comes from the observation that only
a small proportion of individuals infected by oncogenic viruses actually develop
cancer, suggesting that these viruses may only remove a few of the cell's cancer
barriers[38].
Perhaps one of the best understood examples of a pathogen being the primary
cause of cancer is that of human papilloma virus (HPV), the high risk strains (i.e.
HPV 16, 18, and 31) of which are the agents behind cervical cancer. While HPV
produces many different proteins during its life-cycle, only two appear to be required to transform a normal cell into a malignant cell [153]. These two proteins
are E6 and E7, and each is quite efficient at removing various cancer barriers (reviewed in [I53]). E6 activates the catalytic subunit of hTERT (human telomerase
reverse transcriptase), thus removing the replication limit barrier. At the same
time, E6 also removes the apoptosis barrier by binding to and degrading P53. Removal of apoptosis also results in the loss of the G 1 checkpoint, allowing the cell
to divide even when there is DNA damage, a process which may induce chromosomal instability [153]. While E6 is able to remove apoptosis and the replication
limit, E7 seems to playa key role in deregulating the cell cycle. E7 has the ability

to bind pRb, which frees the E2F transcription factors and drives the cell into S
phase, thus removing the anti-growth barrier. Furthermore, E7 is able to bind to
the CDK inhibitors p21 and P27, thereby increasing the levels of cyclins in the
cell and driving it to divide, thus removing the pro-growth barrier[153]. Combined, these observations suggest that high risk HPV is able to de-regulate the
cell cycle, up-regulate telomerase, inhibit apoptosis, and induce genomic instability. This only leaves the metastatic barrier remaining, which might be removed
by one of the other categories of barrier removal (i.e. mutation or non-infectious
environmental cause).
Hosts have evolved a complex set of mechanisms to protect against the damage
caused by infection, some of which may result in cancer. However, in this evolutionary arms race pathogens frequently have an advantage, as they are able to
evolve counter-strategies at a much faster rate due to their high replication rates
and short generation times. zur Hausen [153] developed the concept of three
Cellular Interfering Factor (CIF) pathways that the pathogen must overcome in
order to drive the cell to become malignant. The existence of such pathways were
"initially postulated to explain the restriction of tumor-virus gene expression in
proliferating cells, and the long latency period [-20-30 years] between primary
infection and the eventual emergence of invasive cancer" [153].
The first CIF pathway is CIF-I, which includes all pathways involved in pathogen
recognition by the immune system. For example, T-cells have the ability to recognize HPV antigens presented on the surface of infected cells. It is in the interest
of HPV to find a way to avoid elimination by the immune system. As it turns
out, HPV has indeed evolved a counter-strategy, allowing it to evade detection
by the immune system. The E5 protein of high-risk HPVs can down-regulate
the expression of both MHC class I and MHC class IT molecules, which present
antigens to CD8 and CD4 T-cells, respectively. This process is believed to delay
early recognition by the immune system, although it may not be sufficient to
permit persistent infection [153]. Some lucky HPVs might acquire the ability to
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avoid detection during persistent infection by being fortunate enough to be in a
cell that has also acquired mutations in human leukocyte antigen genes (HLA),
which encode HLA proteins. Indeed, HLA mutations are found in 90% of cervical cancers [153]. It seems reasonable to assume that a cell which has increased
genomic instability, possibly induced by HPV, would also be more likely to have
a mutation in one of these HLA genes, as more mutation events means there is a
greater chance the mutation will land in a particular locus.
The second eIF pathway, elF-II, is the collection of mechanisms that inhibit
the functioning of viral oncoproteins[153]. In the case of HPY, p16INK4 appears
to limit the effectiveness of E6, while p14ARF may be involved in moving E7 from
the nucleoplasm to the nucleolus, thereby preventing E7-induced degradation of
pRb [153]. However, this is only true in cells in which HPV can either express
only E6 or E7, but not both. When both proteins are expressed, E6 blocks effects
of p14ARF , while E7 is able to circumvent the activity of p16 INK4 . Together these
proteins are therefore able to II help II each other, blocking the cell's inhibitory
proteins, allowing HPV's oncoproteins to function.
The third elF pathway is elF-III, and includes all signals involved in paracrine
control, particularly cytokines and chemokines. In particular, TNF-ex (a cytokine
that promotes inflammation and/or induces apoptosis) appears to limit the growth
of HPV-immortalized cells, but not malignant HPV cervical cancer cells. This suggests that TNF-ex is able to limit growth of most HPV infected cells, likely through
the external stimulation of P53-independent apoptosis, and that something must
happen in order for them to become malignant. This IIsomething" might be mutations in the TNF-ex gene, a hypothesis that is supported by the observation that
many polymorphisms in the TNF-ex promoter increase the risk of cervical cancer
[153]·
There has likely been great selection pressure on pathogens to evolve ways to
circumvent these eIF barriers. Those strains that have such abilities will have a
much greater fitness, as they would be able to survive longer and replicate more
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frequently than strains that cannot overcome these barriers. In the case of HPV,
it seems that the high-risk strains have evolved such strategies to overcome the
three elF pathways, a feat which not only increases the fitness of those strains,
but simultaneously increases the risk of cervical cancer.

1.4

CANCER AS AN EVOLUTIONARY PROCESS

If a cell is able to remove the barriers to cancer, through any combination of the

mechanisms described above, it will gain a selective advantage [84].De-regulation
of the cell cycle gives the cell the ability to divide when and where others cannot;
inhibition of apoptosis reduces the probability of cell death; removal of the replication limit allows the cell to divide more times than other cells; metastasis may
give the cell the ability to escape a necrotic environment, moving to one that has
more abundant resources. Given the selective advantage conferred on these cells,
the removal of these barriers can be considered beneficial to the cell, but harmful
to the host.
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MUTATION AND COLORECTAL CANCER

OVERVIEW

Colorectal cancer, the third most common cancer in men and women, is expected
to kill

51,690

the past

20

ginning in

Americans in

2012.

Due to its relevancy, researchers have spent

years trying to understand what drives colorectal tumorigenesis. Be1990,

a hypothesis was put forth that specific mutations, commonly

observed in colorectal tumor tissue, occur in a preferred order and are largely responsible for tumorigenesis. Subsequent studies have built upon this hypothesis,
making it the most commonly accepted argument of colorectal cancer causation.
However, the last ten years have revealed that a common infection, the

IC

poly-

omavirus, is frequently associated with human colorectal tumors. ICV expresses
several viral oncoproteins that interfere with key cellular pathways, which is
known to cause cancer in lab animals. Both observations have led many to further investigate the role of ICV in colorectal cancer.

2.2

STRUCTURE OF COLON AND CRYPTS

The colon is roughly organized as an outer layer of smooth muscle, a central
layer of connective tissue, and an inner layer of absorptive epithelial lining. The
structural subunit of the colon is the colon crypt, a collection of
penetrate into the underlying submucosa

[127, 12].

-250

cells that

Each of these colon crypts is

sub-divided into three sections: the crypt base, the mid-crypt (a.k.a. the proliferative zone), and the upper crypt

[12].

As the cells of the epithelial lining are
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constantly shed into the lumen they must be replaced by cells generated from
the 4 - 6 pluripotent stem cells that reside at the crypt base [12, 105]. These stem
cells are defined by several abilities that set them apart from other cells: stem cells
remain undifferentiated; they are capable of proliferation and self-maintenance;
they are pluripotent (i.e. they can produce many different kinds of cells); they are
able to regenerate tissue after injury; they can divide indefinitely [12]. The cell
cycle time of these stem cells has been measured to be between 12 - 32 hours in
mice, and is believed to be 4 - 8 times longer in humans [104]. This means that
the stem cell cycle time in humans could be between 2 - 10 days; or, if the average
cell cycle time is 22 hours, the average stem cell cycle time should be about five
12+32
.
.
and a half days ( 2
x 6). ApproXImately 95% of the time colon crypt stem
cells produce one daughter transit amplifying cell and one daughter stem cell, a
process referred to as asymmetric division [79]. However, 5% of the time a stem
cell may undergo symmetric division, producing either two daughter stem cells
or two daughter transit cells [79]. If two stem cells are created, another stem cell
is lost by differentiation, displacement, or apoptosis [12].
The transit cells produced by stem cells migrate upwards into the mid-crypt,
where they gradually mature into one of four different cell types: absorptive
colonocytes, mucus secreting goblet cells, and peptide producing endocrine cells
[127]. As the transit cells migrate through the mid-crypt, they continue to repli-

cate along the way; it has been estimated that 60% of the cells in the crypt are
replicating, and most can be found in the bottom two-thirds of the crypt [103].
By the time the transit cells have differentiated, they have moved into the uppercrypt. As transit cells migrate towards the lumen they lose their ability to replicate, possibly because the upper-crypt lacks appropriate growth factors [103].
This limited replicative ability has been confirmed in studies demonstrating that
cells in the upper crypt do not have the ability to regenerate a crypt after radiation injury [52]. Eventually, the differentiated cells reach the most superficial
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part of the epithelial lining, where they undergo apoptosis and are shed into the
lumen [127, 12].

It has been estimated that adding an additional stem cell to a crypt could create
an additional 60 - 120 cells in the crypt, possibly leading to dysplasia [103]. It is
for this reason that the number of crypt stem cells is tightly regulated. It also appears stem cells cannot efficiently repairing DNA damage and often undergo P53
mediated apoptosis [12]. These lost stem cells can then be replaced by symmetric
division. Not only does this process help regulate the number of stem cells in the
crypt, it also prevents the accumulation of carcinogenic mutations [12].
If a mutation provides a stem cell with an advantage or is neutral (possibly

because it is a recessive mutation), that mutation may spread through the crypt
via a niche succession, a process which appears to 'be somewhat stochastic and
dependent upon symmetric division [56, 12]. The process of niche succession
begins when a mutated stem cell produces two daughter stem cells during symmetric division. Afterwards, the mutation is present in each of the two stem cells,
as well as each stem cell's progeny. As this process is repeated, a mutation may
come to be present in all cells in the crypt, a phenomenon that has been estimated
to occur every 8.2 years in humans [63]. Niche succession might be accelerated if
the mutation occurs in a tumor suppressor gene or oncogene, which can increase
the replication and survival rate of the cell [56].

It appears that a mutation might not only be able to spread within a crypt, but
it might also be able to spread between crypts. If a mutation occurs in a gene
that regulates apoptosis, such as P53 or Bcl-2, the apoptotic regulation of stem
cell numbers is lost, leading to an excess of stem cells [12]. Should too many
stem cells accumulate, the crypt will respond by bifurcating, thus distributing
the number of stem cells between the two crypts, a process termed crypt fission
[12]. Thus, any mutations in that first crypt will now be in two crypts. One can

imagine how this can allow a mutation to spread throughout the colon. However,
it appears that crypt fission is a relatively rare event in humans, and has been
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estimated that there can be 30 years between crypt fission events suggesting that
a single mutation may spread across some, but not all, crypts [56].

2.3

MUTATION MODEL: THE CANONICAL VIEW OF COLORECTAL CANCER

Although the incidence of colorectal cancer has been decreasing over the past two
decades, it remains the third most common cancer in the men and women [1].
In 2012, it is estimated that there will be 143,000 new cases of, and 51,690 deaths

from, colorectal cancer [1]. It is also estimated that 50% of the entire Western
population will develop a colorectal tumor by the time they are 70 years old, and
that 10% of those will develop into malignant tumors [64].
Beginning in the 1990S, researches began to put together a theory of colorectal cancer that remains strong to this day [56]. At its heart, this theory argues
that colorectal cancer is initiated by a mutation in a single gene, and that tumorigenesis progresses by the sequential accumulation of other specific mutations.
The process of accumulation is believed to be accelerated by genomic instability
[64, 39]·
Many of the important genes involved in colorectal cancer have been identified
by studying two heritable forms of the disease, Family Adenomatous Polyposis
(FAP) and Hereditary Nonpolyposis Colorectal Cancer (HNPCC) [}9]. FAP is a
dominantly inherited disease that affects ~ lout of 7,000 individuals (or < 1% of
all colorectal cancer cases), while HNPCC accounts for 2 - 4% of all colorectal cancers [64]. In both diseases the median age of developing cancer is 42,
while the median age of sporadic colon cancer is 67 [64]. In the case of FAP,
researchers have identified five genes that are commonly mutated in colorectal
cancer: Adenomatous Polyposis Coli (APC), Kristen Rat Sarcoma Virus (KRAS),
OCC, SMAD, and P53 [39, 28, 64]. It was also discovered that mutations in
Mismatch Repair Enzymes (MMR), such as MHS2, MLH1, MSH6, and PMS2, are
common in HNPCC patients [64,4]. It has been estimated that these MMR muta-
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tions lead to a 2 - 3 fold increase in the mutation rate, making it more likely that
a tumor-suppressor is knocked out or an oncogene activated, leading to tumor
formation [64]. Together, these observations have led researches to conclude that
colorectal cancer develops via the sequential accumulation of specific mutations,
a process which is often accelerated by genomic instability

l39, 64]. Furthermore,

it has been argued that these mutations may spread throughout the crypt via
niche succession, leading to monoclonal conversion of the crypt

l39, 56]. The fol-

lowing sections will review the role of each gene, the proposed timing of each
mutation, and how it drives tumor progression.

2.3.1

APC Mutation Required for Formation of Aberrant Crypt Foci and Early Adenomas

APC regulates the amounts of j3-catenin, the central protein in the Wnt pathway,
which is involved in activating cellular proliferation during development[67l Under normal conditions j3-catenin is degraded by a multi-protein destruction complex that contains APC, Glycogen Synthase Kinase 3 (GSK3), and axin. When
this destruction complex is assembled, GSK3 catalyzes the phosphorylation of
j3-catenin, marking j3-catenin for destruction by proteasomes, leading to a low
concentration of j3-catenin within the cell [67]. However, if an extracellular Wnt
protein binds to a transmembrane Wnt receptor, the destruction complex is prevented from forming, leading to an accumulation of cytoplasmic j3-catenin [67].
j3-catenin accumulates, moves to the nucleus, binds to and activates several transcription factors, such as T-cell Factor (TCF) [83]. The TCF:j3-catenin complex
then activates transcription of mye, preventing cellular differentiation and allowing the cell to divide [142]. Interestingly, j3-catenin also plays a major role in colon
crypt organization, as its expression is down-regulated in the mid-crypt (due to
a decrease in Wnt signals), resulting in cell cycle arrest and differentiation in the
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mid-crypt [142]. Finally, given that other catenins bind to cadherins, it has been
suggested that j3-catenin might also be involved in cellular adhesion [64,40].
It has been discovered that FAP patients have a deletion in one of the two copies

of chromosome 5q [39]. Further research has revealed this deletion is in the APC
gene, and that this deletion results in a truncated and non-functional APC protein [64, 134]. Truncated APC losses its ability to form the destruction complex,
leading to the accumulation of j3-catenin, preventing differentiation and driving
the cell to divide [67], essentially giving the mutated cells a stem cell phenotype
[4]. It is believed FAP patients, being APC+I-, have an increased rate of crypt
fission, allowing the mutation to spread within the colon [56]. However, the true
effects of losing the tumor suppressor abilities of APC are not felt until both
alleles are lost via a mutation or methylation of the normal APC allele [56, 37].
When APC is completely lost, it is believed that transit cells acquire the ability
to divide in the mid-crypt [56]. These APC-I- these cells will then out-replicate
their heterozygous neighbors, leading to monoclonal conversion of the crypt [56].
The combination of monoclonal conversion and crypt fission is believed to lead
to the formation of dysplastic Aberrant Crypt Foci (ACF) (a.k.a. microadenomas),
which are microscopic collections of abnormal crypts [56]. Formation of ACF is
also considered the earliest stage of colorectal cancer, and may lead to the formation of early adenomas (benign epithelial tumors) [39,64].
The removal of APC is often considered the initiating event of colorectal cancers because it is frequently found in ACFs as well as 78% of adenomas [56,60].
Furthermore, APC is lost in 80% of sporadic colorectal cancers, again suggesting that loss of APC is a common mode of initiating colorectal tumorigenesis
[56]. However, it has also been discovered that 15% of colorectal cancers do not
have APC mutations, an observation that suggests other mutations are capable of
initiating tumorigenesis [129]. Gain of function mutations in j3-catenin are also
commonly found in colorectal tumors, occurring in -50% of colorectal tumors
with wild-type APC [130], and thus may account for some of the 15% of cases
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without APC mutations. However, it has also been demonstrated that adenomas
with altered

~-catenin

with APC mutations

are less likely to progress to malignancy than adenomas

(~-catenin

mutations were found in 12.5% of small adeno-

mas, but only in 1.4% of malignant tumors), indicating that APC and

~-catenin

mutations do not have the same effect [119]. Even so, the frequency of APC and
~-catenin

mutations indicates that the Wnt pathway plays a central role in col-

orectal tumorigenesis.

2.3.2 KRAS Mutations Drive Early Adenoma to Intermediate Adenoma

The Ras-MAPK pathway is involved in stimulating cell division in the presence
of growth factors [67]. The signaling cascade is initiated when a growth factor,
such as PDGF or EGF, binds to a growth factor receptor. This binding activates
Ras via phosphorylation, initiating a cascade of intracellular protein kinases (Raf,
MEK, and MAPK) [67]. These kinases in turn: activate the production of nuclear
transcription factors (Ets, Jun, Fos, Myc, and E2F), resulting in the synthesis of
cyclins and CDK molecules that phosphorylate pRb, driving the cell into S phase,
resulting in division [67].
Mutations in KRAS (the gene that encodes the Ras protein), which are found in
40% of sporadic colorectal cancers, can produce a hyperactive form of Ras which
drives the cell to divide even in the absence of growth factors [67, 4]. KRAS
is thus considered an oncogene because mutating it results in a protein that
forces cell division. There are several reasons why it believed KRAS mutations
are responsible for driving an early adenoma to late adenoma [64]. First, KRAS
mutations are found in 50% of adenomas greater than 1cm, but only in 10% of
adenomas less than 1cm. This observation suggests that knocking out Ras might
be required for the tumor to grow more than lcm, after the formation of ACF [39].
Second, it has been discovered that while cells with only KRAS mutations are
hyperproliferating, they do not result in the formation of ACF [60], suggesting

that KRAS mutations are able to accelerate tumorigenesis, but not sufficient to
initiate it.

2.3.3

18q Deletions May Drive Intermediate Adenoma Into a Late Adenoma

I8q deletions are the second most common region lost, and are found in 70% of
colorectal carcinomas and 50% of late adenomas, suggesting that this deletion
drives the formation of late adenomas [39]. There is debate over which genes
are responsible for this shift, although recent candidates include SMAD proteins,
OCC , and cables [102].
SMAD is a protein involved in the

TGF-~

(transforming growth factor) path-

way. The binding of TGF-~ to a TGF-~ receptor (TGFR) triggers the phosphorylation of SMAD [67]. Once activated, SMAD moves the nucleus, where it initiates
transcription of the cell-cycle inhibiting proteins p2I and PI5 (recall that these
proteins inhibit Cyclin Dependent Kinase (CDK)s, preventing the formation of
CDK:cyclin complexes, which are required for division)[67]. Thus,

TGF-~

and

SMAD normally inhibit cellular division. However, SMAD mutations can prevent the transcription of p2I and PI5, leaving the cell free to divide even in the
presence of anti-growth signals, such as

TGF-~.

It has been estimated that 30%

of colorectal cancers have SMAD mutations, and it is believed that these mutations drive intermediate adenomas into late adenomas by increasing the rate of
cellular proliferation [28].
The second most commonly lost region in FAP patients occurs on chromosome
I8q, a region that contains OCC [39, 4]. It was initially believed that OCC is involved in cellular adhesion, as it has significant homology to adhesion molecules
[39]. However, more recent research indicates that DCC is involved in cell growth,
particularly that ofaxons [4, 83]. It is believed that DCC inhibits cell growth
when it is not bound to its ligand, netrin-I [4]. Mutations in DCC are believed
to prevent the binding of OCC to netrin-I, a process that results in abnormal cell
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survival [4]. Even so, recent studies have found that DCC is lost in only about
6% of colorectal tumors, suggesting that it does not play a major role in most
colorectal cancers [102].

Cables is a linker protein that increases the tyrosine phosphorylation of CDKs
by non-receptor tyrosine kinases such as Src, Abl, and Weel [102]. These tyrosine kinases inactivate CDKs by dual phosphorylation at the N-terminal Thr-Tyr
sequence in CDKs, inhibiting cell cycle progression [83] . Thus, loss of cables,
through the 18q deletion, can decrease the concentrations of active tyrosine kinases, increasing the amount of active CDKs, driving the cell to divide. It has be
estimated that loss of cables occurs in 6 - 70 of sporadic colorectal cancers, and
that the other allele might be inactivated by hypermethylation [100].

2.3.4

Loss of P53 Drives Late Adenoma Into a Carcinoma

Researchers have discovered that FAP patients often have deletion in the small
arm of chromosome 17 (Le. 17P), which contains P53 l39]. Complete loss of P53,
through loss of 17P in one chromosome and mutation in the other P53 allele,
can prevent the cell from committing apoptosis, even in the presence of significant DNA damage. Even so, it appears that loss of P53, which occurs in 80% of
colorectal cancers, is a fairly late event in colorectal tumorigenesis [64, 5]. Loss
of P53 is found in 75% of colorectal carcinomas, but is rare in adenomas, suggesting that inhibition of apoptosis is required for an adenoma to develop into
a carcinoma (a malignant epithelial tumor) [64, 39]. Furthermore, patients with
inherited P53 mutations are not at a higher risk of developing colorectal cancer
[46], again suggesting that loss of P53 is not is sufficient for tumor initiation, but
is required for transformation from benign tumor to a malignant tumor.
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2.3.5

Other Mutations Required for Metastasis: Possible Role for the Pl3K Pathway

The above research suggests that APC or j3-catenin mutations initiate carcinogenesis, and that subsequent mutations in KRAS, SMAD, DCC, and P53 increase
cellular proliferation and survival, driving ACF to develop into adenomas and
eventually carcinomas, the aptly named adenoma-carcinoma sequence. The final
step towards metastasis is believed to occur via the accumulation of a variety of
other mutations [56, 64]. One pathway implicated in the metastasis of colorectal cancer cells is the PI3K-Akt pathway. This pathway is turned on when PI3K
becomes activated by Ras (which is activated in the presence of growth factors)
[83]. Activated PI3K catalyzes the addition of a phosphate group to PIPz, converting it to PIP3 [67]. PIP3 in turn recruits kinases which phosphorylate and
activate Akt and Rho/Rac/Cdq2 [67, 71, 83]. Akt is able to phosphorylate and
inactivate several cell cycle inhibitor proteins (p21,P27,MYT1,GSK3, and FOXO)
and pro-apoptotic proteins (Bad, FasL,caspase 8, and FOXO), thus encouraging
division and discouraging apoptosis [83]. Activation of Rho/Rac/Cdq2 changes
actin and myosin, altering the shape of a cell and inducing mobility, resulting in
creeping "ameboid" movement, which could play an important role in invasion
and metastasis [83].
Even though Ras plays a key role in activating the PI3K-Akt pathway, KRAS
mutations may not necessarily result in the activation of Akt or Rho/Rac/Cdq2.
This is because there is a regulatory protein, PTEN, in the PI3K-Akt pathway [67].
PTEN removes a phosphate from PIP3, converting it back to PIPz, thus preventing
the activation of Akt and Rho/Rac/Cdq2 [67]. In normal cells, concentrations of
PTEN are high in the absence of growth factors, and so Akt and Rho/Rac/Cdq2
remain inactive[67].
Recent research has revea.led that PTEN is silenced via promoter methylation
in 82% of Indian patients with sporadic metastatic colorectal cancer [114], and
that PI3KCA activating mutations are found in 32% of colorectal cancers [120].

Furthermore, PI3KCA mutations are only found in 2% of pre-malignant tumors,
but in 32% of colorectal tumors [120]. Taken together, this evidence suggesting
that PI3KCA mutations and/or PTEN silencing arises late in tumorigenesis, just
before invasion and metastasis [120].

2.3.6 COX-2 and Angiogenesis

It has been discovered that COX-2 is over-expressed in 43% of adenomas and

86% of carcinomas [32]. It is believed that over-expression of COX-2 results in an
increased production of prostoglandin E2, which regulates proliferation, survival,
migration, and invasion of colorectal tumors [48]. It is also believed that overexpression of COX-2 induces the production of VEGF and FGF, both of which are
involved in angiogenesis [44]. COX-2'S role in angiogenesis is supported by the
observation that homozygous deletion of COX-2 impairs the growth of tumors
and reduces tumor vascularity [148]. Thus, the over-expression of COX-2 may
accelerate the rate of angiogenesis, allowing the tumor to grow beyond 2mm.

2.3.7 How Many Mutations?

It has been estimated that the human genome contains more than 100 tumor

suppressor genes and oncogenes [67]. However, the above data suggests that only
a handful of mutations are frequently found in colorectal cancer, both inherited
and sporadic. Given that at least 4 - 5 mutations are required for carcinoma
formation, and at least one for metastasis, it has been estimated that a metastatic
tumor may develop after the accumulation of a minimum of 6 - 7 independent
mutations [39,64]. More recent genome wide sequencing studies have discovered
that colorectal tumors have an average of 80 mutations, but estimate that less than
15 of these actually drive tumorigenesis [149,72].

2.3.8

Genomic Instability And Tumorigenesis

As noted in Chapter I, it is argued that, given the low human mutation rate
(-10-9 per cell generation), it is unlikely that all of the genes required for tumori-

genesis can be knocked out within a human lifetime. As such, genomic instability
is often invoked to explain how all of the required genes could be "hit" by mutation [78, 77, 50]. Through the study of HNPCC and FAP patients it has been
discovered that patients with colorectal cancer do indeed exhibit genomic instability.
Microsatellite instability (MSI) has been called the "hallmark" of HNPCC [4].
Defective MMR enzymes, particularly MLHl, MSH2, MSH6, and PMS2, are common in these patients. The loss of DNA replication fidelity (i.e. insertion or deletion of microsatellites), due to defects in MMR genes, have been reported to
increase the mutation rate of HNPCC patients by 2 - 3 orders of magnitude
[7, 124, 36]. Microsatellite Instability (MSI) does not appear to be limited to HNPCC patients either, as it is found in 13 - 20% of sporadic colorectal cancers
[4,64]. MLHI appears to be the primary MMR gene affected, as it is methylated
in 80% of sporadic colorectal cancers with MSI [4]. Tumors with MSI also often
have frameshift mutations in the microsatellite region of the TGFR gene, making
the cell immune to the growth-suppressing effects of TGF-!3[64]. MSI tumors also
sometimes have defects in HLA genes, possibly resulting defective MHC proteins
that allow the tumor cell to evade elimination by the immune system [14].
While MSI is characteristic of HNPCC, Chromosomal Instability (CIN) is regarded as the hallmark of sporadic cancers, as it is observed in 65 - 70% of such
cases [102]. It is also observed that these CIN tumors do not usually have MSI or
higher mutation rates [7, 36], leading some to suggest that tumors only require
one type of genomic instability [64]. Even though CIN tumors do not have a
higher mutation rate, they do exhibit losses or gains of entire chromosomes and

a high frequency of Loss of Heterozygosity (LOH) , which can lead to complete
deactivation of tumor suppressor genes [102].
The three common methods of generating eIN involve chromosome segregation defects, telomere dysregulation, and defects in DNA damage responses [102].
In the case of colorectal cancer, the genes involved in chromosomal segregation
defects are kinetochore proteins involved in the spindle checkpoint (Le. hZWlO,
hZwilch/ FLJ 10036, and hRod/KNT), as well as Ding, a protein that is essential
for proper chromosome disjunction [145]. Plb, which regulates entry into mitosis and centrosome duplication, is mutated in up to 63% of colorectal tumors
[102]. It has also been reported that 77 - 90% of colon cancer cells have shorter

telomeres than the normal surrounding cells, suggesting that telomere dysfunction might also be playing a role in generating eIN in colorectal cancer cells (reviewed in [102]). Only P53 has been directly implicated DNA damage response
defects in colorectal cancer, and may playa permissive role for developing eIN,
likely by letting eIN cells survive despite having severe genomic abnormalities
[102].

Some research suggests that APe may also be involved in generating eIN. This
suggestion comes from the observation that APe also plays a role in cytoskeletal
regulation, and it has the ability to bind spindle micro tubules and centro somes
[102]. However, further investigation has revealed that the genomic instability in

mice with these APC mutations is quite different that that observed in actual
tumors [102]. This finding suggests that APC mutations can cause genomic rearrangements, but that these are not consistent with the CIN observed in tumors,
leading Pino and Chung to conclude that the role of APe in eIN is "provocative
but incompletely defined".
Given that eIN is so common in colorectal cancers, the next question is whether
or not eIN initiates tumorigenesis, or simply exacerbates it. Several studies have
demonstrated that eIN does indeed occur very early in the adenoma-carcinoma
sequence, as eIN is frequently observed in adenomas [125]. Once such study
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found that polyps less than 2mm exhibited CIN on chromosomes Sq, Ip, 8p, lSq,
and 18q, regions that contain many of the genes frequently mutated/lost in colorectal cancer. Mathematical modeling also suggests that CIN initiates colorectal
cancer, although it is difficult to find experimental evidence to support this model
[8S, 97, 12S]· Furthermore, currently there id no data that directly connects CIN
to the acquisition of specific mutations frequently observed in colorectal cancer,
making it difficult to prove that CIN initiates tumorigenesis[102]. Thus, the debate over whether CIN initiates tumorigenesis or simply accelerates it via LOH
continues [102, 126].
While many consider genomic instability a requirement of tumorigenesis, others believe that cancer can develop without such instability [9]. These authors
support their argument by noting that not all colorectal cancers exhibit CIN, and
that MMR mutations generally occur after APC mutations. Furthermore, these
authors argue that selection can drive the mutation to spread within the crypt,
and that selection would thus override mutation as the primary evolutionary
force driving tumorigenesis [9]. These authors also note that mutations in critical
genes, such as APC and PS3, are not truly recessive, and would provide a selective an advantage after a single mutation. Thus, an alternative hypothesis might
be that MMR and CIN do not playa critical role in tumorigenesis, but are simply
the result of mutations that provide the cell with a selective advantage. This hypothesis is also in line with the observation that the aneuploidy, a result of CIN ,
can sometimes inhibit tumor progression [102]. This might be interpreted as CIN
actually providing the cell with a selective disadvantage, leading to the selection
of cells that do not exhibit CIN.

2.3.9

Cancer Stem Cells

Given that transit cells are rapidly sloughed off, it is frequently argued that colon
crypt stem cells accumulate the mutations necessary to convert them into cancer
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stem cells [4, 102]. Cancer stem cells, which make up 0.25% - 2.5% of the cells in
a tumor, are defined as cells that have the ability to self-renew, perpetuate themselves for long periods, maintain the ability generate a variety of differentiated
cells, and have the ability to generate tumors when transplanted into other tissue [102]. However, there is now some evidence suggesting that transit cells may
undergo mutation and selection that enables them to linger in the crypt, giving
them time to accumulate the extra mutations required for tumorigenesis [56, 70]).
While there is no direct evidence to support this, such a process could explain
why colorectal tumors are often composed of differentiated cells [56].
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CHAPTER 3

3.1

IC VIRUS AND COLORECTAL CANCER

OVERVIEW

The last ten years have revealed that a common infection, the JC polyomavirus,
is frequently associated with human colorectal tumors. JCV expresses several
viral oncoproteins that interfere with key cellular pathways, and is known to
cause cancer in lab animals. Both observations have led many to investigate if
JCV is involved in colorectal tumorigenesis. The results from these studies have
generated a body of intriguing evidence implicating a role for JCV in colorectal
tumorigenesis.

3.2

POLYOMAVIRUSES AND TUMORS

The past 10 - 15 years have revealed that a common infection, JC Virus (JCV), has
tumorigenic potential and is frequently associated with a variety of tumors, including colorectal tumors[291. Such oncogenic potential likely results from JCV's
ability to interfere with many of the same pathways that are disrupted in the mutation hypothesis (see Chapter 2). JCV, belongs to the family of polyomaviruses,
which, prior to 2000, were grouped with the papillomaviruses (such as HPV)
under the family of papoviruses [471. Polyomaviruses are named for their well
known oncogenic abilities; poly is Greek for many, while oma is Greek for tumors,
together meaning "many tumors" [82]. There are five human polyomaviruses:
JC Virus (JCV) , BK Virus (BKV) (both discovered in 1971), Karolinska Institute
virus (KN), Washington University virus (WUV) (both discovered in 2007), and
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Merkel Cell polyomavirus (MCV; discovered in 2008) [47]. JCV, BKV, KIV and
WUV are all closely related to the non-human primate polyomavirus simian virus
40 (SV40), whose gene products are frequently used in the lab to induce tumors,
illuminating which pathways are often dysregulated during tumorigenesis [47].
MCV, a close relative of JCV, is linked to the rare but aggressive Merkel Cell
skin cancer (MCC) (reviewed in [47] ). Some of the evidence involved in this
revelation includes the discovery that MCC patients have MCV titers that are 59
times higher than controls [101, 139]; MCV is found in Merkel cell tumors, with
an average copy number of 5.2 MCVs per tumor cell [47]; and MCV's interacts
with several key proteins, such as pRb, HSC70, and PP2A [47]. Interestingly, even
though MCV is the cause of the rare MCC, it is a common virus, as 88% of adults
without MCC are seropositive for the virus [101].It is also widespread throughout the human body [47]. The explanation for this .pattern is that MCV is only
reactivated in the elderly or immunocompromised individuals, and that Merkel
cells may be especially susceptible to transformation by MCV [47]. As discussed
below, this is interesting because JCV, and MCV share many characteristics and
epidemiological patterns.
While JCV is associated with many tumors, it is most commonly known as being the etiologic agent behind the fatal Progressive Multifocal Leukoencephalopathy
(PML). JCV is able to infect the oligodendrocytes of the brain. If reactivation occurs, the virus becomes lytic, leading to demyelination and cytolytic destruction
of the oligodenroglia, resulting in PML [69, 82]. It is believed that immunosuppression is primarily responsible for the reactivation of JCV. This is supported
by evidence that 5% - 8% of AIDS patients develop PML, as they are severely
immunocompromised [6]. Finally, with regards to JCV's association to tumors, it
is interesting to note that the unusual astrocytes associated with PML are indistinguishable from tumor cells in high-grade glial neoplasia [47].
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3.3

JCv EPIDEMIOLOGY

JCV is a very common DNA virus, occurring in 45%-80.5% of adults [144, 18].
JCV is such a common virus that it can be found in all human populations [133],
suggesting that it has been with humans throughout our evolution, lending itself
to studies of human migration patterns [66]. However, as might be expected,
there are several different types and subtypes of JCV found in different regions of
the world, each identified by polymorphisms in their IG region: A (EU) is almost
exclusively found in Europe, B (Af2, Af3, B2, MY, SC, Bl, CY) is most common
in Africa and Asia, while C (Ah) is only found in a few regions in African (subtypes found in parenthesis) [49, 133]. The prevalence of JCV also varies around
the world: JCV DNA shed in urine samples was, on average, found in 13.8% of
samples in Europe, 11.85% of samples in Asia, and 8.9% of samples in Africa
[133]·
Seroprevalence studies for JCV antibodies show that seroprevalence increases
with age. In a study of 2,435 individuals in England and Wales, ranging in ages
from 1-69 years old, Knowles et al. [68] found that 11% of children under 5 years
of age are seropositive for JCV's VPl capsid protein, but that prevalence rises
throughout life, reaching 50% in the 60-69 year old age group 1. In a similar study,
Viscidi et a1. [144] examined the serum of 947 individuals attending out-patient
clinics in Rome, ranging in age from 1-93 years old. Like Knowles et a1. [68], the
authors found that JCV seroprevalence increases with age: the seroprevalence of
individuals 10 years of age was only 9.5%, but jumped to 50% in individuals
10-20 years old [144] . Seroprevalence reaches 68.8% by the time individuals are
40-49, and rna xes out at 80.5% in individuals older than 70 years of age [144] .
Finally, Egli et a1. [33] examined 400 blood donors in Switzerland for the presence

1

Seroprevalence values tend to be higher than prevalence values detected from urine samples, as described
above: In the study conducted by Egli et aI, the seroprevalence for ICV was 58%, while ICV DNA was only
found in 19% of urine samples l331
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of JCV antibodies, finding that 58% of individuals had IgG antibodies for JCV but
no IgM antibodies [33] .
The above studies reveal several aspects of JCV. First, the increasing seroprevalence and spike between the ages of

10-20

suggests that JCV is most frequently

acquired during childhood and adolescence. Second, the absence of IgM (the first
antibody produced during novel infection) and presence of IgG (which is characteristic of persistent infections) indicates that JCV is a chronic infection [90]. This
conclusion is buttressed by the observation that the same strain of JCV can be
found an individual's urine sample, taken several years apart from one another,
indicating the individual is persistently shedding the same strain, as opposed to
being reinfected by a different strain [65].
The above prevalence patterns have led researchers to conclude that transmission of JCV requires close contact, and that JCV is likely transmitted among family members [68]. This conclusion is supported by a study finding that, in Tokyo,
there is no evidence for different JCV genotypes spreading between the local
American and native Japanese populations [61]. Since JCV is frequently found
in urban sewage samples, many authors have concluded that the virus is spread
by consuming contaminated water and/or food, or by coming into contact with
contaminated surfaces (i.e. clothes, countertops, eating utensils, etc... ) (reviewed
in [47]). Once ingested, JCV infects the tonsillar tissue, where it is frequently detected [47,87]. However, JCV is also frequently found in the bone marrow and B
lymphocytes, which may help the virus spread to other tissues (i.e. colon, brain,
etc ... ) via the circulatory system [47,86]. It is believed that JCV eventually infects
the kidneys, where it establishes a persistent infection, leading to the frequent
shedding of virus via the urine [47].

3.4

JCv STRUCTURE AND LIFECYCLE

The circular dsDNA genome of JCV is S130bp long and is encased within a nonenveloped 72 pentamer capsid [47]. JCV's genome is evenly divided into early
and late regions, each with lengths of 2-4 kb and 2.3 kb, respectively [31]. The
early and late regions are separated by a Non-Coding Regulatory Region (NCRR)
that contains the origin of replication and transcriptional control elements, and
usually contains two 98bp tandem repeats that serve as enhancers [47, 31]. The
early region encodes the Large T Antigen (T-ag) (a.k.a LT), the Small T Antigen (tag) (a.k.a. ST), as well as several T' antigens (T'16S, T'136, and T'13S) which are
expressed from alternately spliced early transcripts [141]. Its noteworthy that
these early proteins are named tumor antigens because they were originally detected using antibodies from animals with tumors [47]. The late region encodes
the viral capsid proteins VPl, VP2, and VP3, as well as agnoprotein [47].
It is believed that JCV gains entry into the target cell by using its VPl protein
to bind the cell's GTlb SHT2AR serotonin receptor [34]. After attachment, JCV
enters the cell via clathrin-dependent endocytosis, a process in which the virus
is internalized through the inward budding of the plasma membrane, forming
clathrin coated pits [47, 82]. JCV is then delivered to endosomes and caveosomes,
facilitating the movement of the virus to the endoplasmic reticulum, where viral
un-coating is occurs [82]. Finally, JCV is translocated to the nucleus [82].
Once inside the nucleus, the transcription factors API, NF-1, NF-KB, NFAT, and
YB-1 bind to JCV's promoter region, leading to the transcription of early region

mRNAs, and eventually translation in the cytoplasm [82]. After translation, T-ag
accumulates to high concentrations and initiates cellular division by inhibiting
pRb (see below for more details). T-ag next binds to the origin of replication in
the NCRR , unwinds the viral DNA, and hijacks the hosts DNA polymerase to
replicate the viral DNA [31,82]. Eventually, T-ag suppresses early gene transcription and initiates transcription of the late viral genes, agnoprotein, VPl, VP2,
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and VP3 [82]. Agnoprotein is believed to associate with T-ag help regulate viral
replication [116, 59], while the latter three proteins are assembled together in the
cytoplam and translocated to the nucleus, where viral encapsidation takes place
[47]·
What happens after virion assembly appears to vary. Usually polyomaviruses
spread from cell to cell by lysing their host cell [47]. However, electron microscopy studies have demonstrated that virions can be secreted from the plasma
membrane of intact cells, suggesting that lysis is not always required for cell to
cell transmission [57, 22]. Furthermore, transformed cells may have some viral
DNA integrated into its host genome (not all of the genome has to be integrated
because viral replication is not required to sustain the tumor) [111]. In fact, such
integration may drive transformation because the absence of viral replication and
lysis, but expression of T-ag , can promote cell proliferation and tumorigenesis
[29]. With regard to colon cells, infected cells start to lose viral DNA soon after

infection, and is only detectable up to

21

days after infection, suggesting that

infected colon cells are more susceptible to transformation than lysis [111].
After successful infection, JCV remains with the host for the remainder of their
life. This is supported by the observation that individuals that are positive for
JCV excrete the same strain, have low levels of IgM and high levels of T-ag IgM
antibodies (see Section 3.3). During this period, healthy immunocompetent individuals do not exhibit any specific symptoms even though they have low levels of
viral gene expression and sporadic reactivation, a phenomenon that is observed
in 0.5-20% of individuals [31]. However, if the individual becomes immunocompromised JCV can become completely reactivated, leading to an increase in virus
titers and disease [31,47].

3.5

JCV ONCOPROTEINS AND THE HOST PROTEINS THEY MANIPULATE

JCV increases its fitness by manipulating many host proteins involved in the
cell cycle [47], leading to an increased number of replications for both JCV and
the infected cell. Furthermore, JCV has the ability to increase its survival by
inhibiting innate immune signaling [47]. As might be expected, these processes
increase the probability of oncogenic transformation. Finally, it is noteworthy that
many of the proteins JCV interacts with are the same proteins that are mutated
in the mutation model. The following section will review the plethora of proteins
JCV interacts with.

3.5.1

Large T-Antigen

The large T antigen of JCV plays a critical role in driving viral replication and
transforming cells [47]. Lab experiments demonstrate that infected cells expressing T-ag often become immortalized, can escape contact inhibition, and exhibit
anchorage-independent growth (reviewed in [47]). However, T-ag alone is sufficient to induce immortalization; only the combination of T-ag and hTERT (the
active unit of telomerase) is sufficient to bypass senescence and cell crisis, resulting in an immortalized cell (reviewed in [47]). JCV's T-ag induces these phenotypic changes by interacting with several proteins, including f3-catenin, pRb, P53,
P300/CBP, IRS-I, NbSl, and Bub!.
3.5.1.1

~-catenin

Several studies have demonstrated that T-ag is able to bind f3-catenin [111, 35, 45].
In particular, it has been determined that T-ag residues from 412-688 of T-ag

bind the 695-781 residues (C-terminal) of f3-catenin [45]. Experiments show that
expression of T-ag increases the level of f3-catenin within the cell [45]. T-ag is
also able to stabilize f3-catenin, possibly by preventing f3-catenin from binding to
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the APC/CKI/GSK-3j3 destruction complex [45]. Subsequent experiments have
shown that cells expressing T-ag also have increased levels of T-ag and j3-catenin
in the nucleus, while cells not expressing T-ag only have j3-catenin in the cytoplasm [45]. All together, these experiments demonstrate that T-ag is able transport j3-catenin into the nucleus [45]. Once in the nucleus, j3-catenin increases the
transcription of Myc, driving cell division [35, 67, 45]. The interaction of T-ag
and j3-catenin is significant because the interferes with the Wnt pathway much
like Adenomatous Polyposis Coli (APC) mutations. As it has been argued that
APC mutations initiate tumorigenesis, the finding that T-ag stabilizes j3-catenin,
the target of APC and the center of the Wnt pathway, suggests this may be a
mechanism by which T-ag can initiate tumorigenesis.
3.5.1.2

pRb

Like other tumor viruses, JCV's T-ag can interact with pRb [47, 91]. In fact, JCV
not only interacts with pRb itself, but also with other retinoblastoma proteins,
PlO3 and PlO7[47]. It has been determined that the N-terminal domain of T-ag
(which contains the LXCXE motif) is responsible for binding to the pRb family
of proteins [54]. Such binding of the pRb family proteins disrupts replication
inhibition, releasing E2F proteins, driving the cell to divide [47]. Furthermore,
mice with knocked out pRb, PlO7 and P103 are unable to halt the cell cycle in
Gl, even in the presence of limited resources, contact with other cells (Le. loss of
contact inhibition), and DNA damage [26, 117]. Thus, via its interaction with pRb
proteins, T-ag is capable of driving the cell into S phase, even under conditions
when replication would be normally prevented.
3·5·1.3

P53

Most viruses, including JCV, are able to inactivate the pro-apoptotic P53 protein.
T-ag accomplishes this by binding to P53's core DNA binding domain, thereby
inhibiting P53'S ability to act as a transcription factor [47, 122]. T-ag and P53

expression are positively associated, while T-ag and p21 are inversely related,
suggesting that inhibition of P53 also decreases the amount of p21, thus independently allowing for phosphorylation of pRb, driving the cell to divide [96].
The power of the relationship between pRb and P53 is increased by the fact that
T-ag's inhibition of pRb drives the cell to divide in the presence of DNA damage,
and inactivation of P53 prevents apoptosis or senescence in the presence of such
damage [47]. Another important role of P53 is its ability to inhibit angiogenesis,
especially in tumors [83]. Thus, inactivation of P53 may drive the cell to divide,
avoid apoptosis, and possibly prevent inhibition of angiogenesis. Given that P53
is mutated or deleted in 50% of human cancers [53], including colon cancer, inactivation of P53 by T-ag is important in that it provides' an alternative mechanism
by which this crucial tumor suppressor can be removed.
3.5.1.4

P300/CBP

While most studies suggest that T-ag inactivates P53, there are handful indicating that T-ag may also stabilize P53 (reviewed in [47] ). While the exact results
are unclear, it is hypothesized that such stabilization of P53 may T-ag the ability
to interact with P300/CBP [13]. CBP /P300 are proteins that act as adapters or
co-activators by using their acetyltransferase activity [47]. However, it turns out
that T-ag cannot bind P300/CBP in the absence of P53 [75]. Thus, T-ag may stabilize P53 so as to gain access to P300/CBP [13]. It is argued that T-ag binding to
P300/CBP, using P53 as an adaptor, can result in the production of Myc, driving
the cell to divide [128]. It has also been suggested that T-ag uses P300/CBP to
activate the promotors that are normally inhibited by pRb, such as E2F, again initiating replication [47]. Although how exactly T-ag acts on P300/CBP is unclear
[47], one might speculate that T-ag's interaction with P300/CBP inhibits apoptosis. Normally, P300/CBP acetylates P53, which is accompanied by the removal of
phosphates in the regulatory region of P53 [83]. The Ser residue in the transactivating region of P53 is then free to be phosphorylated, a process that can trigger
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apoptosis [83]. If T-ag inactivates P300/CBP (again, this is unknown), the protein
would not able to acetylate P53, leaving the phosphates in the regulatory region
intact, thus preventing apoptosis.
3.5.1.5

IRS-l

Insulin receptor substrate-l (IRS-I) is docking protein normally found in association with an insulin growth factor 1 receptor (lGF-IR) and the plasma membrane [83, 47]. However, T-ag has the ability to translocate IRS-l from the cytoplasm to the nucleus [106], resulting in cell division, inhibition of apoptosis,
and induction of genomic instability. IRS-l initiates division and inhibits apoptosis via its activation of the PI3K/ Akt pathway, which down-regulates cell cycle
inhibitors (p21,P27,MyTl,GSK3,and FOXO) and pro-apoptotic molecules (Bad,
FasL,caspase 8, and FOXO) [83,47]. Furthermore, nuclear IRS-l has been found
bound to

~-catenin,

resulting in increased transcription of Myc and cyclin D,

thereby increasing cell growth [20] . Nuclear IRS-l has also been found in a
complex with Rad51, which is the main enzymatic component of homologous
recombination directed DNA repair (HRR) [137]. It appears that T-ag, through
its interaction with IRS-I, impairs HRR, which might be compensated for by
an increase in non-homologous end joining (NHEJ), an alternative DNA repair
process [110]. However, this compensatory action of NHEJ is associated the accumulation of spontaneous mutations [140], increasing genomic instability.
3.5.1.6

Nbs 1

NbSI is a component of the MRN (Mrel1, Radso, NbSl) complex, and plays
an important in DNA repair and detection of double strand breaks (reviewed
in [47]). It is believed that T-ag binds to NbSl, and may result in chromosomal
instability, although the particular result of the interaction is largely unknown
[47]. This hypothesis comes from the observation that NbSI is mutated in the
Nijmengen breakage syndrome, which is associated with CIN and an increased

risk of cancer [47]. Finally, it has also been suggested that LT's binding to

NbSl

may allow for increased replication of JCV DNA [150].
3.5.1.7

Bub1

Bub1 is a mitotic checkpoint kinase and is critical in maintaining genomic integrity [25]. T-ag is able to bind Bub1, leading to a compromised spindle checkpoint [25]. Mice with reduced expression of Bub1 have increased tumorigenesis
and aneuploidy (reviewed in [47]), suggesting that T-ag's binding to Bub1 may
induce the Chromosomal Instability (CIN) that is so characteristic of colorectal
tumor cells.

3.5.2

Small t-Antigen

While T-ag is primarily a nuclear protein, t-ag is found in both the nucleus and
cytoplasm [47]. Like its big brother, t-ag has the ability to induce cellular proliferation, even in the absence of T-ag [47]. Microarray analyses have shown that t-ag
can alter many genes involved in proliferation, apoptosis, integrin signaling, and
immune responses [88]. Most of these alterations can be traced to t-ag's ability to
bind and inactivate the serine-threonine protein phosphatase PP2A [47]. PP2A
inactivation leads to stabilization of Myc and has a similar effect as PI3K, leading to increased rate of division, inhibition of apoptosis, and possibly increased
mobility [152, 151]. That t-ag has a similar effect as PI3K is significant because
PI3K is normally activated by Ras, and so may have a similar effect as mutated
Kristen Rat Sarcoma Virus (KRAS).
t-ag's inhibition of PP2A also leads to the activation of several kinases, including MAPK, Akt, and PKC( (reviewed in 47). Activation of MAPK (which normally requires growth factors) initiates the production or activation of several
transcription factors (i.e. Ets, Jun, Fos, Myc, and E2F) that drive the cell to divide
[67]. As discussed in Section 2.3.5, activation of Akt results in the inhibition of
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apoptosis. PKC(, is involved in activating NFKB, a protein that increases inflammation, stimulates cell division, and inhibits apoptosis [67, 83]. It is noteworthy
that several other viruses associated with tumors, either directly or indirectly (i.e.
hepatitis C virus, herpes simplex virus, HIV, and human T-cell leukemia virus),
also up-regulate NFKB [83].

3.5.3

Agnoprotein

Agnoprotein is produced late in the viral lifecycle and is primarily found in
the cytoplasm [27]. In addition to its regulatory role in viral transcription and
translation, Agnoprotein has the ability to circumvent the cell cycle checkpoint,
resulting in an accumulation of DNA damage [27]. While some of this many be
the result of Agnoprotin's ability to bind T-ag and P53, the primary mechanism
by which Agnoprotein generates genomic instability is through its binding of
KU70 and Ku80, DNA repair proteins involved in non homologous end joining
(NHEJ) DNA double strand break repair [27]. This has been demonstrated in an
experiment in which cells expressing agnoprotein were treated with cisplatin, a
DNA damaging agent. It was found that cells expressing Agnoprotein had significantly lower levels of KU70 and Ku80 than controls (which did not express
agnoprotein), resulting in aneuploidy [27]. The authors concluded that Angoprotein's localization of KU70 to the perinuclear region permitted evasion of the cell
cycle checkpoint, leading to the accumulation of DNA damage and CIN [27].

3.6

IN THE LAB: JCv AND TUMORIGENESIS

Given ICV's interaction with several key tumor suppressors and DNA repair
proteins, one might expect that ICV will have the ability to induce tumors. In- .
deed, lab experiments have demonstrated that ICV is capable of transforming
cells in culture as well as in laboratory animals. Transgenic experiments involve
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the insertion of an exogenous gene into the genome of a living organism. It has
been demonstrated that the expression of T-ag in intestinal enterocytes results in
hyperplasia, and eventually dysplasia (reviewed in 47). Furthermore, transgenic
mice that express T-ag and t-ag develop adrenal neuroblastomas, neuroectodermal tumors, pituitary adenomas, and malignant peripheral nerve sheath tumors
(MPNST) [82, 109]. Finally, it is noteworthy that T-ag positive cells eventually
lose expression of T-ag but maintain their transformed phenotype, suggesting
ICV may induce tumorigenesis by some sort of "Hit and Run" mechanism [109].
ICV not only has the ability to induce tumors in transgenic models, but injec-

tion of ICV is oncogenic in several animals, including hamsters, rats, and nonhuman primates [82]. ICV infection of newborn Syrian hamsters results in the
development of several different tumors, including medulloblastomas, primitive
neuroectodermal tumors, astrocytomas, glioblastoma multiforme, and peripheral
neuroblastomas [log]. It has also been demonstrated that hamsters innoculated
with the Mad-1 strain of ICV develop medulloblastomas, while those infected
with the Mad-4 strain develop pineocytomas and medulloblastomas, demonstrating that different strains can cause tumors in different cell types [98]. In the case
of rats, injection of the ICV Tokyo-1 strain into the brain results in undifferentiated neuroectodermal tumors in 75% of infected animals, some of which remain
oncogenic when transplanted into other rats [109]. Finally, owl monkeys and
squirrel monkeys infected with ICV develop astrocytomas, glioblastomas, and
neuroblastomas by 16-24 months of age [109].
All of the above animals are non-permissive for ICV infection, which may make
them more susceptible to transformation, presumably because they integrate ICV
DNA into their genome and are thus unable to lyse the cell, decreasing their intrahost transmission [111]. However, an equally important finding is that colonic
cells infected with ICV start to lose JCV DNA 14-21 days after infection, suggesting that colonic cells are also non-permissive to ICV infection and thus more
susceptible to transformation [111].
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3.7

AN ASSOCIATION BETWEEN JCV AND COLORECTAL CANCER

The above lab experiments demonstrate that ICV has the capacity to be tumorigenic in lab animals. However, there is considerable debate over whether or not
ICV is involved in human cancers. Even so, there is intriguing evidence that ICV
could indeed play such a role. Part of the argument comes from the observation
that 70% of colorectal cancers are caused by chance and environment" (muII

tation and environment), while 5% are from inherited mutations [9]. Similarly,
it has also been estimated that

~25%

of colorectal cancers result from multifac-

torial contributions of different risk factors [9]. While the authors argue that
these 25% of cases occur as the result of inheriting many rare dominant alleles
that have low penetrance, but together increase the risk of colorectal cancer [9],
an alternative hypothesis might be that infection is one of those critical environmental factors that accounts for increased risk to cancer. The hypothesis is
based upon the observation that ICV is frequently associated with many cancers,
including human brain tumors, lung cancer, esophageal cancer, gastric cancer,
(reviewed in [76]), and at least five independent laboratories (and several studies conducted by each lab) have detected both ICV DNA and T-ag in colorectal
tumors [69, 35, 55, 76, 96].
In 1999, the Laghi laboratory used semi-quantitative PCR to detect the presence
of LT in the mucosa of colorectal tumors as well as adjacent tissue [69]. The
authors detected T-ag DNA in 89% of 25 healthy colorectal cells, 25 colorectal
cancer cells, and 4 cancers, indicating that JCV is present in both healthy and
malignant tissue. However, subsequent semi-quantitative PCR revealed that the
ICV viral load is ten times higher in cancer tissue that in the adjacent healthy
tissue, suggesting that ICV is more active in tumor cells. However, the viral load
in these tumor cells is only 0.1 ICV viral copies per human genome [6g]. Rollison
[115] argues that there should be at least

1

viral copy per human genome, and so

the results of Laghi et al. [69] do not indicate that ICV is driving tumorigenesis.

Two follow-up studies by Ricciardiello et a1. were conducted to shed more
light on the association between JCV and colorectal tumors. Like Laghi et a1.
[69], the authors used JCV T-ag specific PCR primers to detect T-ag in 81.2%
of normal healthy colorectal tissues (the use of JCV specific primers is important because it allowed the authors to avoid amplifying other polyomavirus T-ag
sequences)[l12]' Further investigation revealed that only the Mad-1 strain of JCV
, which is characterized by two 98bp deletions in the NCRR, is found in healthy
and malignant colorectal tissue [112]. This is significant because it indicates that
the circulating archetype strain is unable to infect colorectal tissue, which was
confirmed by the finding that the archetype strain was absent in all samples [112].
The authors offer several hypothesis about why only the Mad-1 strain is found in
colorectal tissue: 1) genomic rearrangements resulting in the Mad-1 strain might
occur in non-lymphoid tissue, and then the Mad-1 strain uses lymphocytes to
infect the colon; 2) genomic rearrangements may occur in the colon, giving the
Mad-1 strain the ability to proliferate in colorectal tissue; and 3) Mad-1 may be a
circulating strain that has the ability to infect colorectal tissue [112]. The following year, 2001, further revealed that a variant of the Mad-1 strain, which lacks
one of the 98bp repeats, is found exclusively in colorectal tumors, but is absent
in the adjacent healthy tissue [113]. Given that higher viral loads are found in colorectal tumors, the authors suggest that the

~98

Mad-1 strain is more efficient at

proliferating in colorectal tissue. The authors also suggest that this strain of JCV
might be involved in the generation of CIN [113]. Using the information available, the authors hypothesize that transformation by the

~98

Mad-1 JCV strain

might occur through two mechanisms: 1) Mad-1 has a selective advantage in colorectal tissue, but some impairment of the immune system might select for the
~98

variant, which has the ability to transform cells; 2) Mad-1 integrates into the

human genome, and pre-existing genomic instability results in the
that is capable of transforming cells [113].
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~98

variant

In 2002, the Enam lab used PCR, microdissection, and immunohistochemistry
to detect ICV DNA and proteins in 27 colonic tumors [35]. The authors detected
early region DNA in 81.5% of samples, Agnoprotein DNA in 59.2% of samples,
and VP1 DNA in 14.8 % of samples[35]. Immunohistochemisty, which detects
proteins using specific antibodies, found the expression of T-ag in 62.9% of samples, Agnoprotein 44.4% in samples, but no VP1 protein in any samples [35].
This is significant, because the lack of VP1 protein suggests that JCV! ( JCV!) is
unable to replicate productively in these tumor cells. Subsequent laser capture
microdissection, which is capable of isolating specific cells, was conducted on
normal mucosa, precancerous adenomas, and invasive adenocarcinomas so as to
verify the presence ICV DNA and proteins in these tissues. Gene amplification
revealed that early ICV DNA and T-ag protein are found in both precancerous
adenomas and invasive adenocarcinomas, while only a "weak signal" of ICV
DNA is found in the adjacent healthy tissue [35]. These results suggest that JCV
is only found a few healthy tissues, but at higher concentrations in colorectal tumors, where T-ag is able to interact with key host proteins (i.e. P53 and pRb) [35].
Furthermore, the presence of T-ag and ICV DNA in pre-cancerous adenomas
and invasive adenocarcinomas suggests that ICV could potentially be involved
in initiating tumorigenesis, again by dysregulating key pathways such as the Wnt
pathway, apoptosis, and cell cycle regulation.
In a similar study, Hori et al. used nested PCR, Southern Blot, and immunohistochemistry to detect the presence of T-ag, Agnoprotein, and VP proteins in
23 colorectal adenomas and 20 healthy colonic mucosa from Iapan. The authors
detected T-ag in 26.1% of colorectal cancers, 4.8% of adenomas, and in 0% of
healthy colonic mucosa [55]. Consistent with the findings of Enam et al. [35], VP1
was not detected in any samples, but unlike Enam et al. [35], the authors were
unable to detect Agnoprotein in any samples [55]. The absence of VP1, which
indicates ICV is not actively replicating, suggests that ICV may integrate early

DNA in the the host genome, and that subsequent expression of T-ag is involved
in tumorigenesis [55].
That same year, 2005, Theodoropoulos et al. [138] used PCR to detect the presence of ICV DNA in Greek adenomas and adenocarcinomas, and real-time PCR
to determine the levels of expression. Similar to previous studies, PCR detected
ICV DNA in 61% of adenocarcinomas and 60% of adenomas[138]. Also like Laghi
et al. [69], real-time PCR detected a viral load of 9 x 103 to 20 x 103 copies/llg
DNA in adenocarcinomas and adenomas, but only 50-450 copies/llg DNA in
healthy tissue [138]. The finding that ICV viral load is much higher in cancer
tissue suggests that the higher concentration of ICV increases the risk of cancer.
The authors conclude that ICV is likely to be involved in initiating tumorigenesis,
possibly by inducing chromosomal instability [138].
In 2008, Lin et al. [76] also used PCR and immunohistochemistry to detect ICV
DNA, T-ag , and VPl in 22 colrectal tumors from Taiwanese patients. Similar to
previous studies, T-ag was detected in 63.6% of colorectal cancer tissues but not
in adjacent healthy tissue [76]. Again, VPl was not detected in any tissue [76],
suggesting that ICV integrates into the host genome.
Many of the studies above studies might be criticized because they lack large
sample sizes. However, in 2009 Nosho et al. [96] conducted a large scale study
of 766 colorectal cancer samples. The authors used immunohistochemistry to
detect levels of P53, P21, p-catenin, COX2, Cyclin 01, and ICV T-ag, as well as
whole-genome amplification to detect Loss of Heterozygosity (LOH) in the regions frequently associated with colorectal cancer (i.e. 2p, 5q, 17q, and 18q) [96].
The results show that expression of T-ag is positively associated with expression
P53 (p < 0.0001), nuclear p-catenin (p < 0.006), COX-2 (p = 0.02), and loss of p21
(p < 0.0001) [96]. The positive association of T-ag and P53, accompanied with
loss of p21 (which is activated by P53), strongly suggests that T-ag is able to dysregulate the P53 pathway [96]. T-ag's positive association with nuclear p-catenin
reinforces the argument that JCV is able to translocate p-catenin to the nucleus,
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thereby disrupting the Wnt pathway. The positive association between T-ag and
COX-2 suggests that JCV is able to induce angiogenesis. However, expression of
T-ag is not associated with alterations in Ras, PIK3CA, BRAF or cyclin D1 [96].
The authors also found that T-ag is over-expressed in 35% of colorectal cancers,
again suggesting that T-ag plays a key role in tumorigenesis. Finally, the authors
discovered that T-ag expression is significantly associated with CIN , which was
defined as LOH in chromosomes 2P, 5Q, 17Q, and 18Q [96]. This is noteworthy
because these are the same regions frequently lost in the mutation hypothesis.
While T-ag expression is not significantly associated with patient survival, the
authors conclude that T-ag likely contributes to CIN and dysregulation of the
P53 pathway, the combined effects of which may result in the uncontrolled proliferation of cancer cells [96].
In 2010 Del Valle and Khalili [29] examined 50 commercially available colorectal samples for immunoreactivity to T-ag. Thirty four percent of those samples
were positive for T-ag, and of those 88% were also positive for Agnoprotein,
while none expressed VP1 [29]. These results are significant because they are the
first to indicate that JCV T-ag can be found in commercially available tissue arrays Del Valle and Khalili [29], suggesting that JCV may be responsible for their
transformation. Also, like many previous studies, the absence of VP1 indicates
that JCV is incapable of productively infecting tumor cells, but that those cells
retain the ability to express T-ag and Angoprotein, promoting cell proliferation
and tumor formation [29].
That same year Niv et al. [95] determined JCV titers (using anti-bodies to VP1)
in patients undergoing colonoscopy, some of whom had colorectal cancer and
others who were healthy. This is an important study because it was the first
study to directly compare JCV titers in colorectal cancer patients versus healthy
patients (other studies compared tumor tissue to adjacent normal tissue). While
the sample size was fairly small (7 adenomas and

11

tumors), the authors ob-

served statistically significant higher titers of JCV in patients with advanced ade-
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nomas and tumors, compared to healthy individuals [115]. While the authors
found no correlation between T-ag expression and JCV seroreactivity, it was discovered that JCV antibody levels are higher in individuals with more advanced
disease, suggesting that immunosuppression and/ or JCV reactivation is involved
in disease progression [115].
While the above nine studies suggest that JCV is at least present in colorectal
tumors, and may drive tumorigenesis, there are a handful of studies that were
unable to corroborate those results. A study by Losa et a1. [80] was only able to
detect JCV DNA in one out of 100 colorectal tumors. Similarly, in 2004, Newcomb
et a1. [94] screened 45 healthy donors and 233 colorectal cancer patients for JCV
DNA. The authors were unable to detect JCV in any of colorectal tumor samples
[94]. However, Rollison [115] has noted that these conflicting results are likely to
due to differences in assay sensitivity, possible contamin~tion, and differences in
JCV prevalence in the populations examined. Indeed, Newcomb et a1. [94] have
been criticized for using novel primers (i.e. those not used in the positive studies),
as well as for not using any positive controls to verify that the primers worked in
their formalin-fixed paraffin-embedded samples, which are notoriously difficult
to work with as formalin fixation breaks DNA [10].
In addition to being associated with colorectal tumors, JCV has also been
found to induce chromosomal instability CIN , something many believe initiates colorectal tumorigenesis. Ricciardiello et a1. [111] have demonstrated that
T-ag alone is able to induce CIN. To do this, they used RKO cells, which are
a line of diploid colon cancer cells that express wild-type PS3, f3-catenin, and
APC. They transfected the RKO cells with Mad-l and the t198bp strain. Within
seven days the authors observed CIN, which was characterized by chromosomal
breakages, dicentric chromosomes, and aneuploidy [111]. The controls used in
the study showed no such CIN [111]. The authors concluded that T-ag's binding
of PS3 and f3-catenin are sufficient to induce CIN [111]. It also seems likely that
T-ag's interaction with NbSl, Bubl, IRS-I, and Agnoprotein's interaction with
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KU70, would also contribute to genomic instability. The observations made by

Ricciardiello et al. [111] are also consistent with the study by Nosho et al. [96],
who also found that T-ag expression is significantly associated with LOH , and
is defined as LOH in chromosomes 2P, 5q, 17q, and 18q. Ricciardiello et al. [111]
also observed that cells started to lose viral DNA soon after transfection, and was
only detectable by PCR 14-21 days after initiation of the experiment [111]. Given
these results, the authors proposed the following "hit and run" scenario for ICVassociated colorectal carcinogenesis: 1) after integration of viral DNA into the
host genome (a phenomenon common in polyomavirus transformed cells), expression of the early genes (particularly T-ag ) induces CIN, forcing most cells
might enter crisis, while fortunate few increase their fitness by removing key
tumor suppressors genes via CIN ; 2) those cells retain their transformed phenotype, but continue to lose ICV DNA, reducing the amount of CIN due to the loss
of T-ag; eventually the transformed cells that completely lose expression of T-ag
have the highest fitness, as they re-acquire genomic stability while retaining their
ability to divide without limit, leading to tumor formation [111].
Taken together, the above studies paint the following picture of how ICV might
induce tumorigenesis: 1) ICV is ingested by consuming contaminated water, and
establishes a persistent infection in the kidneys; 2) ICV infects lymphocytes, and
if the Mad-l strain has evolved (either in the kidney, lymphocytes, or colon cells)
ICV is acquires the ability to infect colon cells; 3) once the Mad-l strain infects
the colon, it integrates into the genome, preventing productive infection and thus
expression of VPl; 4) if the

~98

Mad-l strain evolves, possibly due to genomic

instability, T-ag is expressed at high levels, dysregulating the cell cycle and inhibiting apoptosis, driving the cell to divide uncontrollably and inducing CIN; 5)
eventually the cell loses key tumor suppressor genes, along with expression of
T-ag, resulting in a T-ag independent transformed cell. An alternative model is
that ICV Mad-l is able to infect colon cells, and reactivation, due to some sort of
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immunosuppresion caused by mutations in the Cellular Interfering Factor (CIF)
barriers, gives ICV the ability to deregulate the cell cycle and inhibit apoptosis.
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CHAPTER 4

A NEED FOR MODELING

The reviews in Chapters 2 and 3 reveal that there are two models of colorectal
tumorigenesis, the Mutation model and the Infection modeL At its core, the Mutation model proposes that key genes are preferentially removed in the following
order: Adenomatous Polyposis Coli (APC), Kristen Rat Sarcoma Virus (KRAS),
I8q, P53, and perhaps PI3K. One might conclude that the Mutation model hypothesizes that the cancer barriers are removed the the following order: antigrowth (APC mutations prevent differentiation), pro-growth (KRAS and SMAD
mutations allow the cell to divide in the absence of growth factors), apoptosis (inactivation of P53 inhibits apoptosis), metastasis (PI3K mutations activate
Rho/Rac/Cdq2).
The Infection model hypothesizes that IC Virus aCV) plays a role in tumorigenesis by interacting with many of the same or similar proteins involved in
the Mutation model: Large T Antigen (T-ag) transports (3-catenin to the nucleus,
which has similar effect as mutating APC; Small T Antigen (t-ag)' s interaction
with PP2A activates PI3K,much like mutations in KRAS; ICV's inhibition of P53
prevents transcription of P2I, allowing division to occur in the presence of antigrowth signals, thus having the same effect of mutating SMAD; inhibition of
P53 also prevents apoptosis, just like in the Mutation model. Thus, the Infection
model hypothesizes that ICV is able to simultaneously remove the several cancer barriers: T-ag's interaction with (3-catenin and pRb inhibits differentiation
and promotes proliferation, allowing the cell to divide in the presence of antigrowth signals; the pro-growth barrier is removed by T-ag 's interaction with
IRS-I, P300/CBP, and t-ag's interaction with PP2A, allowing the cell to divide
in the absence of pro-growth signals; the apoptosis barrier is removed by T-ag's
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interaction with P53, IRS-I, and t-ag's interaction with PP2A; the metastasis barrier might be removed by t-ag's interaction with PP2A, which activates PI3K,
resulting cytoskeletal changes and increased mobility.
There are two hypotheses of JCV's role in colorectal tumorigenesis. The Hit and
Run model posits that the

~98

Mad-I strain integrates into the host genome and

removes key tumor suppressor genes via T-ag Chromosomal Instability (CIN).
T-ag expression is eventually lost, leading the re-acquisition of genomic stability
and maintenance of the transformed phenotype.
The Reactivation model hypothesizes that JCV becomes latent after infection,
but is reactivated if some sort of immunosuppression occurs when mutation
compromises the Cellular Interfering Factor (CIF) barriers. Once reactivated, JCV
expresses its oncoproteins, removing the pro-growth, anti-growth, and apoptosis
barriers.
Despite the evidence presented Chapter 3, the Infection model is contentious
because it is difficult to determine role of JCV in colorectal caner. A primary
reason for this is that JCV is so prevalent that it is not entirely surprising that
JCV can be found in tumors [82]. It could simply be that JCV latently infects
healthy cells and but remains detectable in the tissue after tumor formation. Furthermore, just because JCV can cause tumors in non-human hosts does not necessarily mean it will cause tumors in humans, as JCV may only cause tumors in
non-permissive hosts. Even so, the criteria frequently used to establish a causeeffect relationship between infection and cancer includes the detection of the viral genome and/or its products in tumor tissue but its absence in healthy tissue,
and a molecular basis for virally induced oncogenesis, and a consistency of the
association [99]. JCV meets these requirements:

~98

Mad-I is found exclusively

in tumors but is absent in adjacent healthy tissue; JCV produces several proteins
that interfere with pathways traditionally associated with colorectal tumorigenesis; at least nine studies from five independent laboratories have demonstrated
an association between JCV and colorectal cancer.
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While controversial, the consistent association between JCV and colorectal cancer, along with JCV's ability to interfere with several tumor suppressors and
induce CIN, strongly suggests that JCV should increase the risk of colorectal cancer. However, is this increase in risk negligible, moderate, or significant? If JCV
does significantly increase the risk of colorectal cancer, it would be worthwhile
to develop a vaccine, which could help prevent colorectal cancer, as opposed to
treating it.
Lab studies are not be ideal for determining how much JCV increase the risk of
colorectal cancer, as it takes decades for the disease manifest itself, much longer
than the lifespan of most lab animals. Animal studies are also not ideal because
they are non-permissive hosts, which may make them more likely to develop
tumors. Furthermore, JCV's high prevalence in the human population makes it
difficult to use population based studies to determine how much JCV increases
risk. Mathematical and computer modeling, on the other hand, can help determine if JCV has the potential to increase the risk of colorectal cancer. The use of
such models allows one to simulate how JCV interacts with cells over a human
lifetime. One can also remove infection from the model to estimate the prevalence of colorectal cancer in the absence of JCV, thereby simulating a population
in which the prevalence of JCV is zero. Such a simulation helps determine if
the prevalence of JCV and colorectal cancer are related. Again, neither of these
conclusions can come from population and lab based studies.
Three models have developed to estimate whether or not JCV is involved in
colorectal tumorigenesis. The first is a probability model that determines the
age-specific probability of developing colorectal cancer by mutation or infection.
Although this is a simple model, it sheds light on whether the mutation or infection is the primary driver of colorectal cancer.
The second model is a separate probability model that estimates the age at
which colorectal cancer develops under the infection and mutation models. This

too is a simple model, but it provides an independent estimate of which force,
infection or mutation, plays the most important role in colorectal tumorigenesis.
The third model is a more complex agent based model (ABM) that simulates
the behavior of cells and their interaction with one another. In this model, tumors
"emerge" from changes in cellular behavior induced by mutation and/or JCV.
Due to the nature of ABMs, this model is able to capture more of the complexities
of tumorigenesis.
The results from these models will shed light on the drivers of colorectal tumorigenesis. Is mutation or infection the primary driver of tumorigenesis? Is
mutation alone sufficient to drive tumorigenesis, and if so, which barriers provide the most protection? If infection is involved, what is its role and how does
it increase the risk of colorectal cancer? The answer to these questions and others may be useful in understanding the drivers of colorectal tumorigenesis, and
how those drivers might be blocked so as to reduce the prevalence of colorectal
cancer.
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CHAPTERS

5.1

PROBABILITY MODELS

OVERVIEW

Two different hypothesis of colorectal tumorigenesis have been put
forth: the first argues that mutation drives tumorigenesis, while the second hypothesizes that IC Virus aCV) infection plays an important role
in tumorigenesis. While much evidence suggests that ICV at least has
the potential to be oncogenic, there is relatively little evidence about
how oncogenic the virus actually is in humans. Much of the difficulty
in assessing the impact of ICV is that fact that it is so common, and so
it is not surprising that it is associated with various cancers. However,
while lab and epidemiological studies may not be able to asses the risk
of ICV infection has on colorectal cancer, mathematical models may be
able to. A probability model developed by Calabrese and Shibata [17]
can be modified to determine the probabilities of developing colorectal cancer, with and without infection. These models can be further
modified to account for genomic instability1 •

5.2

ORIGINAL CALABRESE MODEL [?

I

In 2010, Calabrese and Shibata [17] developed a simple heuristic probability
model that calculates the age-specific cumulative probability that mutation will
remove all cancer barriers, leading to colorectal tumorigenesis. In this model,
1

Please see A or a complete description of the R code used to run this model
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PARAMETERS

fl = 3 x 1000bp x 10- 9 = 3 x 10- 6

mutation rate, 3 genes, lOoobp per gene

d = number of divisions in d days

number of divisions for a given age

k= 6

number of barriers to cancer

No
m

=

=

15

(10 6 )

number of intestinal crypts

8

number of stem cells per crypt

Table 5.1: Original Calabrese Model Parameters [171

Algorithm 5.:1 Probability of Colorectal Cancer Developing by Mutation, per 100,000
individuals [17]
PM=l-

(l-(l-(l-fl)d)

k)Nm x 100,000

there are six cancer barriers, which are derived from the paper by Hanahan
and Weinberg [50]: pro-growth, anti-growth, apoptosis, angiogenesis, replication
limit, and metastasis barriers. In this model, there are five parameters: d, the
number of stem cell divisions; m x N, where m = the number of stem cells in
each crypt, and N =the number of colon crypts, yielding the total number of
stem cells in the colon; k, the number of critical rate-limiting pathway driver mutations (i.e. the number of mutations required to remove all barriers to cancer);
and J.l, the mutation rate [171. The values used in the model are found in Table 5.l.
The logic behind the probability model of Calabrese and Shibata [17] is as follows: 1 - J.l is the probability that there is not a mutation in a gene, so (1 - J.l)d
is the probability that there is not a mutation in the gene after d stem cell divisions. Similarly, (1 - (1 - J.l) d) k is the probability that k barriers are not knocked
by mutation after d divisions. Finally,

(1 - (1 - (1 - J.l)d) k) Nm is the probability

that k barriers are not knocked out in N stem cells, in each of m colon crypts,
divide d times. Therefore, the cumulative probability of oncogenesis by mutation
can be defined as the probability that k barriers are knocked out after Nm stem
cells divided d times, which is summed up in Algorithm 5.l.
Inserting the parameter values in Table 5.1 allows one to calculate the cumulative probability (i.e. prevalence) of colorectal cancer for each age group by using
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different values of d. For example, the predicted prevalence of colorectal cancer
in individuals 70 years or less is
PM70 = 1 -

1- (1 - (1 -3 x 10-6 )6387.5)
(

6)8X1.5X107

= 0.00559, while the preva-

lence of colon cancer in individuals 65 or less is calculated to be

PM65

=

0.0036.

Incidence is the number of new cases between age groups, and so one can convert prevalence to incidence by determining the difference in prevalence between
any two age groups. For example, the incidence of colorectal cancer in 70-75 year
old individuals would be

IM70 = 0.00559 - 0.0036 = 0.00199.

Using these inci-

dence value, one can then predict the incidence of colorectal cancer per

100,000

individuals. For example, the incidence of colorectal cancer in individuals 70-75
years old, per

100,00

individuals, would be 0.00199 x 100000 = 199 individuals

[17]. Incidence values can be calculated for each age group and compared to ob-

served incidence values of colorectal cancer [2], providing a sense of how well
the model predicts colorectal cancer incidence. The results of such a comparison,
using the probability model and parameter values of Calabrese and Shibata [17],
is found in Figure 5.1.

5.3

INFECTION MODEL DERIVED FROM THE CALABRESE MODEL

Calabrese and Shibata's original Mutation model can be modified to determine
what the incidence of colorectal cancer would be if JCV is involved in tumorigenesis. By assuming that JCV removes three protective cancer barriers (pro-growth,
anti-growth, and apoptosis), one can change the number of barriers mutations
must remove from k = 6 to k = 3. The prevalence of JCV must also be accounted
for, as not everyone in the population is infected. By finding the slope of regression line for observed JCV seroprevalence [68], R, one has an estimate of, on
average, how many more individuals are infected by JCV every five years. Figure
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5.2 illustrates this calculation, which finds that R = 0.04205513. By multiplying

R by the prevalence of colorectal cancer, one can thus estimate what fraction of
the age group is infected with JCV and has colorectal cancer. A third modification has to do with the observation that not all stem cells are infected by JCv.
Del Valle et al. found JCV T-Ag in 95% of CD133+/CD44+ rat mesnchymal stem
celis (rMSC), suggesting that JCV has the potential to infect most, but not ali,
stem cells. Asswning that JCV is also able to infect a similar number of colorectal
stem celis, the total number of cells wlder consideration in the Infection model
becomes Nm = 8 x 15000000 x 0.95.
To estimate the probability of infection driven colorectal tumorigenesis it is
necessary to sum across ali combinations of current age and age of infection. The
reason for this is that the probability of cancer in each age group depends up
how long the individual has been infected. For example, an individual who is 70
could have been infected at

ag~

15 or age 65, but the former individual would

have a greater probability of developing cancer than the latter individual. Thus,
to determine the prevalence of cancer for all 70 year old individuals, one must
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Algorithm 5.2 Prevalence of Colorectal Cancer Developing by Infection for each age
group, per 100,000 individuals.
0

P1d=.L:f 1- 1-(1-(1-I1-)d- J )

k-3) NmXOo95] Rx100,000

(
[

sum across all differences in current age, d, and the age of infection, j. Summing
across all ages of infection thus provides the prevalence of colorectal cancer in
that age group. Making these changes to Calabrese and Shibata [17]'S mutation
model yields the infection model found in Algorithm 5.2.
Iterating Algorithm 5.2 across all age groups generates modeled prevalence,
which can be converted to incidence and compared to both Calabrese and Shibata's model and the observed incidence. The modeled incidence values can be
found in Figure 5.3.
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Every individual in the Infection model develops colorectal cancer by the time
they are

10

years old, which is far from reality. Euclidian distances between the

modeled incidence and observed incidence provide a way to determine which
model's results are closest to the real thing. As expected, given the results in
Figure5.), the Euclidian distances found in Figure 5-4 illustrate that Calabrese
and Shibata's original Mutation model is much better fit, while the Infection
model is nowhere close to the observed incidence. Given these results, one can
conclude that, as modeled, infection cannot be involved in tumorigenesis, and
that mutation is the primary cause of colorectal cancer.

PARAMETERS

~=

10- 10 or Ii = 10- 11

stem cell point mutation rate

d = number of divisions in d days

number of divisions for a given age

k= 3,6,9, 12,16

number of barriers to cancer
number of intestinal crypts

m=5

number of stem cells per crypt

Table 5.2: New Parameter Values

In future discussions, these two models will be referred to as the Calabrese
model with Original Parameters (COP) models.

5.4

CALABRESE MODELS WITH NEW PARAMETERS (CNP)

While the mutation model developed by Calabrese and Shibata [17] provides
an exceptional fit to the observed incidence, it makes several assumptions that
may not be valid. The first assumption is that the stem cell mutation rate is
the same as the transit cell mutation rate. However, several authors suggest that
stem cells have mutation rates that are 10-100 times lower than normal cells
[19,43,16], precisely to avoid accumulating oncogenic mutations over a lifetime.

In fact, Frank et a1. estimate that the mutation rate of stem cells may be several
orders of magnitude lower than that of somatic cells, somewhere between 10- 10
and 10- 11 mutations per base pair, assuming the average gene is 1000bp long.
Second, Calabrese and Shibata [17] use eight stem cells per crypt, while
and Cheng [8] estimate

Bjerknes

that there are only 4-6 stem cells per crypt. Third, it has been

estimated that there could be up to 100 genes involved in tumorigenesis[67]. If
there are six barriers there could be up to 16 genes per barrier. The following
probability models thus set the stem cell point mutation rate at either lO- lO or
10- 11 , with number of stem cells per crypt at five, and have 3,6,9,12, or 16 genes
per barrier. A summary of these new parameter values can be found in Table
Table 5.2.
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The incidence values generated from using Algorithms 5.1 and 5.2 with new
parameter values are found in Figure 5.5, while the Euclidian distances are found
in Figure 5.6.
Incidence of Colorectal Cancer
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The results in Figures 5.5 and 5.6 yield several conclusions. The first is that,
given the modeled incidence values, mutation is not able to drive tumorigenesis,
which is in contrast the COP models. This is true across all models, indicating
that the difference between the Original parameter and New parameter models
is due to the lower stern cell mutation rate, whether it be

J..L

= 10- 10 or J..L = 10- 11 .

This in turn reveals that a lower stern cell mutation rate does protect the cell
from accumulating too many oncogenic mutations. Third, the Euclidian distances
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Figure 5.6: Euclidian Distances between Models With New Parameter Values

suggest that infection is only able to produce realistic incidence values if the stem
cell point mutation rate is ~

= 10- 11 , as at

~

= 10- 10 colorectal cancer occurs

far too early and frequently. Finally, the Euclidian distances suggest that the
model with 16 genes and a stem cell mutation rate of ~ = 10- 11 best replicates
the observed incidence. All together, the results from this model suggest that
infection is the primary cause of colorectal cancer, as mutation alone is unable
to generate any cases of cancer. Finally, mutation is required to remove the last
three barriers, and so may be considered a secondary cause.
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5.5

GENOMIC INSTABILITY MODELS

The Calabrese model with New Parameters (CNP) models suggest that JCV infection is absolutely required for colorectal tumorigenesis, indicating that it is
the primary cause of cancer. However, one can easily argue that the models are
far too simple, and that they lack one of the driving forces of tumorigenesis,
genomic instability. A second assumption that CNP make is that all stem cells
have an equal chance of removing all of the barriers. However, it is more likely
that the population of cells that removes the first barrier is the most likely to
remove the second. And that second, smaller, population is the most likely to
remove the third. Thus, the population of cells that are most likely to remove all
of the barriers decrease over time. The following family of models incorporates
this decreasing population size and genomic instability by making a few more
modifications to the Calabrese models.
The decreases population size is accounted for by leaving behind the cells that
do not remove that first barrier, so that
N1

N1

<

No.

Similarly, the population of

of cells that remove the second barrier, Nz, is even closer to metastasis, and

all other cells in

N1

are ignored, meaning that N z <

N1

<

No.

Over time the

population of pre-metastatic cells gradually decreases in a step-wise fashion until
the final population of cells that need to remove the last barrier is determined.
The second modification is based on the assumption that genomic instability
doubles the mutation rate every time a barrier is removed. This value is based on
the observation that Hepatitis C Virus induces a mutator phenotype, increasing
the mutation rate 5-10 fold [81]. Spreading this increase across six barriers means
that the mutation rate can double every time a barrier is removed. Over six barriers, this means that !lO = 1O-10'~1 = 2 x lO-lO,~z := 4 x 1O-1O,~3 = 8 x 10-10,
Il4 = 16 X 10- 10 , and ~5= 32 x 10- 10 (assuming a stem cell point mutation rate

of ~ = 10-10
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Algorithm 5.3 Probability Stems Cell Removes One Barrier, Mutation Model

Algorithm 5.4 Probability Stem Cell Removes One Barrier, Infection Model

These modifications are incorporated into the Genomic Instability Mutation
Model (GIM) in the following manner. The probability that one stem cell knocks
down the first barrier, PM (1,110), is found in Algorithm 5.). The expected total number of cells knock down the first barrier can be calculated as N 1 =
PM (1, 110) No , where No = 5 x 15 (10 6), the total number of stem cells in the
colon. Similarly, N 2 = PM (1, !-l,) N 1. Over time, the population of cells deceases
as fewer and fewer cells have removed each barrier. This process is repeated for
each barrier until the population size of cells that have removed the first five barriers is determined. Using this population size, N s, and the the highest mutation
rate !-ls,

P Mdc = PM

(N s , f..ls) x 100,000 is the prevalence of colorectal cancer in

age group d, per 100,000 individuals.
The Genomic Instability Infection Model (GIl) is modified in a similar fashion,
yielding Algorithm 5-4, which finds the probability one infected cell will remove
one barrier. Note that in the GIl model mutation only has to remove three barriers, as JCV has already removed other three. JCV has also induced genomic
instability, and so the initial mutation rate is !-l3. As in the GIM model, the population size of cells that removed the first barrier is Nl =
model, N2 =

PI

PI

(1, !-l3) No. In the GIl

(Nl, !-l4) is the population size of cells that have removed five

barriers. Thus, the probability that an individual has developed cancer at age d
is

PId

(N2, !-ls). As in the COP and CNP infection models, the prevalence of each

age group is determined by summing all ages of infection for each age group;
P Id

=

Lt [PId (N2, !-ls) -

PIj

(N2' f..ls)] R x 100,000, where d= current age, and j=
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age of infection by JCv. Also like the COP and CNP models, the initial population size of cells used in the infection model is 95% of the cells in the mutation
model. Once prevalence is calculated it is converted to incidence as described
above.
There are two sub-models for each model, and 5 different genes barrier in each
sub-model, creating a total of ten sub-models. The first set of sub-models uses

°,

a stem cell point mutation rate of I-l = 10- 1 and uses 3,6,9,12,or 16 genes. The
second set of sub-models uses the same collection of genes, but has a stem cell
point mutation rate of I-l = 10- 11 . The results of each model are found in Figure
5.7. The Euclidian distances of all models are found in Figure 5.8.
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Euclidian Distance Between Observed and Modeled Data
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Infection
Mutation

The results of the Genomic Instability Models largely agree with those of the
CNP models. Both sets of models find that mutation is unable to drive tumorigenesis, while infection is only able to generate realistic incidence values if the stem
cell point mutation rate is IJ.

= 10- 11 . Again, these results suggest that infection is

the primary cause, as mutation cannot generate realistic prevalence values. However, colorectal cancer cannot occur without mutation removing the last three
barriers, and so mutation may be considered a secondary cause. The results of
these models only differ in that the CNP models find that sixteen genes provide
the best fit, while the

5.6

ell models indicates that three genes per barrier fits best.

CONCLUSIONS

The above results strongly suggest that infection plays a significant role in the
development of colorectal cancer. JCV should thus be considered a major risk
factor. These results are consistent across all incarnations of the model (except
for the original), suggesting that they are robust. The results also show that infection always results in a higher incidence of colorectal cancer than mutation,
again indicating that it increases the risk of cancer. However, this result is not
surprising given that the probability of removing three barriers will always be
higher than the probability of removing six. What is surprising is that mutation
is unable to generate any incidence values, no matter the mutation rate. This is
in contrast to the COP models, where IJ. = 10- 9 , which suggests that lowering the
stem cell mutation rate by one order of magnitude is sufficient to protect against
cancer. However, at IJ.

= 10- 10 infection causes colorectal cancer far to early and

frequently. JCV is a very common infection, yet colorectal cancer is relatively rare,
so this result may indicate that the stem cell mutation rate is IJ.

= 10- 11 so as to

protect against infection induced cancers. This value is consistent with the estimation that the stem cell mutation rate could be
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10-100

times lower than other

All in all, these models require infection for tumorigenesis, and so JCV can
be interpreted as being the primary cause of colorectal cancer. Mutation plays
an important secondary role by removing those barriers that infection does not.
Thus, these results suggest that colorectal cancer is a multi-factorial disease.
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CHAPTER 6

6.1

GEOMETRIC MODEL

OVERVIEW

A fourth probability model is developed to better understand the drivers of colorectal cancer. This model is not built around the work of Calabrese and Shibata
[17], but is based upon the Geometric distribution, which calculates the proba-

bility of a certain number of failed trials before the first success. This algorithm
simulates the minimal number of divisions that need to occur for cancer to develop. This model uses the same assumptions of the probability models, and
is applied to both Mutation and Infection modeL Unlike the other probability
models, the Geometric model finds that the Mutation model best replicates the
prevalence of colorectal cancerl .

6.2

THE GEOMETRIC MODEL

The Geometric distribution is defined as Pr (X = k) = (1 _

V ) k- l

V. Given that V is

the probability of success, and k is the number of Bernoulli trials, the Geometric
distribution can be interpreted as follows: 1 - P is the probability of failure, so
(1 - V) k- l is the probability of failure before the final kth trial, and so (1 - V) k - l V
is the probability that there are k - 1 failures and success on the final k th trial.
In the case of this model, each stem cell division is considered a Bernoulli trial,

where 't he probability of removing a barrier (i.e. a successful event) is

1

Please see B or a complete description of the R code used to run this model
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~.

The

Geometric distribution can therefore be used to determine how many stem cell
divisions are required for each barrier to be removed by mutation.

6.3

IMPLEMENTATION

The program R (v

2 .11.1;

[107]) has the function rgeom(n,prob), which randomly

generates n independent observations of how many trials occur before a successful event, given that the probability of success is p. Each of the n observations can

be thought of as a cell lineage, and the deviates produced by R are interpreted
as the number of divisions required for a barrier to be removed by mutation.
In the Mutation model, b1 = rgeom(n=5 x 15000000, prob=3 x 1000 x 10- 1° ) cre-

ates a vector containing 7.5 x 107 elements. Each element represents the number
of years it takes for a barrier to be removed by mutation in each of the 7.5 x 107
stem cells, given that the probability of removing a barrier in one of three 1000bp
genes is 10- 7 . After the creating of b1, a new vector; b 2, is created in a similar
fashion, except that the mutation rate is doubled, thus taking into account genomic instability. The process is repeated for vectors b3, b4, b5, and b6, doubling
the mutation rate each time a vector is created, so that the mutation rate used to

°.

create b 6 is I.l. = 25 x 3 x 1000 x 10- 1 After their creation, all vectors are added
together into the vector T, each element of which now represents the total number of years it takes for all six barriers to be removed in each of the 7.5 x 10 7 stem
cells. The minimum number of years it takes a lineage to remove all six barriers is recorded, as it represents the first lineage to initiate tumorigenesis within
the individual. This process is repeated 1,000 times, so as to simulate colorectal
tumorigenesis in 1,000 individuals. Unlike the probability models, every individual will develop colorectal cancer at some point, and so the Geometric model
only produces colorectal cancer patients.
The Infection model assumes that JCV is able to remove three barriers and
generate genomic instability. Thus, the only difference between the Infection and

Mutation model is that the mutation rate used to create b1 is in the Infection
Model is

f..L3 =

23 x 3 x 1000 x 10- 10 (assuming there are 3 genes per barrier, and

the stem cell point mutation rate is

f..L

= 10- 10 ) . Similarly, the mutation rate used

to generate b z is twice that used to create b1, and b 3 is twice that used to create
bz. Finally, as in the other probability models, it is assumed that JCV infects 95%

of cells, Otherwise, the two models and their implementation are identical.
Each model is run using either a mutation rate of 10- 10 or 10- 11 , and either
3,6,9,12, or 16 genes per barrier. All results for each combination of genes and
mutation rates are collected and binned into age groups.

6.4

RESULTS

The Geometric models produce the number of new patients in each age group,
and so may be considered incidence values. Since this model is stochastic it is
unlikely it will produce cancer patients in all age groups. For example, it may
produce one or two patients that are 72 and 74, but none that are 76, leaving the
75 - 79 year old age bin empty. This is in contrast to the probability models in
Chapter 5, which produce the cumulative distribution function calculating the
probability of cancer in each age group. Therefore, as the results in Figure 6.1
suggest, modeled incidence values for the Geometric models are slightly deceptive, as the incidence goes up and down, simply because some age groups do
not have any patients in them. Prevalence may provide a better picture of the
results, as it is the total number of individuals that have colorectal cancer at that
age, regardless of when they developed colorectal cancer. For example, the prevalence of colorectal cancer in individuals 70-74 includes everyone that developed
cancer at 30,40,50, etc .... If the stochastic model does not generate an individual for a given age group the prevalence remains the same as the prevalence in
the previous age group, and so does not dip up and down like incidence does.
Finally, prevalence provides more accurate distance measurements, as modeled
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AGE

MORTALITY

< 20

0%

20 - 34

0.6%

35 - 44

2.5%

45 - 54

8.6%

55 - 64
65 - 74

16.5%

75 - 84

29%

85+

20.8%

22%

Table 6.1: Mortality From Colorectal Cancer, 2005 - 2009 [2]

incidence values can skyrocket and then crash to zero. If the observed incidence
is also close to zero for the age group the model will have a low distance score,
despite its poor reproduction of the observed prevalence. Prevalence avoids this
because when the modeled data maxes out, it stays there, and so no calculations
are biased by having the modeled data return to zero.
Incidence is converted to prevalence for a given age group by summing how
many individuals have cancer in all previous age groups. However, some patients
die from cancer before they reach that age group, and so cancer mortality should
be to be taken into account. This can be accomplished by multiplying the prevalence in each age group by l-age specific mortality. This is done before adding
that age group to the next age group, and thus removes the individuals that died
from cancer in that age group. Mortality rates of colorectal cancer can be found
in Table 6.1. After taking mortality into account, prevalence can be calculated.
These Geometric models's prevalence values are found in Figure 6.2, while the
Euclidian distances for each model are found in Figure 6.3.

6.S

CONCLUSIONS

Consistent with findings of the probability models, the results of the Geometric
model strongly indicate that infection increases the risk of cancer. As modeled,
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the Infection model does not fit well with the observed data, no matter if the
mutation rate is Il- = 10- 10 or 10- 11 • However, closeness of fit is highly dependent on the parameters of the model that have been altered and presumably on
parameters that haven't been altered. Therefore, lack of fit should not indicate
that infection is not playing a role. If nothing else, these results illustrate that the
presence of infection dramatically increases the risk of cancer.
Unlike the Calabrese probability models, the results from the Geometric model
indicate that mutation can drive of tumorigenesis, as the modeled and observed
prevalence values are close. However, this is only the case when Il- = 10- 10 , and
when there are 16 genes per barrier. At Il- = 10- 11 the mutation model fails to
produce any colorectal cancer patients, which is in agreement with the Calabrese
model with New Parameters (CNP) and Genomic Instability models from Chapter 5. This indicates that a lower stem cell mutation rate does protect against
cancer, but only if it is

100

times lower than normal. It thus seems that either

mutation or infection can be the driver of tumorigenesis, but that which one
fits best depends on the mutation rate. These mixed results indicate that further
investigation is required.

CHAPTER 7

7.1

AGENT BASED MODEL

OVERVIEW

The family of models described in the previous chapters suggest that both mutation and JCV are capable of initiating colorectal tumorigenesis. However, those
models also make many simplifying assumptions that do not capture the complex process of tumorigenesis. An agent based model is developed to address
these complexities, with the aim of attaining a more accurate picture of mutation
and infection's role in colorectal tumorigenesis. In this model, each mutation
and/ or viral oncoprotein generates a behavioral change in the cell, and the accumulation of these phenotypic changes can result in the emergence of a metastatic
tumor. Agent based models also record a great deal of data which can be used to
determine not only which factors increase the risk of colorectal cancer, but also
how each does so.

7.2

NEED FOR AN AGENT BASED MODEL

The models described in Chapter 5 and Chapter 6 demonstrate both infection
and mutation are able to drive tumorigenesis. However, the argument could be
made that these models are too simple, and ignore many important observations
on colon tissue dynamics, colorectal tumorigenesis, and JCV's lifecycle. For example, symmetric division is not modeled, which is a significant omission as it
is proposed to be a mechanism involved in spreading a mutation throughout the
crypt (i.e. monoclonal conversion). Second, the models assume that a single mu-

tation completely removes each barrier, and yet it is known that a single mutation
in one tumor suppressor allele (i.e. P53, pRb, APC, etc... ) does provide a selective
advantage, but that removal of the other allele is required to gain the full selective advantage[9, 67]. Third, the probability model treats all barriers as equal in
the sense they simply bring the cell one step closer to metastasis. However, the
removal of each barrier provides the cell with a particular selective advantage
that allow the genotype to increase in frequency within the population. Fourth,
the previous models assume a constant population size, which is very unrealistic, as the definition of cancer is uncontrolled growth. This is a particularly poor
assumption, as the more cells there are, the greater the probability that one of
them will acquire all of the mutations required for tumorigenesis. Finally, the earlier models assume JCV is active immediately after infection, and remains active
throughout the host's life. However, in appears that JCV instead becomes latent
upon infecting colon cells, and some sort of reactivation is required for the virus
to express its oncoproteins. Such reactivation may occur either due to immunosuppression, due to mutations Cellular Interfering Factor (CIF)-II genes, or by a
"hit and run" mechanism.
It is not possible to model these complex processes with a simple probability

model, and so an Agent Based Model (ABM) is developed. ABMs are ideal for
such complex processes, as they allow each cell's behavior to change over time,
either in response to internal and/or external changes, in this case mutation
and infection. All of the cells then interact with each other, and combinations of
different behaviors can lead to the emergence of different patterns, in this case
tumor formation. Thus, this ABM seeks to address the simplifying assumptions
of the probability models by modeling how mutation and infection affect the
behavior of cells, and how the combination of these behaviors can result in the
formation of a metastatic tumor.

7.3

OVERVIEW OF MODELS

There are three families of ABMs, each of which is programmed using NetLogo
version 5.0.31 [147]. Each of following models are run using 3,6,9,12,16 genes per
barrier, with the average gene length being 1, OOObp. Thus, there is a total of 25
models, each of which is run 1,000 times.

7.3.1

Mutation Model

The first model is the Mutation Model. In this model, mutation is the only way
that the protective cancer barriers can be removed, even if the individual is infected. As such, the Mutation model assumes that JCV has no role in tumorigenesis. If a single mutation lands in a cancer barrier gene, the mutant phenotype is
expressed 50% of the time. The beneficial phenotype will always be expressed if
a second mutation lands in that same gene.

7.3.2

Infection Models

In the Infection models JCV randomly infects one cell every year. Once that cell is
infected, there is a 2% chance that the infection will spread to its neighbor cell. If
the infection fails to spread to all cells, JCV does not establish a chronic infection
and will attempt to infect the individual the following year. The infection is considered chronic if JCV successfully spreads to all cells. The parameters used in
the Infection models are calibrated so as to represent the observed seroprevalence
of JCV (see Figure 7.1).

1

Please see the ODD in Appendix C for a complete description of the code used in this ABM
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Figure 7.1: Modeled Prevalence of JCV

Each of the following infection models have two sub-models. In each case, the
first model, referred to as the Full Model, has active JCV completely remove
each barrier, while in the second model, termed the Partial Model, JCV partially
removes each barrier. In the case of the Partial models, if there is one pre-existing
mutation, and JCV partially removes that barrier, the entire barrier is be removed.
The situation is the same if JCV partially removes a barrier and then mutation
finishes the task.
7.3.2.1

Reactivation Model

The first infection model is the Reactivation model. This model hypothesizes that
JCV has no effect until the individual becomes immunocompromised. For an individual to become immunocompromised they must acquire two mutations in
the CIF-II genes. Recall from Chapter 1 that the CIF-II barrier is involved in inhibiting the function of viral oncoproteins[153]. If the CIF-II. barrier is removed,
simulating immunosuppression, JCV is reactivated and removes the pro-growth,
anti-growth, and apoptosis barriers (see Chapter 4 for a review of how JCV inter86

feres with these barriers). If there is only one mutation in a CIF-II gene, JCV only
has an effect 50% of the time. This is meant to simulate that the individual is not
completely immunocompromised, and so retains defenses against JCY. However,
if there are two mutations in the CIF-II genes, JCV is always active.
7.3.2.2

Hit and Run Model

The Hit and Run model is the second infection model, and is based upon the
research conducted by Ricciardiello et al. [112, 113] (see Chapter 3 for a review
of their findings). The Hit and Run model hypothesizes that genomic rearrangements in JCV's Non-Coding Regulatory Region (NCRR) lead to the development
of the Mad-I strain, which may use lymphocytes to infect the colon. Alternatively, these genomic rearrangements may occur in JCV that is already in the
colon. Either way, the Mad-I strain develops into the Mad-I .198 strain when
there is a second deletion in the NCRR. This event changes the cell's phenotype
in two ways: 1) the apoptosis, pro-growth and anti-growth barriers are removed;
2) the virus induces genomic instability, increasing the mutation rate 7.5 fold.

The increase in virally induced genomic instability comes from the observation
that Hepatitis C Virus induces a mutator phenotype which increases the mutation rate 5-10 fold [81], and so 7.5 is somewhere between the two. Unlike the
Reactivation model, JCV Mad-I .198 is only active for 14 - 21 days, after which
JCV's oncoproteins cease to be expressed, and the cell returns to its previous
phenotype.

7-4

MODELING THE STRUCTURE OF A COLON CRYPT

Figure 7.2 is the world of the ABM. The box on the bottom left is the colon
crypt, which is divided into the inner crypt (pink) and outer crypt (yellow). The
tissues are laid out in squares so as to represent a columnar crypt that has been
laid flat, so that the crypt base is in the center of the square. The black area

Figure 7.2: Modeled Colon Crypt

outside of the crypt represents the lumen. The green square is the metastatic
tissue, which could hypothetically be anywhere in the body. At the center of the
crypt are five stem cells (blue). Each patch in each tissue represents one cell from
the underlying tissue.
Everyday (i.e each tick) each patch, which assumed to contain underlying
blood vessels, supplies 0.25 units of oxygen to the colon crypt. Each patch then
diffuses 100% of its oxygen to its neighboring patches, 20 times a day, simulating constant oxygen diffusion [21]. The oxygen is thus dispersed throughout the
crypt where it is consumed by cells. Since oxygen dynamics determine cell division and movement, all oxygen related parameters are calibrated so that each
crypt contains an average of 250-300 cells, and so that each stem cell divides
every four to five days [127, 12, 104, 103].
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7.5

7.5.1

WILD-TYPE BEHAVIOR

Stem Cells

At the center of the crypt (Le. the base of the crypt) are five stem cells laid
out in a circle [12, 103, 105]. Each of these stem cells is able to divide either
asymmetrically or symmetrically. Which type of division occurs is determined
using a Bernoulli distribution, where the probability of successful asymmetric
division is p = 0.95 [79]. If symmetric division occurs, the most fit stem cell
(Le. the stem cell with the fewest deleterious mutations) produces two daughter
stem cells, one of which replaces the least fit stem cell (Le. that stem cell with
the most deleterious mutations). This is modeled because it is assumed that the
number of stem cells is tightly regulated, and that the most fit stem cell has the
greatest probability of surviving while the least fit stem cell is most likely to die.
After this selection has occurred, the remaining stem cells divide asymmetrically.
When asymmetric division occurs, each stem cell produces one daughter transit
cell. This model assumes that stem cell division is prevented by contact inhibition.
Thus, a stem cell will only divide if there is an empty patch within its cone of
vision, which has an angle of 180 and radius of 1.5 patch units.
0

During division each stem cell acquires various mutations that are inherited
by their daughter cells (see section 7.6 for details on how mutation is modeled).
Finally the ABM assumes that the crypt can determine if it has too few stem cells,
and will respond by having the most-fit stem cell hatch one daughter stem cell.
The only time this will occur is if one stem cell acquires a metastatic mutation,
giving it the ability to roam throughout the crypt. Again, this is modeled based
on the assumption that the number of stem cells in a crypt is tightly regulated.

7.5.2

Transit Cells

Wild-type transit cells produced by stem cells will only divide if there is an empty
patch within their cone of vision, again simulating contact inhibition. However,
transit cells must also meet further requirements to divide. They must be in the
inner crypt, where they are not fully differentiated; they have enough oxygen
to divide; and they have telomeres remaining. If a transit cell meets these requirements, divides, undergoes mutation, produces one daughter cell, divides
its oxygen equally between itself and the daughter cell, looses one unit of its
telomere, metabolizes oxygen, and randomly moves to one of the empty patches
in its cone of vision, where it consumes oxygen. If the transit cell meets all of the
criteria except for having enough oxygen to divide, the cell will simply move to
one of the empty patches, metabolizing oxygen in the process, and then consume
more oxygen on the patch it now occupies. If there is not enough oxygen in the
. patch the cell moves to, it will consume half of what oxygen is available. When a
cell reaches the outer crypt it will follow the same rules of movement and oxygen
consumption, but will not be able to divide because the cell has differentiated.
Finally, transit cells are shed once they reach the lumen. Transit cells can also die
if they lose all of their telomeres or have a low relative fitness when resources
become scarce during population growth (see subsection 7.8.2 for details).

7-6

7.6.1

MODELING MUTATION

Genome Regions

It is estimated that the human genome contains -7 x 109 bp and 70,000 genes,

each of which has an average length of 1000bp (reviewed in [92]). Assuming
there are six barriers to cancer, and three genes per barrier, one can estimate
that there are 6 x 3 x 1000 = 18,000 bp that if mutated or targeted by JCV will
90

damage a cancer barrier. Interfering with these barriers is beneficial to the cell, as
it either increases the rate of replication or probability of survival (see section 7.7
for details). Therefore, any mutation that lands in these 18,000bp is considered a
beneficial mutation.
Assuming that mutations in the remaining genes are deleterious, one can estimate that mutations in any of the (70,000 - 3 x 6) x 1000 = 69982000bp will
result in a mutation that will decrease a cell's fitness. The ABM also assumes
there are seven different different genomic instability genes that are involved in
Chromosomal Instability (CIN) [102]. Thus, there are 7 x 1000 = 7,000bp that, if
mutated, will increase the mutation rate. Finally, assuming all other mutations
are neutral, one can estimate that any mutation in the 7 x 109 - (70000 x 1000)

=

6.93 x 109bp will have no effect on the cell's fitness.

7.6.2

7.6.2.1

Generating Mutations

Host Mutations

The stem cell mutation rate used in these models was originally!!
the transit cell mutation !!

= 10- 10 , and

= 10-9, but only lout of 25,000 runs developed a

metastatic tumor. This hardly provides any information, so the stem cell mutation rate is set to !! = 10-9 , while the transit cell mutation rate is !! = 10-8 . While
these mutation rates are higher than observed values, they generate plenty of results and maintain the hypothesis that the stem cell mutation rate is lower than
the transit cell mutation rate.
Using these mutation rates, one can calculate the expected number of mutations in each genome region during each division: 18,000 x 10-8
and 18,000 x 10-9

= 1.8 x 10-4

= 1.8 x 10-5 beneficial mutations in transit cells and stem cells,

respectively; 69982000 x 10-8 = 0.69982 and 69982000 x 10-9 = 0.069982 deleterious mutations in transit cells and stem cells, respectively; 7000 x 10-8 = 7 x 10-5
and 7000 x 10-9 = 7 x 10-6 genomic instability mutations in transit and stem
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cells, respectively; and 6.93 x 109 x 10-8 = 69.3 and 6.93 x 109 x 10-9

6.93

neutral mutations in transit cells and stem cells, respectively.
Randomly drawing numbers from a Poisson distribution, which predicts the
number of successes in a fixed interval, allows one to randomly assign how many
of each type of mutation occurs in each genome region during each cell division. For example, drawing a random number from a Poisson distribution with
A = 69.3 will determine how many neutral mutations land in a transit cell during division; a random number from a Poisson distribution with A = 0.069 will
determine how many deleterious mutations occur in a stem cell division.
If a mutation lands in a beneficial region, a random number is drawn from

the Uniform distribution with a range of 1 to 6, one number for each cancer barrier (pro-growth, anti-growth, apoptosis, replication limit, metastasis, and elF-II).
There is an equal probability that each number will be chosen from the Uniform
distribution, so using this method allows one to randomly select which barrier is
mutated.
Each model is run using different numbers of genes per barrier, using either
3,6,9,12,or 16 genes per barrier. Therefore, as the number of genes per barrier
increases, so does the probability of a beneficial mutation. For example, if there
are 16 genes per barrier, there are 6 x 16 x 1000 = 96000bp that can be mutated
to increase the cells fitness. The length of the other gene regions will change
accordingly as well.
Finally, it is likely the case that more than one mutation is required to completely remove a barrier. In this model, and like Knudson's two hit hypothesis,
it is assumed that two events are required to completely remove a barrier, either
by mutation or infection. However, one mutation still has an affect on the phenotype, and the barrier can be considered partially removed. If a cell has one
mutation, the probability that the mutant phenotype will be expressed is 50%,
which is modeled using a Bernoulli distribution where the probability of success
is 0.5. Thus, everyday there is a 50% change that the mutant phenotype will be
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expressed. If a cell has two mutations in a barrier, it is completely removed and
the mutant phenotype is expressed 100% of the time.
7.6.2.2

JCV Mutations

Activation of JCV in the Hit and Run model requires mutations in the NCRR
region, and these mutations are modeled in a similar fashion to host mutations.
The NCRR region is 430bp in length and the mutation rate of JCV is estimated
to between 7.8 x 10-4 and 4 x 10- 6 per site per year [31,47, 121]. This suggests
that the average mutation rate of JCV is 1.074 x 10-6bp / site/ day. Thus, the probability that the JCV strain within single infected cell will acquire one NCRR on
mutation on any given day is 1.074 x 10- 6 x 430 = 4.6182 x 10-4. Therefore, using
the Poisson distribution with A = 4.618 x 10-4 will generate how many NCRR
mutations occur. Finally, NCRR mutations can only occur if the host cell is dividing.

7.6.3

Genomic Instability

Since genomic instability, particularly CIN, is believed to playa role in tumorigenesis, it is modeled as well. Every time a mutation lands in one of the seven
genomic instability genes, the mutation rate increases linearly by a factor of two.
For example, if there is one genomic instability mutation, the new mutation rate
is double the original; if there are four genomic instability mutations the new
mutation rate is eight times the original mutation rate; and so on until the new
mutation rate is fourteen times the original mutation rate.
The JCV Mad-1 .198 strain is able to induce genomic instability in the Hit and
Run model. This virally induced genomic instability is combined with existing
genomic instability, so if the cell has 3 genomic

i~tability

mutations and the

JCV Mad-1 .198 phenotype, the mutation rate will be increased 6 x 7.5 = 45 fold.
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However, once JCV is lost, the mutation rate returns to six times the original
mutation rate.

7.7

7.7.1

MUTANT BEHAVIOR

Stem Cells

Mutations that land in beneficial genes provide that cell with a selective advantage. However, the particular advantage depends on what type of cell mutates.
If a stem cell acquires one mutation in its metastasis barrier it gains the ability
to move around the crypt, moving to the neighbor with the most oxygen. Movement to the patch with the most oxygen is modeled because it has been proposed
as the mechanism that selects for mobile metastatic cells [21]. If the mobile stem
cell accumulates a second mutation in a metastasis gene, and is next to a blood
vessel, it will try to invade the metastatic tissue (these blood vessels are produced
during angiogenesis, see Section 7.8.1 ). However, the probability that the stem
cell will survive the bloodstream and successfully invade the metastatic tissue is
only

1/1000

[67]. If the stem cell does successfully invade the metastatic tissue

it will go through four rounds of symmetric division to produce five metastatic
stem cells, each of which continues to produce transit cells.
If the pro-growth barrier of a stem cell is disrupted, either by mutation or interaction with viral oncoproteins, it gains the ability to divide even if there is not
an empty patch within its cone of vision, thus simulating the loss of contact inhibition. If both the metastasis and pro-growth barriers are removed, the mobile
stem cell is able to move around the crypt and always divide in the inner crypt,
but never in the outer crypt.
If a mobile stem cell has the anti-growth barrier removed, it is able to divide in
the outer crypt, but only if there is an empty patch within its cone of vision. If this
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mobile stem cell has both the anti-growth and pro-growth barriers removed, that
stem cell will be able to move around the crypt and divide anywhere, everyday.
Stem cells that have removed the apoptosis barrier are exempt from the fitness
search conducted during symmetric division, even if they have the most deleterious mutations. This behavior means that a stem cell with the most deleterious
mutations, and possibly the most beneficial mutations too, will survive, spreading their mutations throughout the population. As stem cells are considered immortal, they do not have a replication limit barrier. Finally, any infected stem cell
will reactivate JCV if the CIF barrier is removed by mutation, thus simulating
reactivation by immunosuppression.

7.7.2

Transit Cells

Transit cells that acquire one metastasis mutation change their behavior from
randomly moving to a patch in their cone of vision to moving to the neighbor
patch that has the most oxygen. However, they follow all other wild-type division
rules, and thus will only divide if they are in the inner crypt and there is an empty
patch in their cone of vision. If the transit cell accumulates a second metastatic
mutation, and is next to a blood vessel, it will attempt to invade the metastatic
tissue, again with the probability of success being 1/1000. If the metastatic transit
cell is able to invade the metastatic tissue it will follow the same rules of division
that it followed in the crypt, except that there are not regions in which the transit
cell cannot divide.
If a transit cell removes the pro-growth barrier, it will always divide in the

inner crypt, regardless of whether or not their is an empty patch within its cone
of vision. However, it will remain unable to divide in the outer crypt. If the
cell has both the metastasis and pro-growth barriers removed it will still divide
anywhere in the inner crypt, but will chose to move to the neighboring patch
with the most oxygen.
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Transit cells having the anti-growth barrier removed gain the ability to divide
in the outer crypt, so long as there is an empty patch in its cone of vision. However, if the cell also has pro-growth mutations they will acquire the ability to
divide even when there are no empty patches, meaning that they can divide every day, anywhere in the crypt. If these cells have the anti-growth, pro-growth,
and metastasis barriers removed they will be able to divide anywhere, everyday,
and will move to the neighboring patch with the most oxygen.
If a transit cell has the replication limit barrier removed, it will stop losing its

telomeres during each division. If this mutation occurs in concert with the progrowth and anti-growth mutations, the cell will divide anywhere, everyday, and
without limit. This cell will only stop dividing is if it is shed into the lumen, or
has low fitness and cannot survive when resources become scarce during population growth (see 7.8.2). However, if the cell has the apoptosis barrier removed
it will always survive when resources are scarce, even it has the lowest fitness.

7.8

7.8.1

TUMOR EMERGENCE

Angiogenesis

Unlike the probability models, this ABM does not assume that angiogenesis is
the result of mutation and barrier removal. Instead, this model assumes that
angiogenesis naturally emerges when the tissue becomes hypoxic. This tends to
occur when there are too many cells for the amount of oxygen being produced
by a normal crypt. The body thus responds by producing new blood vessels to
supply the growing tissue with the oxygen it needs.
Angiogenesis is modeled by asking hypoxic patches that do not have any vessels with five patches to create a new blood vessels. Any other hypoxic patches
within a radius of five patches secrete VEGF molecules, which migrate towards
the closest vessel. Once the VEGF molecule is within 0.5 patch units of the blood

vessel, it stimulates the expansion of the existing blood vessel. The result is the
gradual growth of new blood vessels, winding their way to the most hypoxic
areas of the tissue.
Each of the new vessels is assigned a random lifespan that can be as high
as

250

days. Each vessel adds oxygen to each patch, and there can be up to

three vessels on a single patch. The increased amount of oxygen supplied by
angiogenesis increases the number of cells that the tissue can support, allowing
the population to increase in size.
The increase in population size is an important component of the model because, the more cells there are, the greater the chance that at least one will remove
all of the barriers to cancer. Also, because angiogenesis tends to create areas with
higher concentrations of oxygen, metastatic cells migrate towards the blood vessels, where they may attempt to invade the metastatic tissue. This behavior thus
replicates the close relationship between angiogenesis and metastasis.

7.8.2

Population Cap

There are two population size limits in this model. The first is a limit of

300

cells in the colon crypt. The model assumes that the crypt only produces enough
resources to support it's normal number of cells,
rises above

300

~250-300

cells. If the population

cells, resources become scarce and only the most fit cells survive

while the least fit cells die off. Least fit cells are defined as the cells that have
the lowest amount of oxygen and the most deleterious mutations. However, any
cells that inhibit apoptosis are not included in this fitness search, and so there is
selection for apoptosis mutations. If enough cells accumulate the mutation, the
population will grow beyond

300

cells.

Due to limitations in computing power, a second population limit has to be
set. If this limit were not in place the large population sizes would slow the
simulation to a crawl, making it difficult to complete
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1000

runs of each model.

This second population cap is set at 5000 cells, which is more than a sixteen fold
increase in population size. If this population cap is reached, cells are randomly
selected for death until the population returns to 5000 cells. No cells are excluded
from this search, so the probability of being killed is the same for all cells.

7.8.3

Tumor Formation

Due to the population cap and limits in computing power, it is not possible to
diagnose tumor formation by tissue size. For example, a polyp forms when the
population reaches a size equivalent to a sphere with a diameter of 2cm, but this
is hundreds of thousands of cells and exceeds the amount of available computing
power. Due to this limitation, tumors are diagnosed by the presence of cells that
have removed most barriers. A colon tumor is considered to have formed when
at least one cell in the population has completely removed the pro-growth, antigrowth, apoptosis, replication limit barriers.
A metastatic tumor forms when at least one cell successfully invades the metastatic
tissue (which is only possible if the metastasis barrier is removed), and has all of
the other barriers removed. In the case of stem cells, all barrier except the replication limit barrier must be removed. If such a metastatic tumor forms, the age of
metastatic tumor formation is recorded and the run is stopped. The run is only
stopped when metastatic tumors form because the statistics for colorectal tumor
prevalence are for metastatic tumors [2], thus facilitating comparisons between
modeled and observed data. The only other way a run is ended is if an individual
reaches

100

years of age and has not developed a metastatic tumor.

7-9
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RESULTS
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Figure 7.3: Age Distribution of Colorectal Cancer by Model

Figure 7.3 illustrates that all models tend to cause cancer primarily between the
ages of 50-85. While spread of observed and modeled data are quite different,
this finding is consistent with the observation that the average age of colorectal
cancer is 77.
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The age distribution of colorectal cancer in Figure 7-4 illustrates that the data
are not normally distributed, and thus ANOVA cannot be used to compare the
models. However, the Kruskal-Wallis one-way analysis of variance is able to compare multiple datasets that are not normally distributed. This test finds that
the probability of the models being from the same underlying distribution is
p

«< 0.5. This in turn suggests that the process underlying each model do signif-

icantly affect the age distribution of colorectal cancer.
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The primary goal of this paper is determine the role of mutation and infection
in colorectal cancer. Thus, it is useful to know if the infection models are different than the mutation model. Using the non-parametric two-sided KolmogorovSmirnov test on each infection model versus the mutation model reveals all infection models are significantly different than the Mutation model.

7.9.2

Initiators a/Tumorigenesis

Genomic instability is often argued to be the driver of tumorigenesis, and active
JCV would seem to be a key driver if infection plays a role in tumorigenesis. The
ABM records all events and when they take place, providing the opportunity to
examine which events most frequently initiate tumorigenesis. As Figure 7.5 illustrates, the first event is not necessarily the initiating event, as there is frequently
a long time lag between it and the next event. Infection also cannot be considered
an initiating event because latent JCV does not change the behavior of the cell.
Therefore, the initiating event is here defined as the event that has the shortest
time period between it and the next event. This definition is adopted because
this is the event that accelerates, or at least jumpstarts, tumorigenesis, as the following events occur within a shorter time span than before. While this definition
is not perfect, it at least provides some insight into which events accelerate the
accumulation of beneficial mutations. Finally, the mutations of the parental stem
cell could not be recorded, so it is not possible to determine exactly which barriers were removed in stem cells and which were removed in daughter transit
cells.
Figure 7.6 illustrates how many times each barrier removal event initiated tumorigenesis. Inhibition of apoptosis and up-regulation of telomerase are the most
frequent initiators, a result that is consistent with observation that P53 is removed
in 80% of colorectal cancers, while telomerase is up-regulated in 85-95% of cancer
cells [5,

123].
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Inhibition of apoptosis may frequently be an initiating event in stem cells because it allows the stem cell to avoid being replaced during symmetric division,
even if it has the most deleterious mutations. This increases the longevity of the
stem cell, which may provide it with more time to accumulate additional mutations. However, up-regulation of telomerase does not affect the stem cell since it
already has the ability to divide indefinitely.
Unlike stem cells, transit cells would benefit from up-regulating telomerase.
However, even if a transit cell has the potential to divide indefinitely it will still
be shed or die from accumulating too many deleterious mutations. Therefore,
it is not immediately clear why up-regulation of telomerase is so frequently an
initiating event, even in transit cells. Inspecting the mutations that precede the up-
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regulation of telomerase sheds light on why this event may initiate tumorigenesis.
Figure 7.7 shows that the complete removal of apoptosis and up-regulation of
telomerase is preceded by a single metastasis mutation. This mutation gives the
cell the ability to move to the patch with the most oxygen, even if those areas are
lower in the crypt. The transit cell then moves throughout the crypt, looking for
resources, and thus avoids being shed. Subsequent up-regulation of telomerase
and inhibition of apoptosis provide the cell with the ability to divide indefinitely
and avoid apoptosis no matter how many deleterious mutations that cell has. All
three mutations together allow the cell to replicate without limit, but never die
(apoptosis and metastasis). Such an immortal transit cell would have plenty of
time to remove the remaining barriers, and given their higher mutation rate they
may be able to do so at an accelerated pace. This hypothesis is supported by the
research of Lamprecht and Lipkin [70], who presented evidence that transit cells
can acquire mutations that allow them to remain in the crypt.
It may also be that up-regulation of telomerase is frequently an initiator in the

infection models because, while the cells are immune to apoptosis, and can divide anywhere and everyday, they still have limited replicative potential. Without
up-regulating telomerase, the ability to divide so frequently may backfire on the
cells, as they can soon lose their telomeres. However, up-regulating telomerase
via mutation gives that cell the ability to survive, and divide anywhere, everyday, and without limit. This hypothesis is consistent with the observation that
cells expressing Large T Antigen (T-ag)often become immortalized, can escape
contact inhibition, and exhibit anchorage-independent growth, but only if they
also up-regulate hTERT (reviewed in [47]). FInally, this phenotype may provide
the cell with the more opportunities to accumulate additional mutations, as it is
constantly dividing.
Reactivation of JCV by the removal of the CIF-II barrier is also common. Such
reactivation is accompanied by inhibition of apoptosis, and removal of the proand anti-growth barriers. Even if no other barriers are removed, this combination
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of events allows the cell evade apoptosis and replicate more frequently. Since mutation occurs during every division, reactivation gives the cell the opportunity to
accumulate more beneficial mutations at a faster rate. A similar situation occurs
when JCV hits and runs, except that removal of the barriers and increase in mutation rate only lasts for 14 - 21 days. Even though this is a short period of time,
this event (N) can either mutate other tumor suppressor or oncogenes, or initiate
genomic instability by mutation genes involved in CIN. This latter event would
be particularly important, as it allow a mutator phenotype to last after L\98 Mad-l
is lost [109].
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7·9· 3 Role of Genomic Instability

While CIN! ( CIN!) is found in 65-70% of sporadic cancers, there is debate over
whether or not it induces or exacerbate tumorigenesis [4, 102]. As before, genomic instability is considered to initiate tumorigenesis if the following events
occur rapidly. However, it is considered an exacerbating event if it occurs within
an individual but does not initiate tumorigenesis. Finally, if genomic instability
never occurs it does not playa role in colorectal cancer. Defining the role of
genomic instability in this manner produces the results found in Figure 7.8.
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These results suggest that when present, genomic instability generally exacerbates tumorigenesis. Figure 7.8 also illustrates that, as modeled, genomic instability does not often occur in colorectal cancer. This is in contrast to laboratory studies, which find CIN occurs in 65-70% of sporadic cancers, including
colorectal cancer [102]. This indicates that the ABM does not accurately genomic
instability. This could for several reasons: there need to be more genomic instability genes; genomic instability needs to occur when certain barriers are removed,
such as apoptosis; genomic instability needs to increase the mutation rate more
than modeled. However, these modifications may not change the most of the
conclusions because each model takes advantage of genomic instability. Both
Mutation and Reactivation models can mutate genomic instability genes, increasing the chances another barrier is removed. JCV-induced genomic instability can
increase the cell's mutation rate by mutating the hosts own genomic instability
genes. Thus, the overall conclusions may remain similar, but there would like
be more tumors in each model. Even so, any future in carnations of this model
could make the above modifications.

7.9·4

The Role of Infection

If infection plays a role in colorectal tumorigenesis it would be useful to un-

derstand how JCV increases the risk of cancer. Does JCV frequently initiate the
process, or does it exacerbate it? If either are true, this knowledge could be used
to prevent or treat colorectal cancer. Here, an initiating role for JCV is when the
virus' reactivation, either by hit and run or removal of CIF-II, is also the initiating event. JCV is considered to be an exacerbator when activation occurs but is
not the initiating event. JCV has no role if it never becomes active, and mutation
removes all barriers. Non infected individuals are those who were generated during an infection model, but were never infected by JCv. Using these definitions,
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Role of Infection in Tumorigenesis
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the distribution of roles ICV plays in colorectal tumorigenesis can be found in
7·9·
These results indicate that, on average, ICY exacerbates colorectal cancer. This
is likely because immunosuppression, via removal of CIF-IT, occurs at 59.2 years
(SD=20.2 years) in the Full Hit and Run model, while in the Partial Reactivation
model activation occurs at 62.9 years(SD=19.8years). Similarly, the average age
of the first hit and run event is 57 years and 59 years in the Full and Partial Hit
and Run models, respectively. Thus, ICV may primarily act as an exacerbator
because the individual has already accumulated several mutations, and active
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JCV is able to remove the rest, either by forcing the cell to divide (Reactivation
models) and/ or inducing genomic instability (Hit and Run models).
JCV is also frequently an initiator of colorectal cancer. If reactivation of JCV occurs early enough, it would be able to keep the cell alive and dividing constantly,
increasing the chances of future mutations. However, this seems to occur far less
often than when JCV exacerbates colorectal cancer. This likely because the probability of completely removing the CIF-II barrier, inducing immunosuppression,
is only (16000 x 10-8 )2

=

2.56 x 10-8 , at most. This event is so unlikely that it

wouldn't occur in most individuals, and if it did they would most likely be older,
and thus more likely to already have accumulated initiating mutations.
The probability of JCV evolving into the

~98

Mad-l phenotype and hitting and

running is (1.074 * 10-6 * 430bp)2 = 2.132777 x 10-7 . Again, this is a fairly rare
event, and tends to occur in older individuals. However, if JCV did hit and run
earlier, it would likely initiate cancer by inducing genomic instability.

7.9.5

Number of Tumors Formed

Another question one might ask is which model generates the most tumors. This
question can be answered by summing how many of the 25,000 individuals developed cancer, and binning by model. One can further determine whether mutation or infection are responsible for tumorigenesis. Mutation is considered the
cause if a tumor formed when JCV is not present or played no role. Infection is
considered the cause when it either exacerbates or initiates tumorigenesis. The
results can be found in Figure 7.10.
An important conclusion that can be drawn from Figure 7.10 is that mutation is
able to cause colorectal cancer in the absence of JCv. This is true across all models.
Since mutation is required for tumorigenesis, and infection is not, mutation can
be considered the primary cause of colorectal cancer.
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A second conclusion one can draw from Figure 7.10 is that, in the worlds where
infection can cause cancer it does so as much or more often than mutation. This
finding indicates that even though infection is not required for tumorigenesis,
JCV does play in important role in colorectal cancer.
7.10 also illustrates how much exacerbation by JCV increases the risk of cancer.
Three of the four infection models generate more tumors than mutation, indicating that active JCV increases the risk of colorectal cancer. In all cases JCV's
primary role is that of an exacerbator. This adds weight to the hypothesis that
activation of JCV occurs after an individual accumulates several mutations, and
that JCV is able increase the chances all barriers are removed by its ability inhibit
apoptosis and the pro- and anti-growth barriers. In other words, JCV is able to
complete the process of tumorigenesis in individuals that would otherwise not
have developed colorectal cancer. Combined with the finding that JCV activates
at -60 years of age, this suggests that JCV should cause more tumors in older
individuals than the mutation model does. As Figure 7-4 illustrates, this is the
case.
Figure 7.10 also illustrates that the Reactivation models generate the most tumors, suggesting that JCV is most tumorigenic when the host is immunocompromised. This is likely because the formation of a cancer stem cell only requires
that the cell already removed three barriers, and so JCV only needs to remove
the other three. This is particularly true for the Full Reactivation model because
JCV completely removes those three barriers. This is in contrast to the Partial
Reactivation model, as the cell must acquire additional mutations to completely
remove the apoptosis, anti-growth, and pro-growth barriers. This hypothesis is
consistent with the finding that the Full Reactivation model generates many more
tumors than the Partial Reactivation modeL
A surprising finding is that the Full Hit and Run model generates the fewest
tumors. A possible explanation has to do with that fact activation of .198 Mad-1
JCV generates genomic instability and completely removes the apoptosis, pro-
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growth, and ant-growth barriers. Genomic instability will make the cell generate
more mutations than normal, with more being deleterious than beneficial. Removal of the apoptosis, pro-growth, and ant-growth barriers allows the cells to
divide anywhere and everywhere without being killed. Thus, this cell will produce a large volume of daughter cells with the same phenotype. Together this
means that the population will grow rapidly, and that the cells driving the growth
will have an increased number of deleterious mutations. Angiogenesis is a fairly
slow process, as it takes time for the vessels to spread throughout the crypt, and
so it may not be able to provide the rapidly growing population with the oxygen
it needs. This not a problem when ,198 Mad-1 is active, but as soon as it deactivates all of the cells that did not already have apoptosis removed will likely die
because they have too many deleterious mutations. Therefore, the only cells that
will survive are those that either already inhibited apoptosis, or had JCV-induced
genomic instability remove the barrier. This would remove most of the cells that
were hit and run by JCV, almost making the impact of hit and run minimal. This
hypothesis seems to match up with the finding that the Full Hit and Run and
Mutation models generate a similar number of tumors.
This scenario does is not necessarily true for the Partial Hit and Run model.
In this model, while there is JCV-induced genomic instability, the pro-growth,
anti-growth, and apoptosis barriers are only removed half of the time. This will
results in a smaller rate of population growth for two reasons: 1), the population
does not grow as rapidly because the pro- and anti-growth barriers are only removed half of the time, and so the cell cannot divide every time and everywhere;
2) cells that accumulate large numbers deleterious mutations can be die when

apoptosis is not being inhibited by ,198 Mad-1 JCv. The decreased rate of population growth means that, compared to the Full Hit and Run model, there will
be more resources available to cells that survive. Some of these cells would have
acquired beneficial mutations and would have more resources than cells in the
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Full Hit and Run model, so they would be more likely to survive and accumulate
more mutations that result in the formation of a metastatic tumor.
Finally, the above scenario also does not apply to the Reactivation models because after ICV becomes active apoptosis is inhibited for the remainder of that
cell's life, and thus will not be killed when resources become scarce. This is particularly true for the Full Reactivation model, which may also help explain why
it causes the most tumors.

7.9.6

Metastatic Cell Type

It is generally believed that stem cells are the cells which metastasize. The rea-

soning behind this is that stem cells have a long lifespan, giving them plenty of
time to accumulate all of the necessary mutations. This is in contrast to transit
cells, whose existence is fleeting, theoretically preventing them from acquiring all
mutations needed for metastasis. To test this hypothesis, the ABM records which
cell type, transit or stem, metastasizes. The results can be found in Figure 7.11
It seems reasonable to assume that because transit cells inherit their parental

stem cell's mutations, they may only have to acquire one more mutation to have
the opportunity to metastasize. Furthermore, there is only one of these parental
stem cells, while over the course of several years that stem cell will produce hundreds or thousands of daughter cells, any of which can acquire that last mutation.
That transit cells have a higher mutation rate makes this even more likely. It is
also quite possible that the transit cell inherits the stem cell mutations that confer immortality. This long lifespan, combined with a higher mutation rate, gives
these transit cells many opportunities to accumulate beneficial mutations, more
so than stem cells, which have a lower mutation rate. This hypothesis is consistent with the evidence that transit cells may undergo mutation and selection that
enables them to linger in the crypt, giving them time to accumulate the extra
mutations required for tumorigenesis [56, 70].
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7.9.7

Prevalence

The world of the ABM can be interpreted in one of two ways.The first interpretation is that the world represents one crypt in a single individual, and each run
represents lout of 1,000 individuals. The second interpretation is that all runs
represent 1,000 crypts in a single individual. Either situation is far from realistic,
as it has been estimated that there are 1.5 x 107 colon crypts in an individual. That
prevalence can only be calculated by assuming that each run simulates the events
in a single crypt means that modeled prevalence values must be interpreted with
caution. Even so, modeled prevalence values may reveal the age distribution one
might expect given each model's hypothesis, and thus which model is most likely
to be realistic. Each of these models were tested using 3, 6,9,12, or 16 genes, which
will also shed some light on the number of genes per barrier. The modeled prevalence values are found in Figure

7.12,

while the Euclidian distance between the

observed prevalence and modeled prevalence is found in Figure

7.13.

The modeled prevalence values suggest that the Full Reactivation model with
six genes per barrier best replicates the observed prevalence, supporting the hypothesis that infection plays an important role in tumorigenesis. Both the Mutation and Full Hit and Run models with nine genes per barrier are not too far
behind. These results are consistent with the finding that all models are able to
generate tumors.

7.10

CONCLUSIONS

The findings presented above reveal that mutation is the primary cause of colorectal cancer, as it is able to generate a large number of tumors without ICV.
Mutation is also critical in tumorigenesis, not only because it must remove the
barriers infection cannot, but because mutations that up-regulate telomerase and
inhibit apoptosis frequently initiate tumorigenesis.
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While mutation is the primary cause of colorectal cancer, infection plays an
important secondary role, usually exacerbating cancer. The Reactivation models,
which posit that JCV is activated by mild immunosuppression, is most frequently
an exacerbator, but is highly tumorigenic. This is likely because immunosuppression occurs later in life, after tumorigenesis is already initiated. Once activated,
JCV removes three important barriers that keep itself and the cell replicating
and immune to apoptosis. Together, these processes will keep the cell alive long
enough to accumulate additional mutations, thus increasing the chances that a
cancer stem cell will evolve.
The Hit and Run models are also most frequently exacerbators, but they are
less tumorigenic. The transient nature of hit and run means that the cell will
only have genomic instability and the transformed phenotype for a short period
of time, after which it returns to its previous state. The cell will only become
more carcinogenic if it removes other barriers while the L\98 Mad-1 phenotype
is present. JCV-induced genomic instability may mutate the host's genomic instability genes, maintaing a mutator phenotype after L\98 Mad-1 is lost, thereby
increasing the chances additional mutations accumulate [109]. This won't happen with every cell, which may explain why the hit and run mechanism is less
tumorigenic.
While JCV most often exacerbates tumorigenesis, it also frequently initiates the
process. Activation of JCV by immunosuppression may be able to induce cancer
by forcing the cell to divide, increasing the chance of mutation and possible barrier removal. Since the cell is constantly dividing, the likelihood of a beneficial
mutation occurring after reactivation is higher than if JCV is not present, which
may be how JCV initiates tumorigenesis in the Reactivation model. If a hit and
run event occurs early, JCV-induced genomic instability could initiate tumorigenesis by increasing the chances that a mutation in a beneficial gene soon occurs,
thus initiating tumorigenesis.
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Another important finding is that in the infection models mutation is responsible for fewer tumors than in the model where mutation is the only cause of
colorectal cancer. This may be because individuals have already acquired mutations in the cancer barriers prior to activation of JCV, which usually occurs
around 60 years of age. JCV can remove the rest of the barrier either by keeping
the cell alive long enough for it to acquire additional mutations and/or by generating genomic instability. The finding that, more often than not, JCV exacerbates
tumorigenesis is consistent with this hypothesis.
It is difficult to say which infection model is most accurate, as the Hit and

Run models have the most experimental support, while the Full Reactivation
model best replicates the observed data. However, in all cases mutation is the
primary cause of colorectal cancer, but JCV plays an important role by exacerbating, and less frequently initiating, colorectal cancer. Given that mutation and
infection play key roles in tumorigenesis, colorectal cancer can be considered a
multifactorial disease.
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CHAPTERS

CONCLUSIONS

Taken together, the models presented herein indicate that both mutation and
infection play important roles in colorectal tumorigenesis. Each of the probability
models find that mutation is insufficient to drive colorectal cancer, no matter if
the stem cell point mutation rate is f.1 = 10-10 or f.1 = 10- 11 • Conversely, the
infection model is able to generate realistic incidence values when f.1 = 10- 11 •
These results suggest that infection is the primary cause of colorectal cancer,
as tumorigenesis will not occur in the absence of ICV. However, the Geometric
model comes to the opposite conclusion, as it finds that mutation alone is able to
drive colorectal cancer. Where both models agree is in finding that the presence
of infection dramatically increases the risk of colorectal cancer.
The ABM appears to resolve the conflicting results of the probability and Geometric models. This collection of models finds that both mutation and infection
are able to drive tumorigenesis, and that all models can generate realistic prevalence values. Since colorectal cancer does not absolutely require infection, ICV
cannot be considered the primary cause. Despite its secondary role, the presence
of active ICV increases the risk of cancer, as it increases the number of tumors
and initiates or exacerbates tumorigenesis more often that it plays no role. The
finding that both mutation and infection play important roles in colorectal tumorigenesis is also consistent with the estimate that -25% of colorectal cancers
result from multifactorial contributions of different risk factors [9]. While the
authors argue that these 25% of cases occur as the result of inheriting many
rare dominant alleles that have low penetrance, but together increase the risk of
colorectal cancer, the results presented here suggest the alternative hypothesis
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that infection is one of those critical environmental factors that accounts for an
increased risk of cancer.
Colorectal cancers are usually divided into two categories, but these results
suggest that it should be divided into three. This first is all colorectal cancers
caused by germline mutations, primarily Family Adenomatous Polyposis (FAP)
and Hereditary Nonpolyposis Colorectal Cancer (HNPCC). This category contains the fewest individuals, likely because the high-risk alleles reduce the individual's fitness, and have decreased in frequency due to negative selection. The
second category is colorectal cancer caused soley by somatic mutations. As modeled, this is the second largest category. The individuals in this category likely
develop colorectal cancer through the accumulation of the mutations described
in Chapter

2,

namely Adenomatous Polyposis Coli (APC), Kristen Rat Sarcoma

Virus (KRAS), SMAD, and P53.
The third and new category is JCV associated colorectal cancers. As modeled,
this is the largest category of colorectal cancer cases. Individuals in this category
may frequently have somatic mutations in APC , KRAS, SMAD, and/ or P53, predisposing them to colorectal cancer. In the absence of JCV, these individuals may
simply develop benign colorectal tumors, which are present in 50% of the population [64]. Activation of JCV, either by immuosuppression or the evolution of
,198 Mad-I, typically occurs at age 60, after the somatic mutations have occurred.
This event may transform the tumor from benign to malignant, causing tumors in
individuals that would not have developed malignant colorectal cancer without
JCV.
In addition to shedding light on the drivers of tumorigenesis, these models
add weight to the hypothesis that natural selection has favored a lower stem
cell mutation rate. While evolution has the power to select against the germline
mutations that increase the risk of FAP and HNPCC, it cannot directly select
against somatic mutations. However, by selecting for a lower mutation rate in
stem cells, evolution can decrease the frequency of colorectal cancer. Both the
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probability and Geometric models confirm this hypothesis, as mutation is unable
to generate cancer patients when the stem cell mutation rate is

100

times lower

than the transit cell rate. This finding is in agreement with the work of Frank
et al. [43], who also concluded that a stem cell mutation rate that is

100

times

lower provides sufficient protection against cancer.
Unfortunately, not much can be said about the number of genes per barrier,
as the number that fits best is different across each set of models. The primary
conclusion that can be made is that the more genes that are involved in a pathway,
the more likely that pathway is to be disturbed.
The results from these models suggest colorectal cancer is a multifactorial disease. Mutation is required for tumorigenesis, but infection by JCV increases the
risk of colorectal cancer, either by initiating or exacerbating colorectal cancer. In
combination with the findings of numerous studies that demonstrate JCV's oncogenic potential and frequent presence in colorectal tumors, the results presented
here suggest that JCV's role in colorectal cancer deserves more attention. A good
place for future studies to start might be to determine titers of Mad-l JCV in
colon tumors of cancer patients throughout their treatment. If it is found that individuals with higher titers of JCV Mad-l are at higher risk of colorectal cancer,
it would reinforce the hypothesis that JCV is an important risk factor for colorectal cancer. If further studies confirm these findings there would be good reason
to develop a vaccine against JCV. While vaccination would not eradicate colorectal cancer, as mutation can still drive tumorigenesis in the absence of infection,
it would reduce the number of colorectal cancer cases. These results, therefore,
are encouraging, as they present the possibility of decreasing the prevalence of
colorectal by reducing the rate of infection by JCv.
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APPENDIX A

A.1

R CODE FOR PROBABILITY MODELS

ESTIMATING PREVALENCE OF COLON CANCER: CONSTANT MUTATION,
CONSTANT STEM CELL POPULATION

The following code creates two different models of colon cancer development,
but in each case the mutation rate and stem cell numbers remain constant. The
first model argues that mutation drives the development of colon cancer, while
the second hypothesizes that infection initiates the oncogenic process. Each model
is also executed using the parameters from Calabrese and Shibata [17] as well as
more recent parameter estimates 1 •

A.I.1

A.I.I.1

Creating the Initial Dataframe

Import Observational Data

The first step of the program is to import actual data of colorectal cancer (CRC),
using the SEER database SEE [2]. This was accomplished by downloading the
data and creating new vectors (CRC_2003_2007 and CRC_2ooo_2006) containing
the incidence data. The data used in Calabrese and Shibata [17] was found in
the appendix of their paper. The ICV prevalence data was taken from Table 1
of Knowles et a!. [68]. Note that from ages 0-19, prevalence was recorded every
5 years, but from ages 20-69 prevalence was recorded only every 10 years. As
the CRC data are recorded every 5 years, the first five years in each age group
1 The parameters values used in this example are different than the ones used to generate the results in
Chapter 5. Here, genomic instability is 1.5, while in the actual models it is 2. Gene length here is 1500bp,
while in the models it is lOoobp.
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over 20 years old was assigned an NA value. For example, prevalence of JCV at
30-34 is considered "NA", while at the ages of 35-39 JCV prevalence is 0.39 (i.e.
prevalence is not divided across the ten years).
Plots found on the SEER website and Calabrese and Shibata [17] plot incidence
data for the median age of an age group. For example, the incidence of CRC in the
age group of 30-35 is plotted at age 32.5. As such, the vector AverageAgeCancer
was created to contain these median ages. The code used to accomplish these
tasks can be found below:
See r€l3€l7< - read. c s v ( "/Users/ chandlergatenbee/Docurnents/UofL/CancerProbPaper/Observed
Data/CRCQJ-07.csv") #Co lon cance r data f rom SEER 2€l€l3 -2€l€l7

CRC_2€l€l3_2€l€l7<-Seer€l3€l7[,2) #Slice CRC incidence values from table

See r€l€l€l6< - read. c s v ( "/Users/ chandlergatenbee/Docurnents/UofL/CancerProbPaper/Observed
Data/CRCoo-o6.csv") #Co lon cance r data f rom SEER 2€l€l€l -2€l€l6

CRC_2€l€l€l_2€l€l6<-Seer€l€l€l6[,2) #Slice CRC incidence values from table

CalabreseData<-c(€l, €l, €l, €l.€l7, €l.18, €l.47, 1.46, 2.82, 5.59, 11.14, 21.59, 42.72,
77.94, 125.98, 184.€l4, 25€l.96, 319.14, 387.22, NA) #Actual data used in
Calabrese 2€l1€l; from SEER 1992-1999

CalabreseAgeRange<-seq(€l,9€l,5) #Age Values used by Calabrese to calculate
probability of cancer

SeerAges<-Seer€l3€l7[,1) #Age categories used by SEER

JCVPrevalence<-c(NA,€l.11,€l.14, €l.24, €l.22, NA, €l.34, NA, €l.39, NA, €l.34, NA, €l.45,
NA, €l.5, NA, NA, NA, NA) #JCV Prevalence by age From Knowles 2€l€l3

AverageAgeCancer<-rep(€l,length(CalabreseAgeRange))
forti in 2:1ength(CalabreseAgeRange)){
AverageAgeCancer[i)<-mean(CalabreseAgeRange[(i-1):i))}
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A.1.1.2

Create Empty Dataframes that will be filled in with results

Two sets of vectors were created to capture the results from the analysis, the
first set using old parameter values, the second set using new paramter values:
"ProbInfection", "Incidence_Infection", "ProbMutation", and "Incidence_Mutation"
were used to collect the results created using the parameters found in Calabrese
and Shibata [17]; "ProbInfectionNew", "Incidence_InfectionNew", "ProbMutationNew", and "Incidence_MutationNew" were used to collect the results created using new parameter values. The code used to create these vectors can be
found below:
#Empty vectors to be used with parameters from Calabrese
Problnfection<-rep(0,length(CalabreseAgeRange))
Incidence_Infection<-rep(0,length(CalabreseAgeRange))
ProbMutation<-rep(0,length(CalabreseAgeRange))
Incidence_Mutation<-rep(0,length(CalabreseAgeRange))

#Empty vectors to be used with New Parameters
ProblnfectionNew<-rep(0,length(CalabreseAgeRange))
Incidence_InfectionNew<-rep(0,length(CalabreseAgeRange))
ProbMutationNew<-rep(0,length(CalabreseAgeRange))
Incidence_MutationNew<-rep(0,length(CalabreseAgeRange))

A.1.1. 3

Estimating Incidence of ICV Infection

JCV prevalence data from Knowles et al. [68] only contains estimates for ages 1-4,
5-9, 10-14, 15-19, 20-29, 30-39, 40-49, 50-59, 60-69, while the CRC prevalence data

is available for ages 0-85+, in increments of five years. Thus, linear interpolation
of the regression line was performed on the Knowles et al. [68] data set, so as
to fill in all missing values as well as to estimate JCV prevalence in individuals

over 70 years old. The estimated prevalence values were then stored in the vector
"JCVEstimatedPrev". The code used was as follows:
RegPrev<-lm(JCVPrevalence-AverageAgeCancer)
JCVEstimatedPrev<-coef(RegPrev) [2]*AverageAgeCancer+co ef(RegPrev) [1]

These estimated values were then plotted against the actual values from Knowles
et a1. [68] to ensure that the prevalence pattern remained consistent. The following code generated the plot which can be compared to the plot from Knowles
et a1. [68] (Figure A.I):
xrangelm<-AverageAgeCancer
yrangelm<-seq(0,0.5,0.5/(length(xrangelm)-1))
plot (xrangelm, yrangelm, xlab="Age of Infection", ylab="Prevelance of JCY", main="
Estimated Prevalence of JCY Infection", type="n")
points(AverageAgeCancer,JCVPrevalence,pch=l,col=l) #Observed Prevalence
points(AverageAgeCancer,JCVEstimatedPrev,pch=2,col=2) #Estimated Prevalence
abline(RegPrev)
legend(0,0. 5, c( "Actual Prevalence of JCY", "Estimated Prevelance of JCY", "Estimated
Prevelance for Each Age") , lty=c(NA, 1,NA) ,pch=c( 1,NA, 2) ,col=c( 1,1,2))
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Finally, the model developed herein requires JCV incidence, however Knowles
et a1. [68] only provides JCV prevalence. Thus, JCV incidence was estimated by
finding the average change in JCV prevalence, the results being stored in the
vector "JCVIncidence". These values were then averaged, yielding an average
incidence of 0.02716503 every five years (Note: the first incidence value was not
included as it is NA):
JCVlncidence<-rep(NA,length(AverageAgeCancer»
for(i in 2:length(JCVEstimatedPrev»{

JCVIncidence[i]< -JCVEstimatedPrev[i] -JCVEstimatedPrev[(i-Il] }

AvgJCVIncidence< -mean(JCVIncidence[-I]l

A.1.1.4

Creatil1g the Dataframe

All vectors were compiled into a dataframe labeled "CRC" using the code below.
The resulting dataframe can be found in Figure A.2.
CRC<-data.frame(SeerAges, CalabreseAgeRange, AverageAgeCancer, JCVPrevalence,
JCVEstimatedPrev, JCVIncidence, CRC_2000_2006, CRC_2003_2007, CalabreseData,
ProbMutation, ProbMutationNew, Incidence_Mutation,

Incidenc~MutationNew,

ProbInfection, ProbInfectionNew, Incidence_Infection, Incidence_InfectionNewl
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Figure A.z: Initial CRC Dataframe

A.1.2

Setting Initial Parameters

The following code contains the parameter values used in all models. Parameters
ending with a

/1 1 /1

(or no number) refer to values obtained from Calabrese and

Shibata [17] while those ending in /12" refer to those obtained elsewhere. k refers
I

to the number of barriers to cancer; u refers to the mutation rate; Nm refers to the

1 53

number of colon stem cells; N s refers to the number of colon stem cells infected
by JCv.
#Constant Parameters
k1<-6 #number of barriers to cancer (from Hanahan)
k2<-kl-3 #estimated number of barriers left after JCV infection.
u1<-3*(10 A-9)*(1000) # "If three genes are at risk in a pathway, then the
probability of mutation (u) of anyone of the three genes in a single division
is 3 * 10-6 instead of 1* 10-6 with a single gene target[of 1000bp] " Calabrese
2010
u2<-3*(10 A-8)
Nm<-8*lS000000 # Number of stem cells in the colon. 8 stem cells per crypt,
15,000,000 crypts in the colon (From Calabrese)
Nm2<-S*lS000000
Ns=Nm*0.9S #Estimated number of actively infected colon crypt cells
Ns2<-Nm2*0.9S

A.I. 3

Functions Used to Calculate Probability of Cancer

The following code was used to create functions that calculate the probability
of colon cancer for any given age. For the mutation model, the inputs are the
current age, number of stem cells in the colon (N), and the mutation rate (Il-).
The infection model includes all of the above, but with the addition of age of
infection, so that the total amount of time an individual has been infected by JCV
can be calculated.
#Probability Models

#Mutation model
page1<-function(age,N,u){
d1=age*36S*0.2S #Estimated From Calabrese. Number of stem cell divisions.
p0<-1-((1-(1-(1-u)Ad1)Ak1)AN) #Calabrese
p0

}
154

#Infection Model
page2<-function(agenow,ageinfection,N,u){
d2=(agenow-ageinfection)*365*0.25 #Number of infected cell divisions=Number
of years infected with JCV * Number of days in a year * I division every
4 days
pl=(I-(I-(I-(I-u)Ad2)Ak2)A(N))
pI

A.1.4

}

Mutation Model

As the mutation model argues that the oncogenic process begins at birth, calculating the cumulative probability of cancer in the mutation model is simply
a matter of using the above function (pagel.) on each age group. The vector
CRC["ProbMutation"] collects the results when using the parameter values found
in Calabrese and Shibata [17], while CRC["ProbMutationNew"] collects the probabilities when the new parameters are used.
CRC ["ProbMutation" J<-pagel (CalabreseAgeRange, Nm, ul)
CRC [ "ProbMutationNew" J<-page I (Ca lab reseAgeRange, Nm2 , u2)

A.1.5

Infection Model

Calculating the cumulative probability of cancer with infection is a bit more difficult than when dealing with mutation alone. The reason is because one must
take into account how long an individual has been infected, which is the difference in current age and age of infection. Thus, one must create a matrix that has
each possible current age as one row, and each possible age of infection as one
column. Such a matrix was created using the following code:
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agenow< -CalabreseAgeRange
ageinfect<-CalabreseAgeRange
agenowVageinfect<-matrix(nrow=length(agenow),ncol=length(ageinfect),dimnames=list(c(
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AgeInfect85 " , "Agelnfect90" ) ) )

The empty matrix that is created can be found in Figure A.3 .
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Figure A.3

A.1.5 .1

Parameters from Calabrese and Shibata [I7]

The empty matrix from above can be filled in with the probability of cancer for a
given period of infection by using the page2 function, using current age and age
of infection as parameters. Note that Ns is used in these calculations (as opposed
to N), as it reflects the number of infected colon stem cells (95% of colon stem
cells). Only half of the matrix was filled in, since an individual cannot be infected
before they were born (i.e. agenow>ageinfect). The code used to fill in the matrix
is as follows:

for(i in l:length(agenow)){
for(k in l :length(ageinfect)){
ifelse(agenow[ij>=ageinfect[kj,
agenowVageinfect[i,kj< - page2(agenow[ij,ageinfect[kj,Ns2,u2),
agenowVageinfect[i , kj< -0 ) } }

The filled in matrix can be found in Figure A.4
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Each element of the matrix above gives the probability of cancer given a particular length of infection (i.e. current age i-age of infection k), and thus provides
the probability of colon cancer given each combination of current age and age
of infection. However, one must also take into account the probability that the
individual was actually infected by JCV at age k, which can be accomplished
by multiplying each element by the average incidence of JCv. Afterwards, one
can sum across each row to determine the cumulative probability of colon cancer
given infection by JCV for each current age, yielding the predicted prevalence of
colon cancer for each age. The logic behind this is that prevalence is equal to the
total number of cases, which is the sum of all new cases (incidence), past and
present, for each current age. For example, the prevalence of CRC at age 60 includes all individuals that developed CRC at age 30,35,40 ... 60, which is equivalent to summing across each row of the above matrix. These values were then
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stored in CRC["Problnfection"]. The code used to accomplish this is as follows
(Note: if the cumulative probability of colon cancer exceeded

it was replaced

1,

with a value of I):
agenowVageinfect[which(is.na(agenowVageinfect==TRUE))]=0 #replace NA values with 0
for(i in l:length(CalabreseAgeRange)){
ifelse(sum(agenowVageinfect[i,l:length(ageinfect)])<l,
CRC[ "ProbInfection"] [i, l]<-sum(agenowVageinfect [i, 1: length (ageinfect)]) *
AvgJCVlncidence,
CRC["Problnfection"] [i,l]<-l) }

A.1.5.2

New Parameters

The same method as described in A.1.5.1 was used to calculate the expected
prevalence of colon cancer with infection, but using the new parameter values.
The" AgeNowVsAgelnfect" matrix can be found in Figure A.5.After all calculations were completed, they were stored in CRC["ProblnfectionNew"].
agenow<-CalabreseAgeRange
ageinfect<-CalabreseAgeRange
agenowVageinfect<-matrix(nrow=length(agenow),ncol=length(ageinfect),dimnames=list(c(
"Ana1\.h .. ..,,"

.J.~,"",-,"vv ,

"Al'1II::.ll\.hA~"

.J.~"""""'J

,

"Anol\.hA..Mn"
.J.~~"V.vJ

,

"AncJ\.TrnAM

L~'"RJ"V.L5

n

' "Anal\.hA,7""'V\"
.L~~"YQ.J

I

"A.nol\.h,u~"

.L~--..yy,,'J

,

"A.~h,,7""'V\"

.L~~"Yy ,

"

AgeNowju" , "AgeNOwzs" , "~ow8o" , "~0w8s" , "AgENOwgl" ) , c ( "AgeInfecto" , "
Agelnfect5" , "AgeInfectIo" , " AgeInfectI5" , "AgeInfect2o" , "Agelnfect25" , "AgeInfect30
", "Agelnfect35" , "Agelnfect4o", "AgeInfect45" , "Agelnfect50", "AgeInfect55" ,"
Agelnfect6o", "AgeInfect65" , "AgeInfect7o", "AgeInfect75" , "AgeInfectBo","
AgelnfectB5" , "Agelnfect90" ) ) )

for(i in l:length(agenow)){
for(k in l:length(ageinfect)){
ifelse(agenow[i]>=ageinfect[k],
agenowVageinfect[i,k]<-page2(agenow[i],ageinfect[k],Ns2,u2),
agenowVageinfect[i,k]<-0 ) } }

agenowVageinfect[which(is . na(agenowVageinfect==TRUE))]=0 #replace NA values with 0
for(i in l:length(CalabreseAgeRange)){
ifelse(sum(agenowVageinfect[i,l:length(ageinfect)])<l,
CRC ["ProblnfectionNew"] [i, l]<-sum(agenowVageinfect [i, 1: length (ageinfect)] ) *
AvgJCVlncidence,
CRC [ "ProblnfectionNew" ] [i, 1] <-1) }
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Figure A.5

A.1.6

Converting Data from Prevalence to Incidence

The probability values generated reflect the cumulative probability (i.e. prevalence) of colon cancer for each age group. However, the data from SEE [2] are in
the form of incidence per age group, per

100,000

individuals. As such, the preva-

lence data were converted to incidence by taking the difference in probability
of colon cancer between each age group. Afterwards, the incidence values were
multiplied by

100,000

so as to provide the expected incidence of CRC per 100,000

individuals. This was accomplished by using the following code:
#Calculate Incidence of Colon Cancer, per 100,000

#Mutation

159

for(i in 2:length(CRC["ProbMutation")[,I])){
CRC ["Incidence_Mutation"] [i, ]<- (CRC[ "ProbMutation"] [i, ]-CRC ["ProbMutation"
][(i-l),])*leeeee
}

for( i in 2: length(CRC[ "ProbMutationNew"] [,1]) ) {
CRC[ "Incidence_MutationNew"] [i, ]<- (CRC[ "ProbMutationNew"] [i, ]-CRC["
ProbMutationNew"] [ ( i-I) , ] ) * leeeee
}

#Infection

for( i in 2: length (CRC [" ProbInfection"] [, 1]) ){
CRC [ "Incidence_ Infection" ] [i, ] < - (CRC [" ProbInfection"] [i, ] -CRC [ "
Problnfection"] [( i-I) , ] ) *leeeee
}

for(i in 2 :length(CRC[ "ProbInfectionNew"] [, 1])){
CRC[ "Incidence_InfectionNew"] [i, ]<- (CRC[ "ProblnfectionNew"] [i, ]-CRC[
"ProblnfectionNew" ] [ (i - 1) , ] ) * leeeee
}

A.!. 7

A.I.7.l

Results

Dataframe

After being filled in by the above code, the CRC dataframe looks as follows:
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Figure A.6:

Plots

For the purposes of plotting, the incidence data were converted to log-scale, so
as to emphasize the different predictions between the mutation models and the
infection models. If the incidence was 0, then log (0) yields
cannot fit onto the plot. Therefore, values that did yield

- 00,

- 00

which obviously

were replaced with

- 25.22388, which reflects the smallest predicted probability. The code used to
accomplish this is as follows :
#Adjust data so the log can be taken: if prob=0, then 10g(0)=-Inf, which won
't fit on a graph . Set min to -25.22388, the smallest probability
produced in Stepwise Model that was not -Inf
logIMOld<- log (eRe [, "Incidence_Mutation"] )
10gIMNew<- log (eRe [, "Incidence-MutationNew"] )
10gIIOld<- log (eRe [, "Incidence_Infection "] )
logIINew<-log (eRe [, "Incidence_InfectionNew "] )

#Replace -Inf with -25

#Mutation, Old Parameters
forti in 1:1ength(logIMOld)){
ifelse(logIMOld[i]==-Inf ,
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logIMOld[ij<--25.22388,
logIMOld[ij<-logIMOld[ijl }

#Mutation, New Parameters
forti in I:length(logIMNewll{
ifelse(logIMNew[ij==-Inf,
logIMNew[ij<--25.22388,
logIMNew[ij<-logIMNew[ijl

}

#Infection, Old Parameters
forti in I:length(logIIOldll{
ifelse(logIIOld[ij==-Inf,
logIIOld[ij<--25.22388,
logIIOld[ij<-logIIOld[ijl }

#Infection, New Parameters
forti in I:length(logIINewll{
ifelse(logIINew[ij==-Inf,
logIINew[il<--25.22388,
logIINew[il<-logIINew[ill }

After transforming the data, the following code was used to generate plots
comparing the observed data to each model's predictions, given the parameters
used in Calabrese and Shibata [17] (the resulting plot can be found in FigureA.7a

#Log Plot of Predicted Cancer Incidence Probability,As a Function of Age, With Real
Data.lnfection and Mutation Models, Old Parameters

xrange<-CalabreseAgeRange

ymax<-max( CRC [, "Incidence_Infection" jl lymax<-log(ymaxl
lymin<--25.22388 #8ased off results from stepwise model. Otherwise, log(CRC[,"
Incidence_MutationNew"ll yields -Inf for all values because (CRC[,"Incidence_
MutationNew"jl is 0
yrange<-seq(lymin,lymax,(lymax-lyminl/(length(xrangel-III
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plot(xrange, yrange, type="n", xlab="Current Age",Ylab="ln(Incidence of Cancer, per
100,00)" ,main="Incidence of Colon Cancer", sub="k=6N=8,u=3*10"---6") points (
AverageAgeCancer,10g(CalabreseData),pch=19,lty=1)
points (Ave rageAgeCancer, log (CRL2f>f>(L2(:Hl6) ,pch=l, lty=l)
points(AverageAgeCancer,10g(CRC_2f>f>3_2f>f>7),pch=2,lty=1)
lines (CalabreseAgeRange, 10gIMOld, col="red")
lines(CalabreseAgeRange,10gIIOld,col="blue",lty=2)
legend(2f>, -If>,c(''Observed Data 1992-1999", "Observed Data 2000-2006", "Observed Data
2003-2007" , "Mutation Model", "Infection Model"), col=c (1,1,1, "red" , "blue") , lty=c(
NA,NA,NA,1,2),pch=c(19,l,2,rep(NA,2)))

A similar set of code was used to plot the results of each model's predictions,
given the new parameters (the resulting plot can be found in Figure A.7b):
#Log Plot of Predicted Cancer Incidence Probability,As a Function of Age, With Real
Data. Both Models, New Parameters
xrange<-CalabreseAgeRange
ymax< -max (CRC [ , "CRC.2ooo_2006" ) )
lymax<-log(ymax)
lymin<--2S.22388 #Based off results from stepwise model. Otherwise,log(CRC[,"
Incidence_MutationNew")) yields -Inf for all values because (CRC [," Incidence_
MutationNew")) is f>
yrange<-seq(lymin,lymax, (lymax-lymin)/(length(xrange)- 1))
plot(xrange, yrange, type="n", xlab="Current Age",ylab="ln(Incidence of Cancer, per
100,00)" ,main="Incidence of Colon Cancer", sub="k=6N=5,U=3*lo"--8")
pOints(AverageAgeCancer,10g(CalabreseData),pch=19,lty=1)
points(AverageAgeCancer,10g(CRC_2f>f>f>_2f>f>6),pch=l,lty=1)
points(AverageAgeCancer,log(CRC_2f>f>3_2f>f>7),pch=2,lty=1)
lines(CalabreseAgeRange, 10gIMNew, col="red")
lines(CalabreseAgeRange, 10gIINew, col="blue", lty=2)
legend(2f>, -If> ,c( "Observed Data 1992-1999", "Observed Data 2000-2006", "Observed Data
2003-2007", "Mutation Model", "Infection Model"), col=c(l, 1, 1, "red", "blue"), lty=c(
NA,NA,NA,1,2),pch=c(19,l,2,rep(NA,2)))
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A.2

ESTIMATING INCIDENCE OF COLON CANCER: GENOMIC INSTABILITY
MODEL

A problem of the static model described above is that it assumes all cells have
an equal probability of acquiring enough mutations to knock out each barrier.
However, it seems more realistic that a subset of cells will acquire the first mutation, and that this subset will have a head start in the race towards cancer. Thus,
the following model tracks how many cells have acquired x mutations. This task
is accomplished by determining the probability that anyone cell has acquired
a mutation. That probability is then multiplied by the current number of colon
stem cells, yielding the expected number of stem cells that have acquired x mutations. This process is repeated until all barriers to cancer have been removed,
and as such the number of cells carrying x mutations decreases over time. Furthermore, it has been observed that the mutation rate increases throughout the
development of cancer cells, a process known as genomic instability. This model
tries to capture the impact of genomic instability by increasing the mutation rate
by 150% every time a barrier is removed. Finally, this model uses the "new parameters" described above (i.e. !lo

A.2.1

= 3 x 10-8 and m = 5 stem cells per crypt).

Importing the Observed data

Just as in the static model, the first step of this code is to import the observed
data on CRC incidence and JCV prevalence:
See re3e7< - read. c sv ( "I Usersl chandlergatenbee/Docurnents/UofL/CancerProbPaperIObserved
Data/CRO:lJ-07.Csv") #Colon cancer data from SEER 2ee3-2ee7
See reeS6< - read. c s v ( "/Usersl chandlergatenbee/Docurnents/UofL/CancerProbPaperIObserved
Data/CRCoo-06.csv") #Co lon cance r data f rom SEER 2eeS -2ee6
CalabreseAgeRange<-seq(e,9S,5) #Age Values used by Calabrese to calculate
probability of cancer SeerAges<-Seere3e7[,l] #Age categories used by SEER
CRC_2eee_2eS6<-Seereee6[,2] #Getting actual values

CRC_2003_2007<-Seer0307[,2) #Geetting actual values
JCVPrevalence<-c(NA,0.11,0.14, 0.24, 0.22, NA, 0.34, NA, 0.39, NA, 0.34, NA, 0.45,
NA, 0.5, NA, NA, NA, NA) #JCV Prevalence by age From Knowles 2003
AverageAgeCancer<-rep(0,length(CalabreseAgeRange))
for(i in 2:length(CalabreseAgeRange)){
AverageAgeCancer[i)<-mean(CalabreseAgeRange[(i-1):i))
}

JCVAvgPrevalence<-rep(NA,length(JCVPrevalence))
for(i in 2:length(JCVPrevalence)){
JCVAvgPrevalence[i)<-mean(JCVPrevalence[(i-1):i])
}

CalabreseData<-c(0, 0, 0, 0.07, 0.18, 0.47, 1.46, 2.82, 5.59, 11.14, 21.59, 42.72,
77.94, 125.98, 184.04, 250.96, 319.14, 387.22, NA) #Actual data used in
Calabrese; from SEER 1992-1999

A.2.2

Creating Empty Vectors

Two vectors were created to collect the results of this model: "PrevInfectInit" collects the prevalence data generated by the Infection Initiation Model (i.e. Infection
Model); "PrevMutation" collects the prevalence data generated by the Mutation
model:
Prevlnfectlnit<-rep(0, length(CalabreseAgeRange)) Incidence_Infectlnit<-rep(0,length(
CalabreseAgeRange))

PrevMutation<-rep(0,length(CalabreseAgeRange)) Incidence_Mutation<-rep(0,length(
CalabreseAgeRange))
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A.2.3

Estimating leV Incidence

As in the static model, ICV incidence was estimated by linearly interpolating
missing values of the ICV prevalence regression line, and then taking the difference between the prevalence values for each age group. The same code used
above was used here as well:
#Force Regression Line to go through origin: no evidence that JCV is vertically
transmitted
RegPrev<-lm(JCVPrevalence-AverageAgeCancer)
JCVEstimatedPrev<-coef(RegPrev) [2]*AverageAgeCancer+co ef(RegPrev) [1]

#Plot to Verify Predicted Values fit Regression Line
xrangelm<-AverageAgeCancer
yrangelm<-seq(0,0.5,0.5/(length(xrangelm)-I))
plot (xrangelm,yrangelm,xlab="Age of Infection", ylab="Prevelance of ICY" ,main="
Estimated Prevalence of

ICY Infection", type="n")

points(AverageAgeCancer,JCVPrevalence,pch=I,col=l) #Observed Prevalence
points(AverageAgeCancer,JCVEstimatedPrev,pch=2,col=2) #Estimated Prevalence
abline(RegPrev)
legend(0, 0.5, c("Actual Prevalence of ICY", "Estimated Prevelance of ICY", "
Estimated Prevelance for Each Age"), lty=c(NA,I,NA), pch=c(I,NA,2), col=c(1.1,2)

#Calculate JCV incidence
JCVlncidence<-rep(NA,length(AverageAgeCancer))
forti in 2:1ength(JCVEstimatedPrev)){
JCVlncidence[i]<-JCVEstimatedPrev[i]-JCVEstimatedPrev[ (i-I)]
}

AvgJCVlncidence<-mean(JCVlncidence[-I])

A.2.4

Setting Initial Parameters

As noted above, the "new" parameter values were used in this simulation, as
their description is more recent and consistent with stem cell theory. The only
addition to these parameters was "mutincrease", which describes the degree of
genomic instability, here estimated as a

1.5X

increase in the mutation rate every

time a barrier is removed.
#Constant Parameters
u<-3 #Total number of genes that can knock possibly out each barrier.-4 per barrier.
Note, on COSMIC (Catolog of Somatic Mutations In Cancer) there are only 7 genes
known to have mutations related to cancer of the GI tract (http://www.sanger.ac
.uk/ perl/ genetics/ CGP/ cosmic?action=byhist&ss=NS&ss=lymph_node&sn=
gastrointestinal_tract_%28site_indeterminate%29&s=3&hn=carcinoid-endocrine_
tumour&hn=other&hn=carcinoma).
kl<-6 #number of barriers to cancer (from Hanahan)
k2<~3

#estimated number of barriers remaining after JCV infection

ul<-u*(10 -8) #Muations for stem cell lineages. Mutation rate from Frank 2003, and
A

is per gene per divsion (they suggest the division rate for stem cells is
actually between l0 -7 and l0 -10, so l0 -8 is between, although it is still on
A

A

A

the higher side). ul=#genes that can knockout pathway * stem cell mutation rate
* Number of genes active in a cell (Frank 2004)
Nm<-5*(15000000) # Number of stem cells in the colon. 5 stem cells per crypt,
15,000,000 crypts in the colon (From Calabrese). Assuming these cells are C0133+
Ns=Nm*0.95 #Estimated number of stem cells infected by JCV
mutincrease<-l.S #Amount mutation rate is increased by after each barrier is
knocked down: Genomic Instability

A.2.5

Creating the Dataframe

After all vectors were created, they were collected in a dataframe called "CRC"
(the resulting dataframe can be found in Figure A.8):
168

#Main Data frame
CRC< -data.frame(SeerAges, CalabreseAgeRange, AverageAgeCancer, JCVPrevalence,
JCVEstimatedPrev, JCVIncidence, CRC_2000_2006, CRC_2003_2007, CalabreseData,
PrevMutation, Incidence_Mutation, PrevInfectInit,
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A.2.6

Creating Genomic Instability

A vector containing the increase in mutation rate was created using the code
below. A vector was created so that it's elements could be accessed later during
the modeling process. The resulting vector can be found in Figure A.9.
#Genomic Instability

GI< - c(l,rep(NA,kl-l))
for(i in 2:length(GI)){
GI[i]< -GI[i - l] *mutincrease }

>

GI

[lJ 1 .00000 1 . 50000 2.25000 3 . 37500 5 .06250 7.59375
Figure A 9
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A.2.7

Functions Used to Calculate Probability of Cancer

Functions similar to those used in the static model were used here to calculate
each model's probability of cancer. The primary difference is that an individual's
total number of divisions is divided equally among each barrier (i.e. "(age/h)".
For example, in the mutation model an individual that is 30 years old has 5 years
worth of divisions to knock out the first barrier, 5 years worth of divisions to
knock out the second barrier, and so on. In the infection model the number of
divisions is divided among the years an individual has been infected: If now 60
and infected at 30, then the individual has 5 years worth of divisions to knock
out the fourth barrier OCV knocked out the first 3) ,5 years worth of divisions to
knock out the 4th barrier, and 5 years worth of divisions to knock out the final
6th barrier:
#Probability Models

#Mutation
pagel<-function(age,N,u){
dl=(age/kl)*365*8.25 #Estimated From Calabrese. Number of stem cell
divisions. Number of divisions divided equally between barriers
pl<-(I·((I-(I-(I-u)Adl)AI)AN)) #Probability of I cell knocking out I barrier
after dl/kl divisions
pI

}

#Infection
page2<-function(agenow,ageinfection,N,u){
d2=((agenow-ageinfection)/k2)*365*8.25 #Number of infected cell divisions=
Number of years infected with JCV * Number of days in a year * I
division every 4 days. Number of divisions divided equally between
barriers
p2=(I-(I-(I-(I-u)Ad2)AI)A(N)) #Probability of I cell knocking out I barrier
after d2/k2 divisions
p2

}

A.2.8

A.2.8.1

Genomic Instability Mutation Model

Calculating Probability of Oncogenesis with Decreasing Cell Population and Increasing Mutation Rate

The vector "mprev" was created to store the predicted prevalence of colon cancer
for each age group, per

100,000

individuals. A for-loop was created to calculate

the probability of oncogenesis for each age group. The first step of this loop was
to reset all parameters back to their original values every time the probability of
cancer was being calculated for a new age group: "mutrate" is a vector of the
mutation rate at each step; "Nm" is the initial number of stem cells; "mN" is a
vector that stores the number of stem cells that have knocked down k barriers
(the first value is Nm); and "mprob" is a vector of the probability that a cell has
knocked down the kth barrier. A sample of these vectors and values can be found
in Figure A.lO(they are from the last age group, 90 years old).
The first step of calculating the probability of cancer was to calculate the probability that

1

cell would knock down the first barrier, given the individual's age

and the initial mutation rate. This value was stored as "mprob[l]". After this
initial probability was determined, another loop was initiated. This loop first
calculates how many cells are expected to have knocked down the first barrier.
This is accomplished by multiplying "mprob[l]" by the initial number of stem
cells ("mN[(i-l)]"; i starts at 2). After the number of stem cells that have removed
the first barrier has been calculated, the probability of one cell knocking down
the second barrier is calculated, using the next mutation rate ("mutrate[i],,). This
loop thus tracks how many cells are expected to have removed a barrier, as well
as the probability of
mutation rate.

1

cell knocking down the next barrier given the increased

The above loop is repeated until the 5th barrier has been removed. At this
point, "mprob" has 5 probabilities, each reflecting the probability that 1 cell has
knocked out a barrier, up to and including the 5th barrier. "mN" also contains
5 values, each reflecting the number of cells that are expected to have been able
to knock out each barrier, up to, but not including, the 5th barrier. Using these
values, "mN[kI]" (i.e. mN[6]) calculates the number of cells expected to have
knocked out out the 5th barrier. This is the sub-population of cells that can
knockout the final barrier. The probability of this is calculated using page1, that
sub-population of cells ("mN[k1]"; k=6), and the final (highest) mutation rate
("mutrate[k1]"). This final value, "mprob[k1]", thus reflects the probability that
the sub-population of cells that already knocked down 5 barriers knocked down
the final, 6th, barrier. After this final probability had been calculated, it is multiplied by 100,000 and stored in "mprev", which keeps track of the prevalence of
colon cancer per 100,000 individuals, for each age group.
The above loop is then repeated for each age group (j). After the final prevalence value was collected, all prevalence values for each age group were moved
to CRC[,"PrevMutation"].
mprev<-rep(NA,length(CalabreseAgeRange)) #Predicted prevalence of colon cancer for
each age group, assuming the mutation model

for(j in l:length(CalabreseAgeRange)){

#Reset Values for each Age Group
mutrate<-GI*ul #Vector of increase in mutation rate
Nm<-5*(15eeeeee) #Initial number of colon stem cells
mN<-c(Nm,rep(NA,kl-l)) #Vector storing number of cells remaining after each
barrier is knocked down, up to 5th barrier
mprob<-rep(NA,kl)
barrier

#Calculate Probablity

#Vector storing probabilities of knocking down each

mprob[l]<-page1(CalabreseAgeRange[j],l,mutrate[l]) #Probability of 1 cell
knocking down barrier 1

for(i in 2:(k1-1)){
mN[i]<-mprob[(i-1)]*mN[(i-1)]

#Number of cells that would have

knocked out barrier
mprob[i]<-page1(CalabreseAgeRange[j],l,mutrate[i]) #Having knocked
down previous barriers, Probability of 1 cell knocking down
barrier
}

mN[k1]<-mprob[k1-1]*mN[k1-1]

#Number of cells that would have knocked out

barrier 5
mprob[k1]<-page1(CalabreseAgeRange[j],mN[k1],mutrate[k1]) #Probability of
knocking down all 6 barriers

mprev[j]<-mprob[k1]*100000 #Predicted prevalence of CRC, per 100,000
individuals

}

CRC[, "PrevMutation" ]<-mprev

~

mulrale

[lJ 3.000000e-08 4.500000e-08 6. 750000e-08 1.012S00e-07 1.518750e-07 2.278125e-07
~

Nm

[lJ 7. 5e+07
;>

mN

[lJ 7.500000e+07 3.079624e+03 1.896798e-01 1.752382e-05 2.428387e-09 5.047581e-13
;>

mprob

[lJ 4.106166e-05 6.159185e-05 9.238636e-05 1.385763e-04 2.078573e-04 1.110223e-16
I

Figure A.1O

A.2.8.2

Calculating Incidence of Colon Cancer with Mutation Model

As the above results are in the form of prevalence data, they must be transformed
into incidence data so that they are comparable to the observed data. This was ac-
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complished calculating the difference in prevalence between any two age groups,
and then stored in CRCl"Incidence_Mutation"] and "Mutation":
#Calculate Incidence

for(i in 2:length(mprev)){
CRC [i. "Incidence_Mutation" ]<-CRC[i. "PrevMutation" ]-CRC [ (i-I). "PrevMutation"]
}

Mutation<- CRC [ • "Incidence_Mutation"]

A.2.9

A.2·9.1

Genomic Instability Infection Model

Calculating Probability of Cancer Given Length of Infection

As in the stepwise mutation model, a for loop was used to calculate the probability of cancer for each age group. After the probability was calculated, the
parameters were reset to their original values: "mutrate" is a vector of the mutation rates; "Ns" is the initial number of infected stem cells; "iiN" is a vector
containing the number of infected stem cells that have knocked out a barrier
(starting at 0 barriers); "iiprob" is a vector containing the probability that the kth
barrier has been removed. An example set of these values can be found in Figure
A.ll (these values are for 90 year old individuals that were infected at 90 years
old, which explains why iiN and iiprob are zero).
The logic underlying the stepwise infection model is the same as that underlying the mutation model. However, in the case of the infection model, JCV has
already knocked out three barriers, and so only 3 barriers remain. Thus, a complicated for loop seemed unnecessary and the cell population sizes and probabilities were calculated in a series. Of note is that the mutation rate starts at the level
expected if three barriers have already been removed, while the cell population
size is remains at the initial size (see Figure ??). Finally, as in the static model,
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a matrix was created so as to capture the probability of cancer given the length
of infection (current age - age of infection). This matrix was filled in with the
probability of cancer for each combination of current age and age of infection,
and can be found in Figure

A.12.

#Create Matrix
agenow<-CalabreseAgeRange
ageinfect<-CalabreseAgeRange
agenowVageinfect<-matrix(nrow=length(agenow),ncol=length(ageinfect),dimnames=list(c(
II~",

"~'I,

~'I,

"~'I,

"~o",

"~'I,

"~511,

"~",

I'~I',

"~II,

"~5",

"~"

I'~"),C("

Agelnfecto", "Agelnfect5", "Agelnfecho", "Agelnfech 5", "Agelnfect2o", "
Agelnfect25", "Agelnfect30", "Agelnfect35", "Agelnfect4o", "Agelnfect45", "
Agelnfect50", "Agelnfect55" , "Agelnfect6o", "Agelnfect65", "Agelnfect7o", "
Agelnfect75", "AgelnfectSo", "AgelnfectS 5", " Agelnfect90" ) ) )

#Calculate Probability of Cancer for each current age Vs. age of infection

for(i in l:length(agenow)){
for(j in l:length(ageinfect)){
#Reset Parameters for each Age Group
mutrate<-GI*ul #mutation rates
Ns<-5*(15000000)*0.95 #initial cell population size
iiN<-c(Ns,rep(NA,k2-1)) #collects number of cells that have knocked
out each barrier
iiprob<-rep(NA,k2) #collects probability of 1 cell knocking out a
barrier

#Calculate Probability of Knocking out Each Barrier, given N stem cells and
a u mutation rate. Infection Already knocked out 3 barriers

#Probability of knocking-out Barrier 4
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iiprob[1]<-page2(agenow[i],ageinfect[j],1,mutrate[4]) #Probability
of 1 cell knocking down barrier 4

# Probability of knocking-out Barrier 5
#Number of cells that would have knocked out

iiN[2]<-iiprob[1]*Ns
barrier 4

iiprob[2]<-page2(agenow[i],ageinfect[j],1,mutrate[5]) #Having
knocked down previous barriers, this is the probability of 1
cell knocking down barrier 5

# Probability of knocking-out Barrier 6
iiN[3]<-iiprob[2]*iiN[2]

#Having knocked down previous

barriers,Number of cells that would have knocked out barrier 5
iiprob[3]<-page2(agenow[i],ageinfect[j],iiN[3],mutrate[6]) #
Probability of knocking down all 6 barriers, given the number· of
.cells that removed 5 barriers

ifelse(iiprob[3]>0,
agenowVageinfect[i,j]<-iiprob[3],
agenowVageinfect[i,j]<-0) #Makes sure all probabilites are
positive
}
}

;>

mutrate

[1] 3.000000e-08 4.S00000e-08 6.7S0000e-08 1.012S00e-07 1.S187S0e-07 2.27812Se-07
;>

Ns

[1] 71250000
>

iiN

[1] 71250000
;>

o

o

i lprob

[1] 0 0 0

Figure A.ll

A.2.9.2

Calculating Cumulative Probability of Cancer for Each Age Group

As in the static model, the cumulative probability of colon cancer given ICV
infection is found by summing the probabilities of developing cancer for each
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A.12

age group, given all possible ages of infection (i.e. summing across the "Current
Age" rows in the above matrix). This cumulative probability is first multiplied
by the average incidence of JCV infection and then multiplied by
ing the prevalence of JCV induced colon cancer per

100,000

100,000,

yield-

individuals. These

prevalence values are then stored in CRC[,"PrevlnfectInit"]:
iiprev<-rep(NA,length(agenow))
for(i in I:length(iiprev)){
iiprev[i)< -sum(agenowVageinfect[i,)) *IBBBBB*AvgJCVIncidence
}

CRCI, "Pre vlnfectlnit " )< -iiprev

A.2·9·3

Calculating Incidence of JCV Induced Colon Cancer for Each Age Group

Again, the prevalence data need to converted into incidence data, which was
then stored in CRC[i,"Incidence_lnfectInit"] and the vector IIlnfection_Initation":
#Calculate Incidence

for(i in 2:length(iiprev)){
CRCli, "Incid en ce_InfectInit " )<-CRC[i, " Prevlnfectlnit " )-CRCI (i-I), "
Prevlnfectlnit " ) }

Infection_Ini tation< -CRC [ , "Incidence_ Infe c tlni t " I

Results

A.2.1O

Dataframe

A.2.1O.I

The CRC dataframe created after running the above code can be found in Figure
A. 1 3
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Plots

As in the static model, the incidence values from the stepwise models were transformed to the log scale so as the emphasize the difference between the Mutation
and Infection models' predictions. Again, any -Inf values were replaced with -25,
for the reasons stated above. These transformations were accomplished using the
following code:
#Adjust data so the log can be taken : if prob=0, then 10g(0)= · Inf, which won't fit
on a graph. Set min to -25

logMutation<-log (Models [, "Mutation"))
loglnfection<-log (Models [ , "Infection_ Ini ta tion") )

#Replace -lnf with -25.22388

#Mutation
for(i in l:length(logMutation)){
ifelse(logMutation[i)==-lnf,
logMutation[i)<--25.22388,
logMutation[i)<-logMutation[i))
}

#lnfection
for(i in l:length(loglnfection)){
ifelse(loglnfection[i)==-lnf,
loglnfection[i)<--25.22388,
loglnfection[i)<-loglnfectionji))
}

Once log-transformed, the data was plotted against the observed data using
the code below. The resulting plot can be found in Figure A.14.
#Log Plot
xrange<-CalabreseAgeRange
ymax<-max(CRC[, "~2000_2006"))
lymax<-log(ymax)
lymin<-max (log (Models [, "Mutation") ))
yrange<-seq(lymin,lymax, (lymax-lymin)/(length(xrange)- 1))
plot(xrange, yrange, type="n", xlab="Current Age",ylab="ln(Incidence of Cancer, per
100,000)" ,main="Predicted

and Observed Incidence of Colon Cancer", sub="~S U=3*

1O"-8,GI=1.S" )
pOints(AverageAgeCancer,log(CalabreseData),pch=19,lty=1)
points(AverageAgeCancer,log(CRC_2000_2S06),pch=I,lty=1)
points(AverageAgeCancer,log(CRC_2003_2007),pch=2,lty=1)
lines(CalabreseAgeRange,logMutation,col="red",lty=l)
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lines(CalabreseAgeRange, 10gInfection,col="blue", lty=2)
legend (20, -10, c ("Observed Data 1992-1999", "Observed Data 2000-2006", "Observed Data
2003-2007", "Mutation Model,k=6", "Infection lnitation Model,k=3") ,col=c(l, 1, 1,"
red", "blue"), lty=c(NA, NA, NA, 1,2), pch=c(19, 1, 2, rep(NA,2»)

Predicted and Observed Incidence of Colon Cancer
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Figure A.14

Finally, infection's impact on the probability of developing cancer was calculated by dividing the probability of cancer with infection by the probability of
cancer by mutation alone, A value of 1 had to be added to each probability as
many of the mutation probabilities were equal to

0

(see FigureA.13). The result-

ing plot can be found in Figure A.lS.
#Plot of the Increase in Probabilty
RatiolncreaseProb<-(iiprev+l)/(mprev+l)

plot (RatioIncreaseProb-CalabreseAgeRange, main="Impact of Infection 01 Probability
of Cancer", ylab= "Probability Ratio", xlab="Age", ylim=c(0,max(
RatiolncreaseProb»)
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APPENDIX B

R CODE FOR GEOMETRIC MODEL

There are ten models total, each which has a different combination of genes
per barrier and the stem cell mutation rate. The two stem cell mutation rates are
Il = 10- 10 and Il = 10- 11 , while there can be 3,6,9,12 or 16 genes per barrier.
In this example code, there are 3 genes per barrier, and the stem cell mutation

°. In order to provide examples, some of the parameters are

rate is Il = 10- 1

changed, primarily the number of stem cells in the colon and the number of
repetitions. When conducting runs to generate the data presented in Chapter 6,
Nm

B.1

=

5 x 15000000 and reps

=

10000.

SETUP

The first few lines setup the parameters used in the model:
>

genes. per. barrier

>

stem.cell.mutation.rate

>

genomic. instability

>

u<-genes.per.barrier

>

#Number of barriers in Mutation Model

>

kl<-6

>

#Number of barriers in Infection Model

>

k2<-3

>

#initial stem cell mutation rate

>

ul

>

#umber of stem cells in the colon.

<-

<-

3

<-

<-

leee * leA-le

2

u*stem.cell.mutation.rate

>

Nm<- 18# Set to 5*(15888888) in model

>

#5 stem cells per crypt, 15,888,888 crypts (Calabrese).

>

#Estimated number of stem cells infected by JCV

>

Ns=Nm*8.95

>

#Redundent, but used in model

>

mutincrease<-genomic.instability

> #

number of times to run model. Set to 18 here for example

>

#purposes, but lis set to 1888 when collecting all results

>

reps<-18

> #
>

prints when every 18th iteration is completed

printscale<-seq(8,reps,18)
The next chunk of code creates a vector what the mutation rate will be after

genomic instability increases the mutation rate when a barrier is removed:

GI<-c(1,rep(NA,k1-1))

>
>

for(i in 2:length(GI)){

+ GI[ij<-GI[i-1j*mutincrease
+ }
>

mutrate<-GI*u1

>

mutrate

[1] 3.0e-07 6.0e-07 1.2e-06 2.4e-06 4.8e-06 9.6e-06

B.2

MUTATION MODEL

This part of the code creates 6 different vectors that determine how many trials
will occur before the first success (days,mutation) in each of Nm cell lines. This
process is repeated for all six barriers. Note that the mutation increases as each
barrier is removed, thus simulating genomic instbaility .After each vector is cre-

ated, they can be added together to find the total number of divisions it takes to
remove all six barriers.
After the total number division have been calculated, the mean, max, min,
and standared deviation are calculated. Afterwards, the number of divisions are
converted to years, assuming that stem cells divide once every four days, i.e.
N divisions
4days
1year
x 365d
= age in years. The results are exported to
x 1d' ..
IVlSlon
ays
a .csv.Note that in these examples the number of years is high. However, when
there are the vector is 7.5 x 10 7 elements long, some values will be lower.
This procedure is repeated for each value of rep, which in this case is
viduals. As the data are generated they are added to a data frame.
> #
>

#rgeom(n=Nm, prob=mutrate[i))

> #
>

forti in l:reps){

+ #number of divisions required before first mutation.
+ N.div.for.mutaiton.rl<-rgeom(Nm,mutrate[l))
+

N.div.for.mutaiton.rl

+
+ #number of divisions required before second mutation.
+ N.div.for.mutaiton.r2<-rgeom(Nm,mutrate[2))
+ N.div.for.mutaiton.r2

+ # number of divisions required before third mutation.
+ N.div.for.mutaiton.r3<-rgeom(Nm,mutrate[3))
+ N.div.for.mutaiton.r3

+ # number of divisions required before fourth mutation.
+ N.div.for.mutaiton.r4<-rgeom(Nm,mutrate[4))
+ N.div.for.mutaiton.r4

+ # number of divisions required before fifth mutation.

+ N.div.for.mutaiton.r5<-rgeom(Nm,mutrate[5))

10

indi-

+ N.div.for.mutaiton.rS
+ #number of divisions required before sixth mutation.
+ N.div.for.mutaiton.r6<-rgeom(Nm,mutrate[6])

+ N.div.for.mutaiton.r6
+ #Total Number of Divisions

+ Mutation. Total.Divisions <- N.div.for.mutaiton.rl +
+ N.div.for.mutaiton.r2 +
+

N.div.for.mutaiton.r3 + N.div.for.mutaiton.r4 +

+ N.div.for.mutaiton.rS + N.div.for.mutaiton.r6
+ #Calculate mean, standard deviaition, min, and max

+ mean.years<-mean(Mutation.Total.Divisions)*4*(1/36S)
+ stdev.years <- sd(Mutation.Total.Divisions)*4*(1/36S)
+ min.years <- min(Mutation.Total.Divisions)*4*(1/36S)

+ max.years <- max(Mutation.Total.Divisions)*4*(1/36S)
+ #
+ Model <- "Mutation"

+ iteration <- i
+ #
+ #Build data frame
+ if (i==l){

+ #Initiate Data frame

+

Mutation.Data

data.frame(Model,mean.years,

stdev. years, min. years, max. years)

+
+

<-

}

+ else{
+ #Add to data frame

+ New.Data <+

data.frame(Model,mean.years,
stdev.years,min.years,max.years)

+ Mutation.Data <- rbind(Mutation. Data, New. Data)

}

+
+ }
>

Mutation. Data
Model mean.years stdev.years min. years max. years

1 Mutation

58943.96

28289.22 33575.781

120091. 5

2 Mutation

98563.89

61002.97 23388.011

208677.3

3 Mutation

54854.77

37885.94 16042.586

154127.4

4 Mutation

61352.80

34357.45

7745.896

136633.1

5 Mutation

73895.62

36610.36 12873.534

119736.3

6 Mutation

86052.36

35054.35 42257.238

145139.3

7 Mutation

63963.59

28471.03 32581.655

119885.1

8 Mutation

66089.51

36094.76 25705.140

131563.8

9 Mutation

67877.19

40096.74 14720.285

126313.1

10 Mutation

83613.25

39647.85 13310.718

140384.5

B.3

INFECTION MODEL

The infection model is implemented in much the same way as the mutation mode.
One difference is that the population of cells is 95% of the cell population in the
mutation model. A second difference is the the model starts using the fourth
mutation rate because the three previous barriers have all ready been removed.
Finally, the model
>

for{i in l:reps){

+ # number of divisions required before first mutation in 4 barrier
+ Infection.N.div.for.mutaiton.r4<-rgeom{Ns,mutrate[4])
+ # number of divisions required before first mutation in 5th barrier
+ Infection.N.div.for.mutaiton.r5<-rgeom{Ns,mutrate[5])
+ # number of divisions required before first mutation in 5th barrier
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+ Infection.N.div.for.mutaiton.r6<-rgeom(Ns,mutrate[6])

+ #Total Number of Divisions
+ Infection. Total. Divisions

<-

Infection.N.div.for.mutaiton.r4 +

+ Infection.N.div.for.mutaiton.r5 + Infection.N.div.for.mutaiton.r6
+ Model <- "Infection"
+ iteration <- i

+ mean.years<-mean(Infection.Total.Divisions)*4*(l/365)
+ stdev.years <- sd(Infection.Total.Divisions)*4*(l/365)

+ min.years <- min(Infection.Total.Divisions)*4*(l/365)
+ max.years <- max(Infection.Total.Divisions)*4*(l/365)

+ if (i==l){
+

#Initiate Data frame

+

Infection.Data

data.frame(Model,mean.years,

<-

stdev.years,min.years,max.years)

+
+ }
+ else{
+

#Add to data frame

+

New.Data

<-

data.frame(Model,mean.years,

stdev.years, min. years, max. years)

+

+ Infection.Data <- rbind(Infection. Data, New. Data)
+ }
+ }
>

Infection. Data

Model mean. years stdev.years min.years max. years
1

Infection

8547.683

3373.122

4925.898

14949.26

2

Infection

7196.665

4658.234

1649.921

14864.99

3

Infection °19975.619

7244.343

3424.252

23861.61

4

Infection

7297.763

4685.493

3631. 321

19927.34

5

Infection

7867.534

5559.963

2564.679

17529.11
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6

Infection

6748.620

3537.967

1665.644

12705.71

7

Infection

8132.100

6050.912

1092.427

18647.27

8

Infection

5970.298

4333.681

1669.677

13285.05

9

Infection

9644.497

7154.300

1686.542

24798.86

10 Infection

6233.749

3317.813

2677.786

12019.61

Like the Mutation model, the mean, standard deviation, min, and max are
calculated and converted to age in years

B-4

BINNING DATA

The observed data are in groups of 5 years, so the results of the Geometric model
also need to binned in to 5 year age groups. This is done by creating a function
that bins the data and converts to incidence per
>

bin. data

+ indv <-

<-

100,000

individuals.

function( summary. data, age. of. metastatic. tumors) (

length(summary.data[,l])

+ ages1<- (length (subset(age.of.metastatic.tumors,

+

age.of.metastatic.tumors

< 1

+

age.of.metastatic.tumors

>

&
e)))/indv*leeeee

+ ages4<- (length (subset(age.of.metastatic.tumors ,

5 &

+

age.of.metastatic.tumors

<

+

age.of.metastatic.tumors

>=

l)))/indv*leeeee

+ ages9<- (length (subset(age.of.metastatic.tumors ,
+

age.of.metastatic.tumors

<

+

age.of.metastatic.tumors

>=

1e &
5)) )/indv*leeeee

+ ages14<- (length (subset(age.of.metastatic.tumors ,

+

age.of.metastatic.tumors

+

& age.of.metastatic.tumors

< 15
>=

1e)))/indv*leeeee

+ ages19<- (length (subset(age.of.metastatic.tumors ,
188

+

age.of.metastatic.tumors

<

+

age.of.metastatic.tumors

>=

2e &
15)))/indv*leeeee

+ ages24<- (length (subset(age.of.metastatic.tumors ,

+

age.of.metastatic.tumors

< 25

+

age.of.metastatic.tumors

>=

&

2e)))/indv*leeeee

+ ages29<- (length (subset(age.of.metastatic.tumors ,

3e &

+

age.of.metastatic.tumors

<

+

age.of.metastatic.tumors

>=

25)))/indv*leeeee

+ ages34<- (length (subset(age.of.metastatic.tumors ,
+

age.of.metastatic.tumors

< 35

+

age.of.metastatic.tumors

>=

&

3e)))/indv*leeeee

+ ages39<- (length (subset(age.of.metastatic.tumors ,
+

age.of.metastatic.tumors

<

+

age.of.metastatic.tumors

>=

4e &
35)))/indv*leeeee

+ ages44<- (length (subset(age.of.metastatic.tumors ,
+

age.of.metastatic.tumors

< 45

+

age.of.metastatic.tumors

>=

&

4e)))/indv*leeeee

+ ages49<- (length (subset(age.of.metastatic.tumors ,

5e &

+

age.of.metastatic.tumors

<

+

age.of.metastatic.tumors

>=

45)))/indv*leeeee

+ ages54<- (length (subset(age.of.metastatic.tumors ,
+

age.of.metastatic.tumors

< 55

+

age.of.metastatic.tumors

>=

&

5e)))/indv*leeeee

+ ages59<- (length (subset(age.of.metastatic.tumors ,

+

age.of.metastatic.tumors

<

+

age.of.metastatic.tumors

>=

6e &
55)))/indv*leeeee

+ ages64<- (length (subset(age.of.metastatic.tumors ,
+

age.of.metastatic.tumors

< 65

+

age.of.metastatic.tumors

>=

1~

&

6e)))/indv*leeeee

+ ages69<- (length (subset(age.of.metastatic.tumors ,

7e &

+

age.of.metastatic.tumors

<

+

age.of.metastatic.tumors

>=

65»)/indv*leeeee

+ ages74<- (length (subset(age.of.metastatic.tumors ,
+

age.of.metastatic.tumors

< 75

+

age.of.metastatic.tumors

>=

&

7e»)/indv*leeeee

+ ages79<- (length (subset(age.of.metastatic.tumors ,

8e &

+

age.of.metastatic.tumors

<

+

age.of.metastatic.tumors

>=

75»)/indv*leeeee

+ ages84<- (length (subset(age.of.metastatic.tumors ,
+

age.of.metastatic.tumors

< 85

+

age.of.metastatic.tumors

>=

&

8e»)/indv*leeeee

+ ages85up<- (length (subset(age.of.metastatic.tumors ,

+

#age.of.metastatic.tumors

+

age.of.metastatic.tumors

<=lee &
>=

85»)/indv*leeeee

+ #
+

d. f

+

ages19, ages24, ages29, ages34, ages39,

+

ages44, ages49, ages54, ages59, ages64,

+

ages69, ages74, ages79, ages84,ages85up)

<-

c(ages1, ages4, ages9, ages14,

+ #
+ return(d. f)
+ }

The bin.data function is applied to both the infection results to put them into
an age group.
>

options(width=6e)

>

Mutation.Min.Results

>

Mutation.Binned

>

Mutation.Binned

<-

<-

Mutation.Data$min.yea"rs

bin.data(Mutation.Data,Mutation.Min.Results)
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AGE

MORTALITY

< 20

0%

20-34

0.6%

35-44

2.5%

45-54

8.6°/c,

55-64

16.5%

65-74

22%

75-84

29%

85+

20.8%

Table B.1: Mortality From Colorectal Cancer, 2005 - 2009 [2]

[1] 0e+00 0e+00 0e+00 0e+00 0e+00 0e+00 0e+00 0e+00 0e+00
[10] 0e+00 0e+00 0e+00 0e+00 0e+00 0e+00 0e+00 0e+00 0e+00
[19] le+05
> #
>

Infection.Min.Results

>

Infection.Binned<- bin.data(Infection.Data,Infection.Min.Results)

>

Infection.Binned

<-

Infection.Data$min.years

[1] 0e+00 0e+00 0e+00 0e+00 0e+00 0e+00 0e+00 0e+00 0e+00
[10] 0e+00 0e+00 0e+00 0e+00 0e+00 0e+00 0e+00 0e+00 0e+00
[19] le+05

B.5

CONVERTING INCIDENCE TO PREVALENCE

Since each repetition is one individual, the results are incidence of colorectal
cancer. The prevalence of in each age can be determined by summing up the
incidence values of earlier ages. However, some people die before they move
to the next age group, so mortality from colorectal cancer is worked into the
calculation of prevalence by multiplying the prevalence value by the number
of people that did survive colorectal cancer. The mortality rates used in this
procedure are found in Table B.1.

>

Calculate.Prevalence.With.Mortality

+ ages1<- binned.data[l]

<-

function(binned.data){

#ages < 1

+ total <- ages1
+ ages4<- binned.data[2]+total #ages 1-4
+ total

<-

ages4

+ ages9 <- binned.data[3]+total #ages 5-9
+ total

<-

+ ages14
+ total

<<-

ages9
binned.data[4]+total #ages 19-14
ages14

+ ages19 <- binned.data[5]+total #ages 15-19
+ total

<-

ages19

+ #

+ #Mortality in 29-34=9.6%
+ ages24

<-

binned.data[6]*(1-9.996)+total #ages 29-24

+ total <- ages24
+ ages29

<-

binned.data[7]*(1-9.996)+total #ages 25-29

+ total <- ages29
+ ages34

<-

binned.data[8]*(1-9.996)+total #ages 39-34

+ total <- ages34
+ #

+

#Mortality in 35-44=9 2.5%

+ ages39

<-

binned.data[9]*(1-9.925)+total #ages 35-39

+ total <- ages39
+ ages44 <- binned.data[19]*(1-9.925)+total
+ #ages 49-44
+ total

<-

ages44

+ #

+ #Mortality in 45-54=9 8.6%
+ ages49

<-

binned.data[11]*(1-9.986)+total #ages 45-49

+ total

<-

ages49

+ ages54 <- binned.data[12}*(1-8.886)+total #ages 58-54
+ total

<-

ages54

+ #

+ #Mortality in 55-64=16.5%
+ ages59 <- binned.data[13}*(1-8.165)+total #ages 55-59
+ total
+ ages64
+ total

<<-

<-

ages59
binned.data[14}*(1-8.165)+total #ages 68-64
ages64

+ #

+ #Mortality in 65-74=22%
+ ages69 <- binned.data[15}*(1-8.22)+total #ages 65-69
+ total <- ages69
+ ages74
+ total

<<-

binned.data[16}*(1-8.22)+total #ages 78-74
ages74

+ #

+ #Mortality in 75-84=29%
+ ages79

<-

binned.data[17}*(1-8.29)+total #ages 75-88

+ total <- ages79
+ ages84 <- binned.data[18}*(1-8.29)+total #ages 88-85
+ total

<-

ages84

+ #

+ #Mortality in 85+ =28.8%
+ ages85up <- binned.data[19}*(1-8.288)+total #ages 85+
+ #

+

d.t

<-

c(ages1, ages4, ages9, ages14, ages19,

+ ages24, ages29, ages34, ages39, ages44, ages49,
+ ages54, ages59, ages64, ages69, ages74, ages79,
+ ages84,ages85up)
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+
+ returned. f) }

This prevalence function can then be applied to the results generated by the
Geometric model
>

options(width=68)

>

Mutation.Prevalence

>

Mutation.Prevalence
[1]

[10]

o
o

o
o

<-

o

Calculate.Prevalence.With.Mortality(Mutation.Binned)

o
o

o

o
o

o
o

o
o

o
o

o
o

[19] 79200
>

Infection.Prevalence

>

Infection.Prevalence
[1 ]

o

[10]

0

o
o

<-

o
o

Calculate.Prevalence.With.Mortality(Infection.Binned)

o
o

o

o

o
o

o
o

o
o

o
o

[19] 79200

B.6

BUILD FINAL DATA FRAME

The prevalence values calculated above can be added to a summary data frame
that includes both observed values and modeled values.
>

Seer.Age.Group

<-

c("<1", "1-4","5-9", "18-14", "15-19", "28-24","25-29",

+ "38-34","35-39","48-44","45-49","58-54","55-59","68-64","65-69",
+ "78-74", "75-79", "88-84", "85+")
>

Age. Group<-seq(8,98,5)

> #

>

#Observed Data From SEER 1992-1999
194

>

#Build Data Frame

>

Observed.Data<-c(9,9,9,9.97,9.18,9.47,1.46,2.82,5.59,11.14,21.59,

+ 42. 72, 77.94,125.98,184.94,259.96,319.14,387.22,NA)
>

Model

>

Prevalence <-Calculate.Prevalence.With.Mortality(Observed.Data)

>

Obs.Data<-data.frame(Model,Seer.Age.Group,Age.Group,Prevalence)

>

Data<- Obs.Data

<-

rep(IObserved", length (Observed. Data))

> #

>

#Mutation Data

>

Model

>

Prevalence <-Mutation. Prevalence

>

Mutation.Data<- data.frame(Model,Seer.Age.Group,Age.Group,Prevalence)

>

Data<-rbind(Data,Mutation.Data)

<-

rep(IMutation", length (Observed. Data) )

> #
>

#Infection Data

>

Model

>

Prevalence <-Infection. Prevalence

>

Infection.Data<- data.frame(Model,Seer.Age.Group,Age.Group,Prevalence)

>

Data<-rbind(Data,Infection.Data)

>

Data

<-

rep(IInfection", length(Observed.Data))

Model Seer.Age.Group Age.Group

Prevalence

1

Observed

<1

0

0.00000

2

Observed

1-4

5

0.00000

3

Observed

5-9

10

0.00000

4

Observed

10-14

15

0.07000

5

Observed

15-19

20

0.25000

6

Observed

·20-24

25

0.71718

7

Observed

25-29

30

2.16842

8

Observed

30-34

35

4.97150
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9

Observed

35-39

40

10.42175

10

Observed

40-44

45

21. 28325

11

Observed

45-49

50

41. 01651

12

Observed

50-54

55

80.06259

13

Observed

55-59

60

145.14249

14

Observed

60-64

65

250.33579

15

Observed

65-69

70

393.88699

16

Observed

70-74

75

589.63579

17

Observed

75-79

80

816.22519

18

Observed

80-84

85

1091.15139

19

Observed

85+

90

NA

20

Mutation

<1

0

0.00000

21

Mutation

1-4

5

0.00000

22

Mutation

5-9

10

0.00000

23

Mutation

10-14

15

0.00000

24

Mutation

15-19

20

0.00000

25

Mutation

20-24

25

0.00000

26

Mutation

25-29

30

0.00000

27

Mutation

30-34

35

0.00000

28

Mutation

35-39

40

0.00000

29

Mutation

40-44

45

0.00000

30

Mutation

45-49

50

0.00000

31

Mutation

50-54

55

0.00000

32

Mutation

55-59

60

0.00000

33

Mutation

60-64

65

0.00000

34

Mutation

65-69

70

0.00000

35

Mutation

70-74

75

0.00000

36

Mutation

75-79

80

0.00000

37

Mutation

80-84

85

0.00000

Mutation

85+

39 Infection

<1

0

0.00000

40 Infection

1-4

5

0.00000

41 Infection

5-9

10

0.00000

42 Infection

10-14

15

0.00000

43 Infection

15-19

20

0.00000

44 Infection

20-24

25

0.00000

45 Infection

25-29

30

0.00000

46 Infection

30-34

35

0.00000

47 Infection

35-39

40

0.00000

48 Infection

40-44

45

0.00000

49 Infection

45-49

50

0.00000

50 Infection

50-54

55

0.00000

51 Infection

55-59

60

0.00000

52 Infection

60-64

65

0.00000

53 Infection

65-69

70

0.00000

54 Infection

70-74

75

0.00000

55 Infection

75-79

80

0.00000

56 Infection

80-84

85

0.00000

57 Infection

85+
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90 79200.00000

90 79200.00000

PREVALENCE PLOT

The modeled and observed prevalence values can be plotted using ggplot2.
>

library(ggplot2)

>

library(gridExtra)

>

library(scales)
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>

+

Prevalence. Plot

<-

ggplot(data=Data,aes(x=Age.Group,

y=Prevalence,group~odel,colour~odel))

+

+ geom_point() +
+ geom_line(aes(x=Age.Group,y=Prevalence)) +
+ coord_cartesian(ylim=c(9, 2999))+
+ scale_x_discrete(breaks=Age.Group,
+

labels= Seer.Age.Group,name="Age Group") +

+ scale_y_continuous(name="Prevalence (Per 199,999)") +
+ opts (ti tle="Prevalence of Colorectal Cancer",
+
>

axis.text.x

=

theme_text(angle

grid.arrange(Prevalence.Plot, sub

=

45))

= textGrob(

+

expression (paste(frac(genes, barrier), " = 3 , ",mu, "=",19"{-19})),

+

hjust

+

)

>

= 9.87,vjust=9.3, gp = gpar(cex = 9.7))

Prevalence. Plot
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B.8

EUCLIDIAN DISTANCE AND PLOT

The distance between each modeled prevalence point and the observed prevalence point can be calculated using R dist function. However, to make sure the
distance is point to point, the data must be compared as a row
>

Mut:V.Obs<-rbind(Mutation.Data$Prevalence,Obs.Data$Prevalence)

>

Mut.V.Obs
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[,1] [,2] [,3] [,4] [,5]
[1,]
[2, ]

[1,]

[,6]

[,7]

[, 8]

e e.ee e.ee e.eeeee e.eeeee e.eeee

e

e

e e.e7 e.25 e.71718 2.16842 4.9715

[,9]

[,Ie]

[,11]

[,12]

[,13]

[,14]

e.eeeee

e.eeeee

e.eeeee

e.eeeee

e.eeee

e.eeee

[2,] le.42175 21.28325 41.e1651 8e.e6259 145.1425 25e.3358

[1,]

[,15]

[,16]

[,17]

[,18] [,19]

e.eee

e.eeee

e.eeee

e.eee 792ee

[2,] 393.887 589.6358 816.2252 le91.151
>

Mut.Dist<-dist(Mut.V.Obs)

>

Mut.Dist

NA

1

2 16e8.818
>

EDistance

>

EDistance

<-

Mut.Dist[l]

[1] 16e8.818
>

Model<- "Mutation"

>

Dist.Data<-data.frame(Model,EDistance)

>

#Infection Data

>

Inf.V.Obs<-rbind(Infection.Data$Prevalence,Obs.Data$Prevalence)

>

EDistance<-dist(Inf.V.Obs)[l]

>

Model<-"Infection"

>

New.Dist.Data<-data.frame(Model,EDistance)

>

Dist.Data<-rbind(Dist.Data,New.Dist.Data)

>

Dist.Data

Model EDistance
1 Mutation

16e8.818

2 Infection

16e8.818
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Once the distance has been calculated it can be plotted to get a sense of how
well each model replicates the observed data.
>

+

Dist.Plot

<-

ggplot(Dist.Data,

aes(x=Model,y=EDistance,color~odel,size=188,alpha=8.5) )+

+ geom_point()+
+ scale_size(range

= c(2, 15))+

+ guides(size=FALSE,alpha=FALSE)+
+ coord_ trans(y=ll og2")+
+ opts(title="Euclidian Distance Between Observed and Modeled Prevalence")+
+ ylab(IDistance")
>

grid.arrange(Dist.Plot,

+

sub=textGrob (expression (paste(mu, "=",18"{-18})),

+

hjust

>

= 8.87,vjust=8.3, gp = gpar(cex = 8.7)))

Dist.Plot
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ABMODD

APPENDIXC

C.l

Cl.l

OVERVIEW

Purpose

This model was designed to better understand the roles of mutation and infection in the development of colon cancer. Is mutation alone sufficient to generate
the emergence of metastatic tumors, or is infection needed to "kick-start" the
process of oncogenesis? How does the order of mutations affect the probability
of developing a metastatic tumor? Does this order change if infection is present?
If infection does turn out to play an important role, how much does the age of

infection by ICV affect the probability of developing a metastatic tumor?

C.l.2

Entities, State Variables, and Scales

The model has six entities: patches, stem cells, metastatic stem cells, transit cells,
VEGF molecules, and vessels.
There are 3721 patches laid out in a grid, creating a non-wrapping square
world that is 6lX6l patches, centered around patch (0,0). Each patch is meant to
represent the cells underlying stem and transit cells of the colon crypt. This world
is subdivided into a colon crypt and metastatic tissue. The colon crypt is centered
around patch (-17,-17), and is 25x25 patches, creating a total of 625 patches. The
crypt is further subdivided into the inner and outer crypt. The inner crypt, also
centered around patch (-17,-17), is l5x15 patches, and is colored yellow. The
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outer crypt is composed of the remaining crypt patches and is colored pink. The
metastatic tissue is centered around patch (13,13), and is 30x30 patches, for a
total of 900 patches. All remaining patches are colored black. The state variables
of each patch can be found in Table C.l on page 204.
PATCH STATE VARIABLES

oxygen
infected
Table C.l: Patch State Variables

Stem cells are located in a circular layout around the center of the colon crypt,
and face outwards. Stem cells are responsible for producing the initial transit
cells in the model. Each stem cell has several state variables, which are listed in
Table C.3 on page 205

STEM CELL STATE VARIABLES

count-stem-cell-divisions

CIF-II-removed?

stem-cell-mutation-rate

count-barriers-removed

count-neutral-mutations

order-of-barrier-removal (list)

count-deleterious-mutations

age-of-barrier-removal (list)

count-beneficial-mutations

infected?

count-pro-growth-mutations

stem-cell-age-of-infection

count-anti-growth-mutations

transformed?

count-anti-apoptosis-mutations completely-transformed?
count-metastasis-mutations

age-of-transformation

count-CIF-II-mutations

successful-invasion?
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count-telomerase-mutations

parent

order-of-mutations (list)

most-recent-event

age-of-mutation (list)

tissue

pro-growth-removed?

count-JCV-NCRR-mutations

anti-growth-removed?

JCV-Mad-l-d98-survival

anti-apoptosis-removed?

JCV-Mad-l-d98-evolved?

metastasis-removed?

JCV-Mad-l-d98-days-active

telomerase-removed?

JCV-Mad-l-d98-deactivated?

Table C.3: Stem-Cel1-State-Variables

Metastatic stern cells have the same state variables as regular stern cells (see
Table C.3 on page 205); they simply have the ability to survive in the metastatic
tissue if they successfully invade.
Transit cells have many of the same state variables as stern cells, except that
track telomere length, telomerase mutations, oxygen levels, and hypoxic state.
See Table C.5 on page 206 for a complete list of the transit cell state variables.

TRANSIT CELL STATE VARIABLES

count-transit-cell-divisions

count-barriers-removed

transit-cell-mutation-rate

age-of-barrier-removal (list)

count-neutral-mutations

infected?
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count-deleterious-mutations

transit-cell-age-of-infection

count-beneficial-mu tations

transformed?

count-pro-growth-mutations

completely-transformed?

count-anti-growth-mutations

age-of-transformation

count-anti-apoptosis-mutations successful-invasion?
count-metastasis-mutations

oxygen

count-telomerase-mutations

metastatic?

count-CIF-II-mutations

telomere-length

order-of-mutations (list)

parent

age-of-mutation (list)

most-recent-event

pro-growth-removed?

tissue

anti-growth-removed?

count-JCV-NCRR-mutations

anti-apoptosis-removed?

JCV-Mad-l-d98-survival

metastasis-removed?

JCV-Mad-l-d98-evolved

telomerase-removed?

JCV-Mad-l-d98-days-active

ClF-I1-removed?

JCV-Mad -1-d98-deactivated

Table C.5: Transit Cell State Variables

VEGF molecules do not own any state variables, but the vessels they are attracted to do, and can be found in Table C.6 on page 207.
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VESSEL STATE VARIABLES

lifespan
time-alive
Table C.6: Vessel State Variables

Finally, there are many global variables, which can be found in Table C8 on
page 219.
In this model, one time step is equal to one day.

C.1.3

Process Overview and Scheduling

The schedule of this ABM is as follows:
1. determine-if-simulation-should-end (global procedure)
2.

tick (global procedure)

3. determine-if-mutant-phenotype-on
4. determine-location
5. infection-modeled?

= true [infection] (occurs only if infection is being mod-

eled)
6. hit-and-run? (if true, the "Hit and Run" infection model is run)
7. stem-cell-determine-division-type (symmetric or asymmetric; a global procedure)
8. stem-cell-replace-metastatic-stem-cell
9. metastatic-stem-cell-fill-tissue
10.

metastatic-stem-cell-determine-division-type (symmetric or asymmetric; a
global procedure)

207

11.

transit-cell-consume-oxygen

12.

transit-cell-division-mutation-and-movement (transit cell procedure)

13. angiogenesis (turtle procedure)
14. oxygen-replenish (patch procedure)
15. oxygen-diffusion (global procedure)
16. oxygen-recolor-patches (patch procedure)
17. transit-cell-death (turtle procedure)
18. maintain-population-cap (turtle procedure)
19. evaluate-state-and-record-data (global procedure)

This schedule is repeated until one of two events occur:

1)

the crypt reaches

100

years, or 2) a metastatic tumor forms and at least one cell in that tumor has
completely removed all of the cancer barriers.
The details of each sub-model can be found in Section C.3.3

C.2

C.2.1

DESIGN CONCEPTS

Basic Principles

The basic principle of this model is the formation of metastatic tumors, and the
roles that mutation and infection play in this process. It is commonly accepted
that stem cell mutations playa critical role in the development of colon cancer Michor et al. [85], Boman and Huang [11], but there is also experimental evidence
indicating that infection by Je Virus may also playa role in tumor formation
[35, 69, 82, 89, 24]. Thus, this model aims to determine the roles that mutation
and infection play in the development of colon cancer. It is hoped this model
can answer this question by determining how many crypts develop metastatic
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tumors by mutation alone, and how many develop metastatic tumors with infection and mutation.
It has also been argued that a particular order of mutations is most likely

to cause colon cancer [85, 39], although this is not universally accepted [132].
This model will also look for a relationship between the order of mutations and
timing of tumor development and tumor size. Furthermore, as infection is being
considered, it seems worthwhile to determine if there is any relationship between
the age of infection and the age of tumor formation, and the strength of any such
relationship.

C.2.2

Emergence

The accumulation of mutations and presence of infection can lead to changes in
cellular behavior that result in the emergence of metastatic tumors.

C.2.3

Adaptation

In this model, cellular behavior changes to match patterns observed in cancers (i.e. the agents exhibit indirect-objective-seeking behavior). Behaviors change
whenever there is a mutation in a beneficial gene belonging to one of six categories: pro-growth genes; anti-growth genes; anti-apoptosis genes; metastasis
genes; telomerase genes; elF-II pathway genes.
The effect of disrupting each pathway was hypothesized using the descriptions
provided in [50, 153, 67].
Mutations in pro-growth genes allow cells to divide every time step, so long
as they are in the inner-crypt and their telomeres have not deteriorated.
Mutations in anti-growth genes allow transit cells to divide in the outer crypt.
Mutations in anti-apoptosis genes allow cells to avoid death by accumulation
of deleterious mutations. For stem cells, this means that these cells are never lost

during symmetric division. For transit cells, this means that these cells are never
killed when the population reaches its maximum size (normal-max-pop-size). For
both cell types, any anti-apoptotic mutations also increases the mutation rate via
genomic instability.
A single mutation in a metastasis gene gives stem and transit cells the ability
to detect the neighbor patch with the most oxygen, and then move to that patch
. If angiogenesis has occurred, and a cell has two metastatic mutations and is

close to a blood vessel (produced by angiogenesis) the cell will try to invade the
metastatic tissue. However, successful invasion is not certain, and is controlled
by the parameter probability-of-successful-invasion.
Mutations in the telomerase gene prevent the degradation of telomeres, essentially giving transit cells the ability to divide without limit.
If a cell is infected by JCV, and has acquired mutations in ClF-II, then JCV will

remove the pro-growth, anti-growth, and apoptosis barriers. In the "Full Transformation" version of the model, JCV completely removes each of those barriers,
while in the "Partial Transformation" version JCV only partially removes each of
those barriers. Thus, mutations in the ClF-II pathway are required for transformation by JCv.

C.2-4

Objectives

As the cells use indirect-objective seeking behavior, there are no specific agent
objectives.

C.2.5

Learning

No agents in this model learn from past experiences.·

210

c.2.6

Prediction

No agents in this model make predictions.

C.2.7

Sensing

Un-mutated cells must decide if they can divide. They do so by determining if
there is an unoccupied patch within a cone with an angle of

0

180

and radius of

1.5 pathes. If there is such an empty patch, the cell will divide and move to the
empty patch; if not, the cell will remain where it is and not divide.
During angiogenesis, VEGF molecules sense the closest vessels and move towards them.

c.2.8

Interaction

During asymmetric division, stem cells produce daughter transit cells, who inherit their parent's mutations. Likewise, daughter transit cells inherit their parent
transit cell's mutations.
During angiogenesis, VEGF molecules are produced by hypoxic patches, and
those VEGF molecules are attracted to the closest vessel.

C.2.9

Stochasticity

The order in which cells are chosen to move/divide is decided randomly.
The number of mutations per division is modeled by choosing a Poisson random number, with an appropriate mean (see C.3.3.6 for a detailed description)
Determining whether stem cell division will be symmetric or asymmetric is
decided randomly (see C.3.3.6 for details)
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The direction that stem cells face each run is chosen randomly, so that there is
no bias on a particular stem cell orientation (i.e. those that directly face a corner
could divide more frequently).

C.2.1O

Collectives

There are three primary collectives in this model: stem cells, metastatic stem
cells, and transit cells. Stem cells usually produce transit cells (during asymmetric division), but occasionally produce a stem cell (during symmetric division). Metastatic stem cells also arise from stem cells that accumulate sufficient
metastatic mutations. Finally, transit cells produce other transit cells.

C.2.11

Observation

This model tracks the population size of the colon crypt and metastatic tissue so
as to determine the presence and size of polyps and tumors, and the age at which
they occur. This model also tracks the order and timing of each mutation in each
cell, as well as the order and timing of when cancer barriers are removed in each
cell. From this one can determine if a certain order of mutations leads to more
rapid tumor development. Finally, the age of infection, whether the infection has
become chronic, and time to transformation are tracked so as to help determine
the role of infection.
The results of experiments will be recorded in .csv files. At the end of each run,
the following data will be recorded in a row in the experiment's output file:
• date-and-time
• run-number
• infection-modeled?
• mutations-added-by-transformation
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• age
• age-when-infection-became-chronic
• metastatic-tumor-formed?
• colon-tumor-formed?
• count-crypt-transit-cells
• mean-transit-cells
• mean-stem-cell-div-rate
• count-transformed-cells
• age-of-colon-tumor-forma tion
• age-of-metastasis
• count-metastatic-cells
• pro-growth-spread?
• anti-growth-spread?
• anti-apoptosis-spread?
• telomerase-spread?
• metastasis-spread?
• cif-ii-spread?
• m.tumor.cell.type
• m.tumor.cell.number
• m.tumor.cell.parent
• m.tumor.cell.mutations

21 3

• m. tumor.cell.mutations. timing
• m. tumor.cell.barriers.removed
• m. tumor.cell.barriers. timing
• stem-cell-with-most-mutations
• count-mutations-of-most-fit-stem-cell
• mutations-of-most-fit-stem-cell
• timing-mutations-of-most-fit-stem-cell
• count-barriers-of-most-fit-stem-cell
• barriers-of-most-fit-stem-cell
• timing-barriers-of-most-fit-stem-cell
• metastatic-stem-cell-with-most-mutations
• count-mutations-of-most-fit-metastatic-stem-cell
• mu tations-of-most-fit-metastatic-stem-cell
• timing-mutations-of-most-fit-metastatic-stem-cell
• count-barriers-of-most-fit-metastatic-stem-cell
• barriers-of-most-fit-metastatic-stem-cell
• timing-barriers-of-most-fit-metastatic-stem-cell
In addition to this data, more detailed data on each run will be also be collected,
in the event that more resolution is needed (see C.3.3.18 for details.)
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C.3

DETAILS

C. 3.1

Initialization

The model is initialized by creating the world that is 61X61 patches, and centered around patch (0,0). Each patch is meant to represent the cells underlying
stem and transit cells of body. This world is subdivided into a colon crypt and
metastatic tissue. The colon crypt is centered around patch (-17, -17), and is
25x25 patches, creating a total of 625 patches. The crypt is further subdivided
into the inner and outer crypt. The inner crypt, also centered around patch
(-17,-17), is 15x15 patches, and is colored yellow. The outer crypt is composed

of the remaining crypt patches and is colored pink. The metastatic tissue is centered around patch (13, 13), and is 30x30 patches, for a total of 900 patches. All
remaining patches are colored black.
Five stem cells are created around the the center of the colon crypt, and laid
out in a circle. Each each stem cell faces outward, but their position in the circle
is chosen randomly during the setup procedure. Below is a table of the initial
global parameter values

MONITORS
PARAMETER

VALUE

mean-transit-cells

o

mean-oxygen-per-patch-in-crypt

o

mean-stem-cell-div-rate

o

count-metastatic-cells

o

age-of-metastasis

o

metastatic-tumor-formed?

false

colon-tumor-formed?

false
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SOURCE

count-transformed-cells

0

count-metasta tic-cells

0

age-of-colon-tumor-formation

0

pro-growth-spread?

false

anti-growth-spread?

false

anti-apoptosis-spread?

false

telomerase-spread?

false

metastasis-spread?

false

cif-ii-spread?

false

CRYPT
PARAMETER

VALUE

crypt-center-x

-17

crypt-center-y

-17

outer-crypt-width

25

inner-crypt-width

15

number-of-stem-cells

5

number-of-metastatic-stem-cells

0

number-of-transit-cells

0

normal-max-pop-size

300

max-pop-size

5000

probability-of-asymmetric-stem-cell-division 0·95
metastatic-cell-type
ini tial-telomere-Iength

9
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SOURCE

[12]

[12]

[79]

MUTATION
PARAMETER

VALUE

initial-stem-cell-mutation-rate

10-9

initial-transit-cell-mutation-rate

10-8

ratio-transit-mutation-to-stem-mutation

10

candidate-genes-per-barrier

variable

mutations-needed-to-remove-each-barrier

2

SOURCE

GENOME
PARAMETER

VALUE

SOURCE

genomic-instability

2

[143]

genome-length

7 x 109bp

[9 2 ]

genes-per-genome

70,000

[9 2 ]

average-gene-Iength

lOoobp

[43, 17]

count-netural-genes-bp

varies

see C3.3.6

count-genomic-instability-bp

varies

see C3.3.6

count-beneficial-genes-bp

varies

see C3.3.6

count-deleterious-genes-bp

varies

METASTATIC TISSUE
PARAMETER

VALUE

metastatic-tissue-center-x

13

metastatic-tissue-center-y

13

metastatic-tissue-width

30

probability-of-successful-invasion

1
1000
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SOURCE

successful-metastasis?

false

metastatic-vessel-detection-radius

5

INFECTION
PARAMETER

VALUE

SOURCE

probability-of-JCV-spreading-to-neighbor

0.02

calibrated

frequency-of-infection-years

1

calibrated

chronic-infection?

false

cell-type-transformed

""

transformation-location

""

count-transformed-cells

o

JCV
PARAMETER

VALUE

SOURCE

JCV-NCRR-region-Iength

43 0

[47]

JCV-mutation-rate-per-day

1. 0 74

[3 1]

JCV-mutation-in-NCRR

4.6182 x 10-4

JCV-genomic-instability

7·5

[81]

PARAMETER

VALUE

SOURCE

amount-of-oxygen-per-patch

1

OXYGEN

calibrated

oxygen-in-non-tissue
oxygen-replaced -by-patch-each-time-step

218

0.25

calibrated

oxygen-needed-to-move

0.1

calibrated

oxygen-consumed -by-cell

1

calibrated

oxygen-metabolized-d uring-division

1

calibrated

oxygen-diffused-by -cell

1

calibrated

oxygen-of-hypoxic-cells

6 x 10-4

calibrated

PARAMETER

VALUE

SOURCE

vessel-detection-radius

5

vessel-forward -movement

1

ANGIOGENESIS

oxygen-added -by-vessel

calibrated

Table C.8: Initial Parameters

C.3.2

Input Data

There is no input data in this model.
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C.3.3

C.3.3.1

Submodels

Determine If Simulation Should End

This sub-model determines whether or not the simulation should continue. The
simulation will end if either of the following conditions are true: a metastatic
tumor has formed; the crypt has reach

100

years of age.

C.3.3.2 Determine if Mutant Phenotype is On
The model as a whole assumes that it takes more than one mutation to remove
each barrier, but that any single mutation would still have some effect on the
cell's behavoir. Thus, a sub-model is needed to determine if a mutant phenotype
is expressed, based on the number of mutations in each barrier. This is accomplished by using a Bernoulli reporter to determine if the phenotype is expressed,
where the probability that the mutant phenotype is expressed is equal to number
of mutations in that barrier divided by how mutations it takes to remove each
barrier. For example, if a cell has one pro-growth mutation (i.e. count-pro-growth-

mutations = 1) and it takes two mutations to remove each barrier (Le. mutationsneeded-to-remove-each-barrier = 2) , then the probability that the pro-growth phenotype is expressed is equal to

1

"2 = 0.5. Thus, that particular cell will exhibit the

pro-growth phenotype 50% of the time.
If a stem cell has one metastatic mutation it will find the neighbor with the

most oxygen, and then move to that neighbor (even if there is already another cell
there). If the stem cell has two metastatic mutations, and is there is a blood vessel
the radius of

1

patch, then the stem cell will attempt to invade the metastatic

tissue. The probability that invasion will be successful is determined using the
Bernoulli reporter report-successful-invasion?, where the probability of success is

probability-of-successful-invasion. If invasion is successful, the stein cell moves to
the center of the metastatic tissue, hatches a metastatic stem cell, and dies. This
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leaves only the metastatic stem cell, but it inherits all of the parent stem cells
variables (i.e. mutations, barriers removed, mutation rate, ect...).
Similarly, if a transit cell has one metastatic mutation it will move to the neighbor with the most oxygen, and if it has two mutations it will try to invade the
metastatic tissue. See C.3.3.11 for a full description of the metastatic mutations
interact with the other mutations.
VERIFICATION

This sub-model was verified by creating a world with

100

stem cells, with

the option to manually add a mutation to any barrier in all of the stem
cells. Next to the "world view" are histograms of how many stem cells
are expressing the mutant phenotype during that tick. If one adds a single
mutation, then the histogram hovers around 50 (i.e.

-50

of the 100 stem cells

are expressing the mutant phenotype); if an additional mutation is added
to that barrier, all of the stem cells will express the mutant phenotype.
C.3.3.3

Determine Location

This sub-model simply reports which type of tissue (colon crypt or metastatic
tissue) each cell is in when a critical event occurs. Such critical events include
mutations, barrier removal, transformation, etc..See C.3.3.18 for a complete list
of events recorded during each run.
C.3.3.4 Infection

JCV is a common virus, and most individuals tend to be infected by adolescence
Viscidi et al. [144], Knowles et al. [68]. Thus, if infection? is set to "true", then
infection is modeled by giving JCV the opportunity to infect each crypt every

frequency-of-infection-year years. During each infection attempt, a random transit
cell is chosen to be infected. This infected transit cell can then infect one of its randomly chosen neighbors, with the probability of successful infection being equal
to probability-of-JCV-spreading-to-neighbor. If all of the cells in the crypt become
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infected, then the cell is considered to have become chronic, and the global parameter chronic-infection? is set to true, and the age at which the infection became
chronic is also recored.
Initially, an infected cell's phenotype remains the same as other wild-type
cells of the same breed (i.e. transit cell or stem cell). This is because the cell's
CIF-II pathway is preventing the expression of viral oncogenes [153]. However,
if the CIF-II pathway is "removed" by the accumulation of "beneficial" mutations, then viral oncoproteins are expressed. JCV produces several oncoproteins
that, in animal models, strongly interfere with apoptosis (P53), and cell division
(pRb,(3-catenin, MAPK (via PP2A», resulting in multi-nucleation, increased doubling time, growth in anchorage dependent conditions, uncontrolled cell growth,
and chromosomal instability (reviewed in [82]). In the "Full Transformation"
model, these processes can be modeled by completely removing the apoptosis
barrier (chromosomal instability and uncontrolled cell growth), the pro-growth
barrier (growth in increased doubling time and anchorage dependent conditions;
i.e. no contact inhibition), and the anti-growth barrier (uncontrolled cell growth).
In the "Partial Transformation" model, each of these barriers are only partially

removed; however, if there is already a mutation in one of those barriers, then
JCV will serve to completely remove that barrier. In the "No Infection" model,
mutations in if the ClF-II pathway do not have any effect.
Note that transformation is modeled by adding mutations to the pro-growth,
anti-growth, and anti-apoptosis barriers whenever CIF-II-removed? is true. However, it is not hypothesized that removing the ClF-II pathway literally adds mutations to each of these pathways; this method was chosen simply because it allows
one to easily change the phenotype of the cell using the existing code.
VERIFICATION

The infection model was visually verified by creating a model in which
cells do not move, and then randomly selecting a cell to infect, and then
changing the shape and size of that infected cell. One could then watch the
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infection spread among neighboring cells, each changing to the infected size
and shape.
Varying the probability-of-JCV-spreading-to-neighbor parameter between 0 and
1

also ensured that the infection sub-model is behaving as expected. Low

values of probability-of-JCV-spreading-to-neighbor resulted in a large number
of time steps until the entire crypt is infected, while large values of probability-

of-JCV-spreading-to-neighbor resulted in few time steps until every cell is infected.
Transformation was verified by manually adding a single pro-growth, antigrowth, anti-apoptosis, and CIF-II mutation to each stem cell. One could
then step through the model and inspect the stem-ceIl's pro-growth-removed?,

anti-growth-removed?, apoptosis-removed?, and CIF-II-removed? parameters. Whenever CIF-II-removed? was true, each of the other three barriers had a mutation added to it. However, when CIF-II-removed? was false, the mutations
returned to its previous value. This verifies that the transformation procedure only adds mutations when CIF-II is removed.
CALIBRATION

The parameters frequency-of-infection-year years and probability-of-JCV-spreading-

to-neighbor were calibrated so that the modeled incidence of infection had
a pattern similar to that observed in Viscidi et al. [144], Knowles et al. [68].
After several parameter sweeps, frequency-oJ-infection-year was set to

1,

and

probability-of-JCV-spreading-to-neighbor was set to 0.02. In other words, each
crypt is exposed to infection once a year, and there is only a 2% chance that
each infected cell would be able to infect its neighbor.

C.3.3.5 Hit and Run Model of Infection
An alternative infection model is built upon the research of [113], who argue
that JCV may increase the risk of colorectal by some sort of "hit and run" mecha223

nism. Under this hypothesis, JCV first infects the kidneys, mutates into the Mad-1
strain, giving it the ability to infect colorectal cells. This mutation event is then
followed by a deletion in the non-coding control region (NCRR), which may allow JCV to express its oncoproteins in the colon cells, as well as increasing CIN,
a process that may result in the formation of a colon cancer stem cell. Such transformation may occur for 14-21 days, which how long LT can be detected after
transfection [111].
The infection component of the "Hit and Run" model is conducted in the same
manner as described in C.3.3+ However, in this case mutations in the CIF pathway are not required for transformation. Instead, mutations in the NCRR region
allow for transformation. In this case, JCV mutations events in JCV's NCRR region are determined by the reporter report-JCV-NCRR-mutation?, which uses a
Bernoulli random distribution, where the probability of success is JCV-mutation-

in-NCRR, which is calculated as JCV-NCRR-region-length x JCV-mutation-per-day.
If a cell is dividing and has infected?=true and report-JCV-NCRR-mutation?=true,

the cell acquires one NCRR mutation. Ensuring that NCRR mutations only occur when the host cell divides was accomplished by inserting the JCV-mutation
within each cell's division procedure. In this Hit and Run model, a single NCRR
mutation simulates cell's acquired ability to infect the colon, but does not otherwise affect the cell's phenotype. If a second mutation occurs, and infected?=true,
the cell is expresses its oncoproteins, removing the pro-growth, anti-growth, and
apoptosis barriers. Additionally, the expression of these oncoproteins induces
CIN, increasing the cell's current mutation rate 7.5 fold [81].
Once the JCV starts expressing the oncoproteins it is assigned a random lifespan between 14-21 days, which is recorded under the JCV-Mad-l-d98-survival
parameter of the cell. Similarly, once the cell accumulates two NCRR muta. tions it has its JCV-Mad-l-d98-evolved? set to true, and JCV-Mad-l-d98-days-active
set to o. Every time the cell divides it increases JCV-Mad-l-d98-days-active by
and when JCV-Mad-l-d98-days-active

I,

= JCV-Mad-l-d98-survival the cell returns to
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its previous mutation rate, removes the effects of ICV's oncoproteins on the
barriers, resets JCV-Mad-l-d98-days-active back to zero, and sets JCV-Mad-l-d98-

evolved? back to false. Returning to the previous mutation rate is accomplished
by dividing the infected cell's mutation rate by JCV-genomic-instability, thus removing ICV induced genomic instability. Similarly, returning to the previous
number of barriers removed is accomplished by subtracting mutations-added-by-

transformation from count-anti-growth-mutations, count-pro-growth-mutations, and
count-anti-apoptosis-mutations. By doing so, any additional mutations accumulated during the genomically unstable transformation period will remain present.
FInally, JCV-Mad-l-d98-days-active is reset to zero because it is assumed that ICV,
and not the cell, become inactive. This means that the cell can be re-infected. If
this occurs, the cell will acquire a new value for ICV-Mad-l-d98-survival, ICVMad-l-d98-evolved? set to true, and the process will repeat.
VERIFICATION

The Hit and Run model was verified by creating a world in which all cells
were infected and NCRR mutations could be added manually, one by one. It
was verified that when a cell has only one NCRR mutation there is no phenotypic change, but when there are two NCRR mutations pro-growth-removed?,

anti-growth-removed?, and apoptosis-removed? were all set to true. Similarly,
the mutation rate was increased 7.5 fold. By inspecting each transformed
cell, one is also able to confirm that JCV-Mad-l-d98-days-active increases by
one every day, and that the cell does die when JCV-Mad-l-d98-days-active

= JCV-Mad-l-d98-survival.

By creating links between parent and daughter

cells, one can also verify that daughter cells inherit the parental values of

JCV-Mad-l-d98-days-active and JCV-Mad-l-d98-survival. By following these
same cells, one can also verify that the mutation rate returns to its previous
state, that the effect of ICV's oncoproteins on the barriers is removed, and
that JCV-Mad-l-d98-days-active returns to zero and JCV-Mad-l-d98-evolved?
returns to false when JCV-Mad-l-d98-days-active
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= JCV-Mad-l-d98-survival.

Furthermore, by manually adding NCRR mutations to those same cells after JCV-Mad-l-d98-evolved? is reset to false, one can verify that the cell is
assigned a new value for JCV-Mad-l-d98-survival.
That NCRR mutations only occur when the cell divides was verified by
setting JCV-mutation-in-NCRR to

I,

and filling the crypt with cells. In this

scenario the stem cells cannot divide, and so no NCRR mutations occur.
However, when the crypt is not filled, the cells are able to divide and if they
are infected they can acquire NCRR mutations. This was further verified by
having each infected cell print a message that it divided and had a mutation
in the NCRR.

C.3.3.6 Stem Cell Determine Division Type
Stem cells can either divide asymmetrically or symmetrically [12]. During asymmetric division, each stem cell produces one daughter transit cell and one daughter stem cell. During symmetric division, the stem cell produces either
cells or

2

2

stem

transit cells. It has been suggested that symmetric division occurs 5%

of the time [79].
To model this process, one can use the reporter asymmetric-division?, which uses
a Bernoulli random distribution, where the probability of success is probability-of-

asymmetric-stem-cell division. If "true" is returned, asymmetric division occurs; if
"false" is returned, symmetric division occurs.
ASYMMETRIC DIVISION

If asymmetric division occurs, then any stem cells that have pro-growth-removed?

and anti-growth-removed? as false will call the stem-cell-normal-division procedure.
In this procedure, each the stem cell will undergo mutation (see the C.3.3.6 for

details of the mutation procedure) and hatch a transit cell if there is an empty
patch within a cone having an angle of 1200 and radius of 1.5 patches. If there is
no such empty patch, the stem cell will not undergo mutation or division. If this
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stem cell is mobile (because it has one metastatic mutation), it will only be able
to divide in the inner crypt.
Any stem cells with pro-growth-removed? as true but anti-growth-removed? as
false, call the stem-cell-pro-growth-division procedure. When this procedure is called,
the stem cell will always undergo mutation and division, producing a transit cell
that moves to a randomly chosen patch with a cone with an angle of

120

0

and

radius of 1.5 patches. If this stem cell is mobile (because it has one metastatic
mutation), it will only be able to divide in the inner crypt.
Any stem cells with anti-growth-removed? as true but pro-growth-removed? as
false, call the stem-cell-anti-growth-division procedure. When this procedure is
called, and if the cell is in the inner-crypt, the cell will divide as in the stem-

cell-normal-division procedure. However, if this stem cell is mobile (because it has
one metastatic mutation), it gains the ability to divide in both the inner crypt and
the outer crypt.
Any stem cells with anti-growth-removed? as true and pro-growth-removed? as .
true, call the stem-cell-anti-and-pro-growth-division procedure. When this procedure is called, the stem cell will always undergo mutation and division, producing a transit cell that moves to a randomly chosen patch with a cone with an
angle of

120

0

and radius of 1.5 patches. Furthermore, if this stem cell is mobile

(because it has one metastatic mutation), it also gains the ability to divide in both
the inner crypt and the outer crypt.
SYMMETRIC DIVISION

If asymmetric-division? returns false, then symmetric division will occur. Dur-

ing symmetric division, the stem cell with the most deleterious mutations
is killed and replaced by a daughter from the stem cell with the fewest
deleterious mutations. However, it is important to note that any stem cells
with anti-growth-removed? as

true will be exempt from symmetric division.

It is thus possible that the true least fit stem cell could survive symmetric

division (assuming it has anti-growth-removed? as true). All of the other stem
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cells (i.e. not the least or most fit stem cells) will follow the asymmetric division procedure rules. Symmetric division is modeled this way to capture
the idea that the stem cell crypt has evolved to minimize the risk of disease
by periodically killing off the least fit ( most deleterious) cells [12].
STEM CELL MUTATION

The number of each type of mutation added during each division is determined by drawing a random number from a Poisson distribution, with an
appropriate mean (.\). Mutations of each type accumulate over the life of
the cell. Finally, the mutation rate will increase proportionately with count-

anti-apoptosis-mutations xgenomic-instability.
NEUTRAL MUTATIONS

The human genome is ~7 x 109bp, and there are 70,000 genes, each of
which has an average length of 1000bp (reviewed in [92]). Assuming
that mutations anywhere in any of these 70,000 genes will either result in a deleterious of beneficial phenotype, then mutations elsewhere
must be neutral. Thus, one can assume that 7 x 109 - 70000 (1000) =
6.93 x 109bp of the genome are neutral. If the stem cell mutation rate
is 1 x 10-9, then one should expect 10-9 x 6.93 x 109 = 6.93 neutral
mutations per stem cell division. Thus, to determine how many neutral mutations will occur during each division, one can draw a random
number from a Poisson distribution with .\ = 6.93 mutations per division.
BENEFICIAL MUTATIONS

Assuming there are 6 barriers to cancer, 3 candidate genes that can inhibit each one of those barriers, each with an average length of 1000bp,
then there are 6 x 3 x 1000 = 18,OOObp, that if mutated will remove a
barrier to cancer. As these mutations increase the cell's ability to survive
and replicate, they can be considered beneficial mutations. Thus, one
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can expect that there are 1 x 10-9 x 18000 = 1.8 x 10-5 beneficial mutations during each stem cell division. Thus, one can determine how
many beneficial mutations will occur by drawing a random number
from a Poisson distribution with ,\ = 1.8 x 10-5 mutations per division.
If a beneficial mutation does occur, then a random number X is drawn

from a Uniform distribution that has a range from

1

to 6. This number

then determines which kind of beneficial mutation will occur. If X = 1
there is a pro-growth mutation; if X = 2 there is an anti-growth mutation; if X = 3 there is an anti-apoptosis mutation and the mutation rate
is increased by multiplying it by genomic-instability; if X = 4 there is a
telomerase mutation; if X = 5 there is a metastatic mutation; if X = 6
there is a elF-II mutation. A Uniform distribution is used because it is
assumed that the mutation is equally likely to "land" in anyone of the
beneficial genes, since they all have equal lengths.
GENOMIC INSTABILITY MUTATIONS

Assuming there are 7 genomic instability genes, there are total of 7 x
1000 = 7000bp, that if mutated will increase the mutation rate. Therefore, the expected number of genomic instability mutations per division
is ,\ = 7000 x 10-9 = 7 x 10-6 . Each mutation that lands in a genomic
instability gene linearly increases the mutation rate by a factor of two.
For example, one mutation doubles the mutation rate, 3 mutations increase the mutation rate by a factor of 6, and so on until the mutation
rate is increased 14 fold.
DELETERIOUS MUTATIONS

Assuming that there are 70,000 genes, each with an average gene length
of 1000bp, then there are 70000 (1000) = 7 x 107bp that are not neutral
when mutated. If there are 6 barriers to cancer, 3 candidate genes that
can inhibit each one of those barriers, then there are 6 x 3 x 1000 =
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18,000bp, that if mutated will remove a barrier to cancer. These mutations can be considered beneficial. Finally, there are 7000bp that induced genomic instability when mutated. Thus, the remaining 7 x 107 18,000 -7000 = 69975000bp, if mutated, will be deleterious. One should
then expect 1 x 10-9 x 69982000 = 0.069982 deleterious mutations per
each stem cell division. Thus, to determine how many deleterious mutations there will be during each stem cell division, one can draw a
random number from a Poisson distribution with A = 0.069982 mutations per division.
PARTIAL BARRIER REMOVAL

Whether or not a mutation will be expressed is determined using the
reporter express-mutation? This reporter will randomly report a true or
false value, using a Bernoulli distribution where the probability of success is

count-mutations-in-barrier
F
l'f
.
.
. . or examp e, 1 mutatlOnsmutatlOns-needed-to-remove-each-barrzer
needed-to-remove-each-barrier = 2, and count-pro-growth-mutations = 1, then

p =

p

=

~

=

0.5. If "true" is returned, the mutation will have its effect; if

"false" is returned the mutation will not have its effect. NetLogo does
not include a built in Bernoulli distribution, but Grimm and Railsback
do provide the code for how to create such a distribution [108].
Partial barrier removal is included in the model to capture the idea
that it likely takes more than a single mutation to completely remove a
barrier to cancer, but disruptions in the pathways(s) by single mutations
still have some affect on the phenotype.
VERIFICATION

The rate of symmetric division was verified simply by adding a monitor
that recorded how frequently symmetric division occurred. Once also had
the option to change the rate of asymmetric division, which did result in a
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change in the monitored rate of symmetric division (i.e. increasing the probability of asymmetric division decreased the rate of symmetric division).
The code used to identify the least fit and most fit stem cells during symmetric division was verified by outputting each stem-cell's number of deleterious mutations, and which cells were being identified as the most fit, least fit,
and other stem cells. The code was verified because the cell with the most
deleterious mutations was successfully identified, colored green, and then
killed off in the next round of division. Similarly, the most fit stem cell was
successfully identified, changing its shape, and producing a daughter cell
(with the same shape) during the next round of division.
The code for partial barrier removal was verified by creating a world with
100

stem cells. Next to the world were histograms of how many cells had the

pro-growth phenotype, anti-growth phenotype, etc ... One could then manually add mutations to all of the stem cells. The parameter mutations-needed-

to-remove-each-barrier was set to two, so when one mutation was added to
all of the stem cells, the histogram showed that -50% of the cells exhibited
the mutant phenotype, verifying the the mutated cells expressed the mutant
phenotype -50% of the time. When a second mutation was added, all of the
stem cells expressed the mutant phenotype.
Normal stem cell division (i.e. only divide when there is an empty patch
ahead) was verified by creating a world with only two stem cells, each of
a different color. One can place a stationary transit cell in front of the stem
cell, and then ask the stem cell to identify all patches that it could have its
daughter transit cell move to. This verifies that the code works because the
stem cell will identify all patches within their cone of vision, except for that
with a transit cell already on it.
The pro-growth phenotype was verified by filling the crypt with stationary
transit cells and then setting pro-growth-removed? to true for one stem cell,
and then adding a single metstatic mutation. When the simulation is run,
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the stem cells produce transit cells, even though there are already transit
cells on every patch. However, it is only able to divide in the outer crypt
The anti-growth phenotype was verified by giving one of the stem cells
one metastatic mutation (making it mobile), and then setting anti-growth-

removed? to true. This mobile stem cell will then divide in divide in both the
inner and outer crypt.
The CIF-II deficient phenotype was verified by infecting one stem cell, adding
two ClF-II mutations, and adding one metastatic mutation. Stationary transit cells were then added to every patch in the crypt. When the simulation
was run, the mutated and transformed stem cell then had cif-ii-removed?, pro-

growth-removed?, anti-growth-removed?, and anti-apoptosis-removed? as true, verifying that transformation removed these other barriers. Furthermore, the
mutated and transformed cell was able to move around the crypt (because
of the metastatic mutation) and divide everywhere, even when proability-of-

asymmetric-division is set to 0 (verifying the anti-apoptosis phenotype).
It was also verified that stem cells with apoptosis-removed? as true were excluded from being identified as the least fit cell. This was accomplished by
choosing one stem cell and manually adding

100

deleterious mutations, set-

ting apoptosis-removed? to true, and changing its color to black. Throughout
the simulation, this stem cell was never killed off, even though it had the
most deleterious mutations.
See C.3.3.7 for a description of how the behavior of stem cells with metastatic
mutations was verified.
C.3.3.7 Stem Cell Replace Metastatic Stem Cell
This model assumes that the crypt can determine if it has too few stem cells, and
will respond by having the most-fit stem cell (i.e. that stem cell with the fewest
deleterious mutations) hatch one daughter stem cell. The only time the crypt will
have too few stem cells will be if one stem cell acquired a metastatic mutation,
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giving it the ability to roam around the crypt. Again, if this occurs, the most-fit
stem cell hatches a daughter stem cell, returning the number of non-metastatic
stem cells to its normal amount.
VERIFICATION

The creation of metastatic stem cells from stem cells was verified by creating
a world where the probability-of-successful-invasion was set to 1, vessels could
be added manually, and metastatic mutations could also manually be added.
After adding vessels and one metastatic mutation, the mutated stem cell
moves toward the neighbors with the most oxygen, which in this case are
the neighbors with vessels. The mutated stem cell will keep moving around
the vessels as long as it only has one metastatic mutation. One can then
add a second metastatic mutation to this stem cell, after which the stem
cell moves the metastatic tissue, hatches

1

metastatic stem cell, which then

hatches four more metastatic stem cells.
C3.3.8 Metastatic Stem Cell Fill Tissue

After a stem cell invades the metastatic tissue, it hatches number-of-stem-cells -

1

metastatic stem cells. After there are number-of-stem-cells metastatic stem cells, the
metastatic stem cells are laid out in a circle.
C3.3.9

Metastatic Stem Cell Determine Division Type (symmetric or asymmetric; a global
procedure)

This procedure is identical to the stem cell division type procedure, except that
it applies only to metastatic stem cells in the metastatic tissue.
C3.3.1O

Transit Cell Consume Oxygen

Each transit cell will consume a certain amount of oxygen every time step. If the
underlying patch has enough oxygen, then the transit cell will consume oxygen-

consumed-by-cell units of oxygen. If there is less than oxygen-consumed-by-cell units
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of oxygen in the patch, then the transit cell will only consume half of the available
oxygen.
For a description of the calibration process for how much oxygen each cell
consumes, see C3.3.14.
C3.3.11

Transit Cell Division, Mutation, and Movement (turtle procedure)

Every time a transit cell divides it undergoes mutation (see C3.3.11 for details),
uses up some oxygen (determined by the parameter oxygen-metabolized-during-

division; if there is not enough oxygen the cell will not divide), divides its oxygen
equally between itself and it's daughter, and decreases it's telomere length by
one unit (so long as there aren't any telomerase mutations). After hatching the
daughter cell, the parent then moves to a different patch, using some more oxygen in the process (determined by the parameter oxygen-needed-to-move). Where
exactly the parent cell can divide and move to is determined by which (if any)
mutant phenotypes it has.
If the transit cell has no pro-growth, anti-growth, or metastatic mutations, it

will call the transit-cell-normal-division procedure. In this procedure, the transit
cell will only divide if it is in the inner crypt and there is an empty patch with its
cone of vision, which has an angle of

0

180

and radius of 1.5 patch units. If it can

divide, the parent then randomly choses and moves to one of the empty patches
in it's cone of vision. If the cell is in the outer crypt, it will use the same rules to
decide to move (Le. there must be an empty patch)
If the transit cell has no pro-growth, anti-growth, but one metastatic mutation,

it will call the transit-cell-normal-metastasis-division procedure. In this procedure,
the transit cell will only divide if there is an empty patch with its cone of vision,
which has an angle of

0

180

and radius of 1.5 patch units. If the parent can divide,

it moves to the empty neighbor with the greatest amount of oxygen.
If the transit cell has pro-growth-removed? as true (see C3.3.2 for details) , but

not anti-growth, or metastatic mutations, it will call the transit-cell-pro-growth-
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division procedure. In this procedure, the transit cell will only divide if it is in
the inner crypt, but it does not require that there be an empty patch within it's
cone of vision. If it can divide, the parent then randomly choses and moves to
one of the patches in it's cone of vision. If the cell is in the outer crypt, it will use
the same rules to decide to move (i.e. it can move to any patch within its cone of
vision).
If the transit cell has pro-growth-removed? as true, one metastatic mutation, but

no anti-growth mutations, it will call the transit-cell-pro-growth-metastasis-division
procedure. This procedure is very similar to the transit-cell-pro-growth-division procedure, but randomly choosing a patch in the cone of vision, the parent moves
to the neighboring patch with the most oxygen, regardless of whether or not that
patch is already occupied. Again, these transit cells can only divide if they are in
the inner crypt.
If the transit cell has anti-growth-removed? as true (see C.3.3.2 for details), but no

pro-growth or metastatic mutations, it will call the transit-cell-anti-growth-division
procedure. In this procedure, division requires that there be an empty patch
within the transit cell's cone of vision, but these transit cells can divide in both
the inner and outer crypt. If it can divide, the parent then randomly choses and
moves to one of the empty patches in it's cone of vision.
If the transit cell has anti-growth-removed? as true, one metastatic mutation, but

no pro-growth mutations, it will call the transit-cell-anti-growth-metastasis-division
procedure. This procedure is very similar to the transit-cell-anti-growth-division
procedure, but instead of randomly choosing an empty patch in the cone of
vision, the parent moves to the empty neighbor patch with the most oxygen.
If the transit cell has both anti-growth-removed? and pro-growth-removes? as true

(see C.3.3.2 for details), but metastatic mutations, it will call the transit-cell-anti-

and-pro-growth-division procedure. In this procedure, the transit cell does not require that there be an empty patch within it's cone of vision, and it can divide
in both the inner and outer crypt. When these cells divide, they randomly chose
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and move to one of the patches in it's cone of vision, regardless of whether or
not it is already occupied.
If the transit cell has both anti-growth-removed? and pro-growth-removes? as true

and one metastatic mutation, it will call the transit-cell-anti-and-pro-growth-metastasis-

division procedure. This procedure is very similar to the transit-cell-anti-and-progrowth-division procedure, but instead of randomly choosing a patch in the cone
of vision, the parent moves to the neighbor patch with the most oxygen, even if
it is already occupied.
If any transit cell has telomerase-removed? as true, the telomeres do not decrease

in length after division.
For a full description of the apoptosis mutations, see C3.3.17. For a description
of how elF-II mutations affect the transit cell's phenotype, see C3.3-4.
MUTATION

The mutation procedure for transit cells is nearly identical to that of the
stem cells, except that the mutation rate is ten times higher, increasing the
expected number of mutations per division accordingly.
Transit cells will also exhibit partial barrier removal, using the same process
as described in the stem cell mutation section.
VERIFICATION

The code used for mutation is exactly the same as that used for stem cells
(see C3.3.6), except that the transit cells use the transit-cell-mutation-rate instead of stem-cell-mutation-rate, and so was already verified.
Normal transit cell movement was verified by randomly placing stationary transit cells around the crypt, and then following mobile transit cells.
The mobile transit cells identify all potential target patches by changing
the patch color, and then moves to one of them. The movement code was
verified because patches with stationary transit cells on them were not identified as target patches, and the mobile transit cells did not move to them.

Furthermore, it was verified that the parent moves to the target patch by
changing the color of the parent celL
The pro-growth mutation was verified by removing the pro-growth barrier
in one stem cell (i.e. setting count-pro-growth-mutations to two), and changing
the color of all of its daughter cells to green (instead of red). One can then
step through each tick, verifying that, when in the inner crypt, the mutated
cells will move to occupied patches, and divide (visualized by creating links
between the parent and daughter cells). One can also observe that the mutated transit cells cannot divide in the outer crypt, which can be verified by
inspecting such a cell and making sure that count-transit-cell-divisions does
not increase.
The anti-growth code was verified by removing the anti-growth barrier in
one of the stem cells (i.e. setting count-anti-growth-mutations to two), and
stepping through the model until some of the mutated cells (colored brown
instead of red) reached the outer crypt. Once the mutated cell reaches the
outer crypt, one can inspect it and continue to step through the model,
allowing the mutated cell to move and divide in the outer crypt. Count-

transit-cell-divisions continues to increase (so long as telomeres remain and
there are empty patches in the cone of vision), verifying that the anti-growth
code.
It was also verified that the pro-growth and anti-growth phenotypes worked

together; that is, transit cells with both of these barriers removed can divide
anywhere in the crypt, even if there are not any empty patches within their
cone of vision. This was verified by removing both barriers in one stem cell
(i.e. setting count-anti-growth-mutations to two and setting count-pro-growth-

mutations to two), and filling the outer crypt with stationary transit cells. The
mutated cells have the ability to move to and divide on occupied patches
in both the inner and outer crypt, verifying that code for the two mutant
phenotypes work together.
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The anti-apoptosis phenotype was verified by randomly hatching

300

tran-

sit cells, each with a random number of deleterious mutations, ranging between

1

and

100.

Afterwards,

20

of those transit cells had the apoptosis

barrier removed, their number of deleterious mutations set to 200, and their
shape changed to a square (instead of a circle). Next, the population cap procedure was executed, but all of the cells with apoptosis removed survived
the cap (see C.3.3.17). This verifies that anti-apoptotic cells a exempt for the
fitness search conducted during the population cap procedure, giving them
the ability to survive even though they have the most deleterious mutations.
The metastasis phenotype was verified in the same manner as described
in C.3.3.7, except that if the transit cell successfully invades the metastatic
tissue it still behaves as if it were in the crypt (i.e. it still uses the transit-cell-

division-mutation-and-movement procedure).
The telomerase mutation was simply verified by removing the telomerase
barrier in one of the transit cells, and then inspecting it to make sure that

telomere-length did not decrease even when the cell underwent division.
C.3.3.12 Angiogenesis (turtle procedure)
Angiogenesis is the production of new blood vessels during hypoxic stress. Such
stress can occur if there are too many cells and not enough oxygen; in this situation, the body responds by producing new blood vessels to supply oxygen to
the extra cells. This process is modeled by asking any patches that oxygen levels
below oxygen-of-hypoxic-cells and no other vessels within vessel-detection-radius to
sprout a new blood vessel. If a patch is hypoxic (i.e. oxygen levels below oxygen-

of-hypoxic-cells), but there is a blood vessel within vessel-detection-radius, it will
sprout a VEGF molecule. The VEGF molecule then detects the closest vessel and
moves towards it one patch unit for each tick. Once the VEGF molecule is within
0.5 patch units of the nearest vessel, it stimulates the vessel to produce one more

vessel, which moves forward vessel-forward-movement patch units. After such vessel growth, the stimulating VEGF molecule dies.
Each blood vessel is randomly assigned a lifespan, ranging from
Chen et al.

1-250

days

[21].

During each tick, the vessels add oxygen-added-by-vessel units of oxygen to the
underlying patch, thus increasing the amount of oxygen available to the crypt.
VERIFICATION

Angiogenesis should only occur when there is not enough oxygen in the
crypt for the number of cells present, which would occur if the population
increased beyond its normal size. Such a population increase would only
occur if mutations drive the cells to divide more frequently than normal, as
occurs when many of the cancer barriers are removed. This was verified by
running the model and manually adding mutations to the stem cells. When
there are no mutations, angiogenesis does not occur. However, after several
barriers are removed, angiogenesis begins to occur, increasing the amount
of oxygen available, and allowing the population to increase from

~250

cells

to 5000 cells (see C.3.3.17 for a description of why the population is capped
at 5000 cells).
C3.3.13

Oxygen Replenish (patch procedure)

Each tick, oxygen-replaced-by-patch-each-time-step is added to each patch in the
colon crypt. This process is meant to simulate the process of the underlying
bed of blood vessels supplying oxygen to support the cells in the crypt. Until a
cell successfully invades the metastatic tissue, all patches in the metastatic tissue
have their oxygen kept at amount-of-oxygen-per-patch, so as to simulate homeostasis prior to invasion.
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C.3.3.14 Oxygen diffusion (global procedure)
Oxygen diffusion is modeled using NetLogo's built in primitive, diffuse. Thus,

oxygen-diffused-by-cell percent of the patches oxygen is divided equally among
the patch's neighbors. Also, all patches that do not represent tissue (Le. the black
patches) have their oxygen levels set to oxygen-in-non-tissue. These two processes
are repeated
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times each tick, so as to stimulate constant oxygen diffusion

throughout the day Chen et al. [21].
CALIBRATION OF OXYGEN AND ANGIOGENESIS PARAMETERS

It has been observed that colon stem cells divide approximately once ev-

ery four to five days, there are

~250

cells in each colon crypt, and an-

giogenesis does not occur under normal growth conditions Potten et al.
[103], Booth and Potten [12], Kleinsmith [67]. As oxygen levels determine
whether or not a transit cell can divide or move (making room for other
cells), a series of seven parameter sweeps were conducted on all oxygen parameters to narrow down a final set of values to sweep. The values tested
in this final sweep were: oxygen-added-by-vessel ranged from 0.1 - 0.5 in 0.1
increments; oxygen-replaced-by-patch-each-time-step ranged from 0.25 - 1 in
0.25 increments; oxygen-metabolized-during-division ranged from 0.25,0.5, 1.0;

oxygen-of-hypoxic-cells ranged from 3 x 10-4 - 8 x 10-4 in increments of 1 x
10-4 ; oxygen-consumed-by-cell was tested at 0.25,0.5, 1.0; oxygen-diffused-by-

cell was tested at 0.5,0.75, 1.0; oxygen-in-non-tissue was tested at 0.5,0.75, 1.0.
All values were tested in combination using NetLogo's "Behavior Space",
resulting in a total of 4860 runs, each of which lasted 500 ticks. The final set
of parameter values, which can be found in C.S, resulted in a average stem
cell division rate of 0.2212 divisions per day (or one division every 4.5 days),
an average of 255.766 transit cells in the crypt, and 0 vessels.
Of note is that mutations were turned off during the parameter sweeps mutation. This was done because mutations affect the cell's phenotype, chang-

ing the rules about when and where division can occur, and thus the stem
cell's division rates and total population size (which could induce angiogenesis). By turning off mutation, one can thus get a better idea of the stem
cell's division rate and population size under normal conditions.
C3.3.1S

Oxygen Recolor Patches (patch procedure)

The shade of each patch can be changed to reflect the amount of oxygen that it
has. This can easily be accomplished using NetLogo's scale-color primitive, using
oxygen as the number input.
C3.3.16

Transit Cell Death (turtle procedure)

In a normal crypt, transit cells die in one of two ways: they move outside the

crypt and are shed, or they completely lose their telomeres.
C3.3.17 Maintain Population Cap (turtle procedure)

In this model there are actually two maximum population sizes, normal-max-pop-

size and max-pop-size. If the population grows larger than normal-max-pop-size, the
number of excess cells is determined by subtracting the current population size
from normal-max-pop-size. Next, a sub-population of the least fit cells (Le. most
deleterious mutations) of size 1.5 x number of excess cells is found. The oxygen
levels of each of these "least fit" cells is then determined. In the end, excess-

cells least fit cells with the lowest oxygen levels are then killed off, bringing the
population size back to normal-max-pop-size. The idea behind this is that when
resources become scarce, the least fit cells with the fewest resources (in this case
oxygen) would be the most susceptible to death.
It is important to note that cells with anti-apoptosis-removed? as true are ex-

cluded from the search for the least fit cells. This is because the apoptosis mutations prevent cell death, even in the presence of deleterious mutations and
limited resources. This means that if enough cells have anti-apoptosis-removed? as

true, the population grow much larger than narmal-max-pap-size. Due to limited
computing power, a second population size limit had to be created, so as to
prevent the computer from freezing while it attempts to track tens to hunderds
of thousands of cells. This absolute limit is set by max-pap-size, and when it is
reached the number of excess cells is calculated (as above) and excess-cells are
randomly chosen from all cells to be killed off, returning the population size
back to max-pap-size.
VERIFICATION

This procedure was verified by filling the crypt with

300

transit cells, each

with a random number of deleterious mutations, ranging between 1 and
and a random oxygen level, ranging between 0 and

1.

100,

The color of each cell

was also scaled according to how many deleterious mutations they had; the
lighter the color, the more deleterious mutations. One could then identify
the 1.5 x number of excess cells with the most deleterious mutations, and
change their shape to a small circle. The average number of deleterious mutations in the ID'd cells was higher than the average number of deleterious
mutations in the cells not identified as being the most deleterious, verifying
that the search procedure was working correctly. Next, of those least fit cells,

excess-cells were identified that had the lowest oxygen levels. Again, the average oxygen levels of these cells was lower than the average oxygen levels
of the cells not identified as being "least fit" or most hypoxic. Together, this
verifies that the population cap procedure successfully identifies the least
fit cells, and then finds the most hypoxic of those cells. Finally, one can kill
of the least fit and most hypoxic cells, returning the population level back
to max-pap-size.

C.3.3.18

Evaluate state and Record Data (global procedure)

In addition to the summary data (described in C.2.11), major events of each run
are also recored, in the event that more details are needed about what led to
tumor formation. Such major events include:
• Stem cell mutation
• Metastatic stem cell mutation
• Stem cell barrier removal
• Metastatic stem cell barrier removal
• Stem cell transformation
• Metastatic stem cell transformation
• Stem cell symmetric division
• If a mutation has spread to all stem cells, either by symmetric division or

mutation
• Formation of colon tumor (i.e. cell in crypt has pro-growth, anti-growth,
apoptosis, and telomerase barriers completely removed)
• Successful invasion into metastatic tissue
• Formation of metastatic tumor (i.e. cell invaded metastatic tissue and has
pro-growth, anti-growth, apoptosis, metastasis, and telomerase barriers completely removed)
Every time a major event occurs in a run, the following data is recorded by the
cell experiencing the major event:
• Date and time
• Infection.Modeled (true/false)
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• Mutations.Added.By.Transformation (0,1,2)
• Age
• Tissue
• Event
• Cell.Type (i.e. transit cell, stem cell, metastatic stem cell)
• Cell.Number
• Parent
• N.Beneficial.Mutations
• Beneficial.Mutations (list of mutations)
• Timing.of.Beneficial.Mutations (list)
• N.Barriers.Removed
• Barriers.Removed (list of barriers removed)
• Timing.of.Barrier.Removal (list)
• Cell.Infeded (true/false)
• Cell.Transformed (true/false)
• Cell.Invasion (true/false)
• N.Cells.in.Crypt
• N.Metastatic.Cells
• Mean.5tem.Cell.Div.Rate
• Metastasis.Occurred (true/false)
• Age.of.Metastasis

• Colon.Tumor.Formed (true/ false)
• Metastatic.Tumor.Formed (true/false)
• N.Transformed.Cells
• Age.When.lnfection.Became.Chronic
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ACRONYMS

APPENDIX D

CDK Cyclin Dependent Kinase
EC

Endothelial cell

VEGF Vascular Endothelial Growth Factor
CAM Cell-Cell Adhesion Molecules
MSI Microsatellite Instability
CIN Chromosomal Instability
LOH Loss of Heterozygosity
CIF

Cellular Interfering Factor

FAP Family Adenomatous Polyposis
HNPCC Hereditary Nonpolyposis Colorectal Cancer
APC Adenomatous Polyposis Coli
KRAS Kristen Rat Sarcoma Virus
MMR Mismatch Repair Enzymes
ACF Aberrant Crypt Foci
GSK3 Glycogen Synthase Kinase 3
JCV JC Virus
PML Progressive Multifocal Leukoencephalopathy
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NCRR Non-Coding Regulatory Region
T-ag Large T Antigen
t-ag

Small T Antigen

COP Calabrese model with Original Parameters
CNP Calabrese model with New Parameters
GIl

Genomic Instability Infection Model

GIM Genomic Instability Mutation Model
ABM Agent Based Model
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